Raily Aesthetic Medicine International Holdings Limited

瑞麗醫美國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code: 2135

ANNUAL REPORT 2022

CONTENTS

COMPANY PROFILE

Raily Aesthetic Medicine International Holdings Limited (the "Company", together with its subsidiaries "the Group") is a leading aesthetic medical service provider in Zhejiang Province, the People's Republic of China (the "PRC"). We principally engage in the provision of a broad range of aesthetic medical services to our clients to meet their different aesthetic and anti-aging objectives. We own and operate a network of four private for-profit aesthetic medical institutions, three of which are located in Zhejiang Province (Hangzhou City and Ruian City, Wenzhou), and one is located in Anhui Province (Wuhu City). Our flagship institution, Hangzhou Raily Aesthetic Medical Hospital Co., Ltd. ("Hangzhou Raily") is one of the five aesthetic medical institutions in Hangzhou City that were awarded "5A" recognition by the Chinese Association of Plastics and Aesthetics ("CAPA"). Our aesthetic medical services principally include (i) aesthetic surgery services, comprising aesthetic surgical procedures performed on various parts of the face or body; (ii) minimally-invasive aesthetic services, primarily comprising aesthetic injection procedures, whereby a drug is mixed with or proportional to a drug or a certain drug of a single unit is injected into the skin to perform the function of beauty or perplexing; and (iii) aesthetic dermatology services, primarily comprising various aesthetic energy-based procedures and photoelectric items, which can improve the aspects of skin color, facial wrinkles, skin sagging and so on. At the same time, we also provide aesthetic medical management consulting services to third-party aesthetic medical institutions and physicians. We have initially entered into the sales network of our medical aesthetic equipment and products, focusing on the sales of surgical implants and medical aesthetic skincare products.

In addition, we also sell aesthetic medical equipment products. We have acquired the Shenzhen Jiumei Xinhe Medical Equipment Co., Ltd ("Jiumei Xinhe") which sells the Chuzhen facial implant, a brand of e-PTFE (expanded polytetrafluorethylene) facial implant from South Korea. Jiumei Xinhe is one of the three institutions which have been authorized by the PRC Medical Device Registration Department to import the e-PTFE (expanded polytetrafluorethylene) facial implant. Suzhou Yonglan Biotechnology Science and Technology Co., Ltd. ("Suzhou Yonglan"), a subsidiary of the Group, is building the productive capacity of the subcutaneous injection products, with a plant area of approximately 4,660 sq.m. It is located in the No. 7 Building, Phase I of Maidi Medical Equipment Industry Innovation Port, No. 26 Jinxing Road, Zhangjiagang, Suzhou and is expected to have the manufacturing capacity of product in 2024. We have cooperated with the technical team of well-known universities and colleges in China to jointly research and develop new subcutaneous injection products. We will continue to cooperate with well-known universities and colleges in China to build a research and development platform of aesthetic medical equipment products through joint planning, research and development and manufacturing. We will become an advanced and professional minimally-invasive aesthetic medical integration institution.

I. AESTHETIC MEDICAL SERVICE

1. AESTHETIC SURGERY SERVICES

Our aesthetic surgery services involve the provision of aesthetic surgical procedures to enhance the esthetic appearance of our clients. Aesthetic surgical procedures are invasive and are performed to alter the appearance of various parts of the face or body, such as eyes, nose, breast and facial shape and other parts of the body. Our main aesthetic surgical procedures include: eye surgery, improving the shape and appearance of the eyes or eyelids, and correcting eyelid deformities, e.g., double eyelid surgery, canthi correction, eye bag shaping and ptosis correction; rhinoplasty, changing the shape of the nose, and/or modifying the outer shape of the nose by implanting a prosthesis or cartilage extracted from other parts of the body; breast surgery, enlarging or reducing breasts, lifting sagging breasts or changing the shape of the breasts; lipoplasty/fat transfer, removing excess fat tissue from specific parts of the body which, at the request of clients, may or may not be further processed and then injected into other specific parts of the body; and linear shaping, implanting bio-protein lines under the skin at different parts of the body to promote skin blood circulation and to stimulate collagen proliferation to achieve the effects of lifting and firming of specific parts of the skin and sculpting body contours.

2. MINIMALLY-INVASIVE AESTHETIC SERVICES

Our minimally-invasive aesthetic services are the provision of minimally-invasive procedures involving minimal penetration into the body tissue with no surgical incisions and short recovery period. Such procedures primarily comprise injection of botulinum toxin type A and dermal fillers (such as hyaluronic acid and collagen, etc.) into different parts of the body and face in order to reduce wrinkles and/or to achieve body or facial contouring. Our main minimally-invasive aesthetic procedures include: injection of botulinum toxin type A, injection of botulinum toxin type a drugs to facial, subcutaneous or intramuscular layer in order to reduce wrinkles; and injection of dermal fillers, injection of dermal fillers to facial, subcutaneous or periosteal layer in order to reduce wrinkles, lift sagging skin and restore volume under the skin, with more natural effect.

3. AESTHETIC DERMATOLOGY SERVICES

Our aesthetic dermatology services primarily comprise energy-based procedures performed with equipment that utilize various forms of energy such as laser, radiofrequency and intense pulsed light for various purposes such as acne and pigments removal, skin rejuvenation, whitening, skin lifting and tightening, and hair removal to stimulate collagen regeneration. We strive to provide safe and high quality aesthetic dermatology services with our energy-based devises. All of our major energy-based devises have been approved by the NMPA for their safety and effectiveness. In addition, we have implemented a number of safety protocols in relation to the use of the equipment, such as evaluating and assessing by our practitioners before deployment, providing operating brochures for our staff and implementing maintenance by our suppliers from time to time.

4. OTHER SERVICES

We also provide other aesthetic medical services which primarily consist of aesthetic dental services. We provide aesthetic dental services in Hangzhou Raily, which focuses on improving the appearance of a person's teeth. Our services include orthodontics, dental implant and dental whitening. The provision of aesthetic dental services allows us to provide our client a full range of aesthetic medical services. These services also facilitate cross-selling of our aesthetic medical services which we believe can improve clients' experience and increase clients' retention. Our aesthetic dental services are provided by qualified dentists. Beside aesthetic dental services, we also provide ancillary services such as anesthesiology services, nursing services for inpatients and physical examination services, being some of the key stages in the process of our aesthetic medical services. Generally, we provide anesthesiology services for all of our aesthetic surgical procedures.

II. AESTHETIC MEDICAL MANAGEMENT CONSULTING SERVICES

Leveraging our years of experience in managing aesthetic medical institutions and expertise in sales and marketing of aesthetic medical services, we provide management consulting services to third-party aesthetic medical institutions, primarily in relation to their operations and management, sales and marketing, and consulting services to third-party physicians, primarily in relation to the establishment, sales and marketing of their professional qualifications and the operation and management of their aesthetic medical business.

III. SALES OF AESTHETIC MEDICAL EQUIPMENT PRODUCTS

We have entered the field of selling upstream medical equipment in the aesthetic medical industry and are gradually researching and developing and producing new products. We engage in the sales of Chuzhen facial implant, a brand of e-PTFE facial implant imported from South Korea, and other surgical implants and aesthetic medical skincare products.

Chuzhen e-PTFE (expanded polytetrafluoroethylene) facial implant is rich in fluorinated ethylene propylene (FEP), with greater strength and good support, is easy to sculpt, anti-deformation, and can be shaped into a perfect realistic nose. When the material needs to be taken out, it only needs to do "blunt peeling", and it can be taken out completely immediately, which is very convenient and will not cause damage. The histiocytes only grow into 1mm, and the material will not become hard after the Chuzhen product is used. The gap of the Chuzhen material is 60 microns, the porosity is larger, tissues and blood vessels are easier to invade and grow, and the Chunzhen material has the advantages of quick recovery, no displacement and better stability. Chuzhen e-PTFE facial implant is available in two hardness series with nearly 100 types of molded bulk and block sizes namely (i) Chuzhen reinforced type: the hardness is close to that of cartilage, and it is used for filling bony tissues such as nose bridge, chin, zygomatic, temporal or orbit. Its hand feel is realistic and natural; (ii) Chuzhen soft type: it feels like soft tissue, and is used for filling soft tissues such as forehead, nasolabial groove or deep wrinkles.

We have set up an aesthetic medical skincare products sales platform entitled "潤色護膚品集合店". Based on the principle of customer first and with the help of a team of senior skin experts, we have selected domestic and foreign aesthetic medical skincare products which are more effective, and have simpler and milder ingredients that can be used safely. This sales platform can meet the diverse skincare needs of the customers ranging from skincare for post aesthetic medical treatments or for daily skincare. Moreover, it has been authorized by many domestic and foreign brands. From product selection to user services, 潤色護膚品集合店 is dedicated to satisfy the needs of the customers. Customers are able to buy and collect our products at our shops or through online sales coupled with express post.

CORPORATE INFORMATION

BOARD OF DIRECTORS

Executive Directors

Mr. Fu Haishu *(Chairman)*
Mr. Song Jianliang *(Chief Executive Officer)*
Mr. Wang Ying

Non-executive Directors

Ms. Fan Qirui *(resigned on 19 September 2022)*

Independent Non-executive Directors

Mr. Cao Dequan
Mr. Liu Teng
Ms. Yang Xiaofen

AUTHORIZED REPRESENTATIVES

Mr. Fu Haishu
Mr. Chan Oi Fat

COMPANY SECRETARY

Mr. Chan Oi Fat

AUDIT COMMITTEE

Mr. Liu Teng *(Chairman)*
Mr. Cao Dequan
Ms. Yang Xiaofen

NOMINATION COMMITTEE

Mr. Fu Haishu *(Chairman)*
Mr. Cao Dequan
Ms. Yang Xiaofen

REMUNERATION COMMITTEE

Mr. Cao Dequan *(Chairman)*
Mr. Fu Haishu
Mr. Liu Teng

REGISTERED OFFICE IN THE CAYMAN ISLANDS

4th Floor, Harbour Place
103 South Church Street
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

3–5/F, Minhang Tower
No. 290 North Zhongshan Road
Gongshu District
Hangzhou City
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

17/F., Leighton Centre
77 Leighton Road
Causeway Bay
Hong Kong

AUDITORS

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

HONG KONG LEGAL ADVISER

TC & Co. Solicitors
Units 2201-3, 22/F
Tai Tung Building
8 Fleming Road
Wanchai, Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS

Harneys Fiduciary (Cayman) Limited
4th Floor, Harbour Place
103 South Church Street
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited
17/F., Far East Finance Centre
16 Harcourt Road
Hong Kong

PRINCIPAL BANKS

Bank of Jiangsu
Hangzhou Binjiang
Small and Micro-enterprise Sub-branch
Rooms 101–104, 201
1786 Binsheng Road
Binjiang District
Hangzhou City
PRC

China Merchants Bank
Hangzhou, Yuhang Sub-branch
1/F, Building 4
Chuangxin Time Plaza
84 Longyuan Road
Yuhang District
Hangzhou City
PRC

STOCK CODE

2135

INVESTOR RELATIONS

Email address:
investor.relationship@raily.com

COMPANY'S WEBSITE

http://www.raily.com

MILESTONES

Major events

01 In May 2022, the Group began to cooperate with well-known universities and colleges to conduct of aesthetic medical equipment product research, and to invest in the research and development of product

02 In June 2022, the Group formally established the Hainan Bellafill Medical Center in the Lecheng International Medical Tourism Pilot Zone, Boao Town, Qionghai City, Hainan Province

03 In October 2022, Hangzhou Raily completed a reconstruction and expansion and became a major aesthetic medical institution with a single store operating area of about 8,000 square meters in Hangzhou

04 In November 2022, Suzhou Yonglan completed a plant design, which was located in No. 7 Building, Phase I of Maidi Medical Equipment Industry Innovation Port, No. 26 Jinxing Road, Zhangjiagang, Suzhou

05 In December 2022, Hangzhou Raily was awarded the Advanced Unit with Grade A by the Association of Aesthetic Medical Industry of Zhejiang Province

06 In December 2022, Hangzhou Raily passed the initial evaluation of the 5A-level medical esthetic medicine hospital by the Association of Aesthetic Medical Industry of Zhejiang Province

CHAIRMAN'S STATEMENT

Dear Shareholders:

In the past five years, the aesthetic medical market in China has been developing rapidly. However, the growth of the industry began to slow down in 2019 due the adverse impact of the COVID-19 pandemic (the "Pandemic"). In 2022, the year of mass testing of the virus, the aesthetic medical market in China was badly hit by the Pandemic. Moreover, the aesthetic medical industry also experienced significant changes. Although the Pandemic has a negative impact on the aesthetic medical industry, with the relaxation of the national pandemic prevention measures, the PRC economy will recover and the consumption of aesthetic medical services will rebound. The aesthetic medical industry is highly resilient to industry recovery as it is in the emerging consumer track. With the gradual recovery of consumer sentiment and customer flow, coupled with the high retention and strong repurchase attributes of aesthetic medical services, the prospect of the aesthetic medical services in China is good. After being tormented by the Pandemic, the aesthetic medical industry will undoubtedly return to a balanced and rational development in 2023.

For the year ended 31 December 2022 (the "Year"), the Group has diversified its business. While actively developing its core business of providing aesthetic medical services, the Group has striven to expand into the upstream aesthetic medical industry, and has broaden the scope of aesthetic medical equipment products it offers. We have also co-operated with well-known universities and colleges in the development of new aesthetic medical equipment products and have set up a factory to manufacture aesthetic medical equipment products. With the help of the pioneer piloting policies adopted by the Hainan Boao Lecheng International Medical Tourism Pilot Zone, the introduction of overseas advanced medical technologies and products has strengthened our development in the aesthetic medical field.

BUSINESS REVIEW

For the year ended 31 December, 2022, our performance has declined due to the adverse impact of the Pandemic. We recorded a total revenue of approximately RMB164.5 million, representing a decrease of 12.7% when compared with the total revenue of RMB188.4 million in 2021. In 2022, the gross profit margin of the Group was approximately 40.6% (2021: 37.0%). Among them, the gross profit margin of the Dermatology Department was approximately 43.8% (2021: 47.6%). The net loss for the Year was approximately RMB20.2 million (2021: RMB18.3 million), and a net loss attributable to shareholders of the listed company was approximately RMB15.9 million (2021: RMB17.7 million). The decrease in the Group's revenue and the continuous loss were mainly due to (i) COVID-19 pandemic and changes in national prevention and control measures resulted in restrictions on the normal operation of medical institutions; (ii) the profit guarantee of Jiumei Xinhe failed to realise; (iii) the increase in investment in the research and development activities of Suzhou Yonglan; and (iv) the impairment of goodwill of Hangzhou Bellafill Aesthetic Medical Outpatient Department Co., Ltd.

BUSINESS PERFORMANCE

To provide our clients better aesthetic medical services, we set up a team of experienced physicians. This medical team is led by highly esteemed experts who have been rewarded financially by the State Council of the PRC. We also invite well-known plastic surgery experts in China to provide medical consultations to our clients in our hospitals periodically. We are committed to providing high-quality and personalized services to the beauty-loved clients relying on our advanced medical technology and high standard of medical safety and quality.

FUTURE OUTLOOK

As the social life gradually returns to normal, the aesthetic medical industry has also embraced its growth. The quality of aesthetic medical services will continue to improve, the penetration rate of the aesthetic medical industry will further increase, and the Group's revenue and profit are expected to grow in the future. There is huge room and potential for the growth of aesthetic medical consumption, especially non-surgical consumption. The growing market size and the surging demand for beauty, coupled with the continuous updating of aesthetic medical products and technologies, combined with the strong national policy orientation in China, only aesthetic medical brands with higher quality and value can achieve rapid development. The Group will continue to increase investment in non-surgical projects, actively introduce, research and develop and produce advanced technologies and products, and strengthen the Group's brand building and enhance its brand value.

The Group will adopt the following strategies by focusing on the current development status of the aesthetic medical industry and combining with future industry challenges and opportunities:

(i) Expand the network of aesthetic medical service institutions

At present, most of the renovation and expansion of the Hangzhou Raily flagship store and the construction of the Hainan Bellafill Medical Center will be completed soon. We will continue to select aesthetic medical institutions with excellent track record and good reputation, and acquire medical institutions with price advantages to expand the scope of our own aesthetic medical service system and the fashion brand of aesthetic medical chain.

We plan to continue to renovate and expand the operation area of the aesthetic dental service room to enhance our integrated service capability.

(ii) Increase investment in scientific research, cooperate in research and development and manufacture of new aesthetic medical equipment products

We have begun to cooperate with well-known universities and colleges in China and invested in the research and development of our first dermal injection product. In the future, the Group will continue to work with well-known universities and colleges in China to jointly plan, research and develop and manufacture, so as to build a research and development and manufacturing platform of aesthetic medical equipment products, which will enable the Group to increase revenue and control the cost of aesthetic medical equipment products.

(iii) Introduction of new technology and aesthetic medical service equipment to extend the spectrum of our services offered in our current aesthetic medical institutions

We plan to continue to introduce new technologies and invest in advanced equipment, especially aesthetic dermatology service equipment by following the facilitation of pioneer piloting policies of the Hainan Boao Lecheng International Medical Tourism Pilot Zone to extend the spectrum of our services offered in our current aesthetic medical institutions and achieve the goal of extending our production capacity.

(iv) Strengthen the construction of brand in an activity manner and improve service quality

The Group will strengthen product training, carry out academic activities, organize medical records sorting, build Raily College, and strengthen the cultural construction within the Group and external publicity. We will promote the Group's experts, technologies and products through short videos, and actively participate in public welfare organizations to carry out poverty alleviation and social emergency public welfare undertakings to enhance our brand influence.

Fu Haishu
Chairman

31 March 2023

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

Overview

We are a leading aesthetic medical service provider in the Yangtze River Delta region of the PRC. We offer our clients a broad range of aesthetic medical services which include aesthetic surgery services, minimally-invasive aesthetic services and aesthetic dermatology services. After over 15 years of development, our network of service institutions continues to expand. As of 31 December 2022, we own and operate a network of four private for-profit aesthetic medical service institutions in the PRC, while three of them are located in Zhejiang Province and one of them is located in Anhui Province. In addition, we provide aesthetic medical management consulting services and engage in sales of aesthetic medical equipment products. We have started to enter into the field of research and development and production of aesthetic medical biotechnology.

The pandemic in 2022 has the greatest adverse impact on our aesthetic medical institutions. The medical institutions of the Group have been unable to operate normally for a long time. With the relaxation of the national pandemic prevention measures, the management expects that PRC aesthetic medical industry will gradually recover in the coming years.

The following table sets forth the comparison of our revenue in 2021 and 2022:

	2022			2021		
	the first half RMB'000	**the second half RMB'000**	**Total RMB'000**	the first half RMB'000	the second half RMB'000	Total RMB'000
Aesthetic medical service	**87,773**	**63,888**	**151,661**	89,194	94,518	183,712
Aesthetic medical management consulting services	**27**	**–**	**27**	2,298	875	3,173
Sales of aesthetic medical equipment products	**6,597**	**6,237**	**12,834**	–	1,482	1,482
Total	**94,397**	**70,125**	**164,522**	91,492	96,875	188,367

For 2022, the Group's revenue was approximately RMB164.5 million, representing a decrease of 12.7% as compared with the income of approximately RMB188.4 million for the year of 2021. Our loss for the year attributable to owners of the parent and our loss for the year was approximately RMB15.9 million (2021: RMB17.7 million) and RMB20.2 million (2021: RMB18.3 million), respectively. Our basic and diluted loss per share attributable to ordinary equity holders of the parent was RMB0.76 cents (2021: RMB0.85 cents).

The decrease in revenue and the continuous loss were mainly attributable to: (a) in the last month of the Year, the business of medical institutions in Zhejiang and Anhui regions was badly affected by the widespread outbreak of the COVID-19 pandemic, resulting in the difficulty of the customers in visiting the Group's institutions, and the medical institution business of the Group had been suspended for nearly one month, which adversely affected the Company's results in the second half of the Year; (b) the non-fulfillment of the profit guarantee in respect of Jiumei Xinhe for the Year with a shortfall of approximately RMB4.9 million; (c) in order to accelerate the Group's research and development and production of new materials for medical devices, the Group increased its investment in the research and development activities of Suzhou Yonglan. For the year ended 31 December 2022, the research and development expenses, factory design expenses and research and development personnel's remuneration expenses of Suzhou Yonglan amounted to approximately RMB5.8 million. Such increase in expenses had not yet been recovered by the economic benefits to be derived therefrom during the Year; and (d) due to the adverse impact of the pandemic, the number of customers visiting Hangzhou Bellafill Aesthetic Medical Outpatient Department Co., Ltd.（杭州貝麗菲爾醫療美容門診部有限公司）("Hangzhou Bellafill", formerly known as "Hangzhou Raily Tiange Plastic Surgery Outpatient Department Co., Ltd.（杭州瑞麗天鴿整形外科門診部有限公司）") had decreased significantly during the Year. The management of the Group predicts that the future customer flow of Hangzhou Bellafill will not be fully restored. After careful consideration, the management of the Group made a decision on impairment of goodwill of Hangzhou Bellafill in the amount of approximately RMB6.4 million.

In 2022, under the ongoing adverse impact of the COVID-19 pandemic, we have incurred a significant loss. The number of active aesthetic medical clients also decreased from approximately 65,500 in 2021 to approximately 49,900 in 2022, representing a decrease of approximately 23.8%; among them, the number of new clients was approximately 18,400 (2021: 25,800), accounting for 36.9% (2021: 39.4%) of the total number of aesthetic medical clients in 2022. The proportion of new clients remained relatively stable. On the other hand, we have increased the marketing and promotion in non-surgical treatments with the advantages of fashion, speed, convenience, minimized risks, and shortest recovery period, which has improved the consumption level of clients. The average consumption per client was approximately RMB3,000, representing an increase of approximately 7.1% from the average consumption per client of approximately RMB2,800 in 2021. The increase in the average consumption has partially offset the adverse impact of loss of active clients on the revenue of the aesthetic medical services business segment for the Year.

In addition, we have gradually moved forward with the following development planning and strategic layout:

1. **Expand the scale of the Group's flagship stores in various cities, and introduce advanced technologies and updated equipment and products**

   With the change of consumption concept, the improvement of consumption ability and the increase in the proportion of low-age consumers, non-surgical items have won more consumers' favor and maintained rapid market growth. In order to meet customers' demand for new products and technologies, the Group has enhanced the capacity of its non-surgical aesthetic medial services through renovation and expansion and introduction of new equipment in the past 18 months, especially increased the investment in minimally-invasive aesthetic services and aesthetic dermatology services rooms.

The following table sets forth certain operating data of our aesthetic medical institutions before and after the renovation and expansion as of 31 December 2022:

		Before the renovation and expansion				After the renovation and expansion			
Aesthetic medical institution	Commencement date of operation	Approximate gross floor area (sq.m)	Number of minimally-invasive aesthetic services rooms (Room)	Number of aesthetic dermatology services rooms (Room)	Number of other services rooms (Room)	Approximate gross floor area (sq.m)	Number of minimally-invasive aesthetic services rooms (Room)	Number of aesthetic dermatology services rooms (Room)	Number of other services rooms (Room)
Hangzhou Raily	August 2013	2,800	5	13	4	7,800	23	32	21
Ruian Raily	March 2013	2,900	4	10	4	2,900	6	17	4
Hangzhou Bellafill	August 2008	1,000	2	5	3	1,000	3	10	5
Wuhu Raily	July 2015	1,400	2	6	3	2,900	8	18	10
	Total	8,100	13	34	14	14,600	40	77	40

2. Promoting new concept brands in aesthetic medical industry

In June this year, we have established the Hainan Bellafill Medical Center in the Boao Lecheng International Medical Tourism Pilot Zone of the Hainan Free Trade Port, which is expected to be approved by the National Health Commission in the first half of 2023 and then to obtain the approval for special filing application for imported medical devices. The Group has designated the second branch hospital in the Hangzhou region as the first benchmark hospital under the new brand name of Bellafill, and will introduce international leading products and technologies to customers, promote the development of non-surgical aesthetic medical consumption concept brands, and pave the way for connecting domestic and overseas advanced technologies, equipment, products and services.

3. Continuous application of digital management model

We will continue to use, transform and upgrade the digital medical service management systems, and adopt the comprehensive marketing model which integrates precision marketing, digital marketing and thematic marketing. Through the analysis of the consumer's historical data, i.e. the consumer's past behaviors, the number, types and time of receiving services to determine the preference of the consumers and to develop a corresponding marketing strategy.

4. Expand the market share of facial implant brand

We have acquired Jiumei Xinhe in the second half of 2021 and started to sell of aesthetic medical equipment products. Jiumei Xinhe's Chuzhen facial implant, a brand of e-PTFE (expanded polytetrafluorethylene) facial implant imported from South Korea, is the flagship product of the Group's aesthetic medical equipment products. We will continue to improve our sales network in order to increase our market share. Moreover, we will accelerate the introduction of more new products through registered import agency, in-house research and distributor service to further increase the market share of facial plastic surgery materials.

5. **Establish a R&D and manufacturing platform for advanced aesthetic medical equipment products**

During the Year, Suzhou Yonglan has relocated to a new site and has commenced the construction of an aesthetic medical equipment product factory. Moreover, it has jointly developed new skin injection products with the technical team of well-known universities in PRC. We will continue to plan, research and develop and manufacture jointly with well-known universities and colleges in PRC to build up a research and development and manufacturing platform for advanced aesthetic medical equipment products and to become a supplier of non-surgical aesthetic medical products in the upstream of the industry.

6. **Vigorously developing sales channels on e-Mall**

The Group is operating RunSe skin care product collection store, which is a professional platform of aesthetic medical skincare products and integrates domestic and foreign professional skincare brands. It will provide the customers with complete solutions for aesthetic medical post-surgery care and repair and daily skin maintenance by adopting a new skincare and consumption model of online sales, offline experience, skincare consultation, medical director guidance and professional after-sales. We will continue to expand the sales volume of the brand in this mall and to increase our marketing and promotion efforts to expand the customer flow of the Group.

The following is a summary of the consolidated statement of profit or loss and other comprehensive income:

	Year ended 31 December		
	2022	2021	Change
	RMB'000	RMB'000	%
Revenue	**164,522**	188,367	(12.7)
Gross profit	**66,783**	69,692	(4.2)
Loss before tax	**(22,101)**	(22,948)	(3.7)
Loss for the year	**(20,247)**	(18,266)	10.8
Attributable to:			
Owners of the parent	**(15,911)**	(17,691)	(10.1)
Non-controlling interests	**(4,336)**	(575)	654.1
	(20,247)	(18,266)	10.8

Note: The increase in loss for the year 2022 as compared to that for the year 2021 was mainly due to the fact that the share option expenses increased to approximately RMB3.8 million (2021: approximately RMB1.0 million) and the additional impairment of goodwill of approximately RMB6.4 million (2021: Nil). If the impact of the above two non-recurring items is excluded, the net loss for the year 2022 will be RMB10.0 million (2021: RMB17.3 million).

PRINCIPAL RISKS AND UNCERTAINTIES

– Medical liability insurance. In 2022, we did not maintain medical liability insurance for our aesthetic medical institutions or our physicians (who include employee physicians and contract physicians) and medical staff, and may be subject to liability claims arising from physicians and medical staff at our aesthetic medical institutions.

– Performance of our physicians and other medical staff. Our physicians' and medical staff's treatment performance, communication and relationship with our clients are vital to our business and results of operations.

– Brand recognition. We need to maintain and enhance the brand image for a long time. Our corporate development and continued growth depend substantially on our brand image, market reputation and consumer trust.

– Adverse impact of the COVID-19 pandemic. The continuation or recurrence of the COVID-19 pandemic may have a certain adverse impact on the normal operation of the Group and the consumption of consumer in medical institutions.

– The development of the cities where medical institutions are located. If the average spending power of the population in the cities where our medical institutions are located, namely Hangzhou City, Ruian City and Wuhu City, declines or the economic growth in these regions slow down, our operating results and profitability may be adversely affected. Changes in laws and regulations in these regions and the occurrence of any natural disasters, acts of God and epidemics may affect our operations and revenue.

– Research and Development (R&D) risk. The R&D and production of aesthetic medical equipment products that we initially engaged need the investment of a large amount of R&D fees and factory construction costs in the early stage. If the R&D of products fails, the investment in the early stage will not achieve the expected effect.

OUR CLIENTS

During the Year, all the aesthetic medical service clients were individual retail clients. Aesthetic medical institutions are clients for our aesthetic medical management consulting services whereas sales agencies and individual retail clients are customers of our aesthetic medical equipment products for sale.

The following table sets forth the approximate number of aesthetic medical procedures we provided, the approximate average spending per procedure, the approximate number of active clients and the approximate average spending per active client during the Year:

	Year ended 31 December	
	2022	2021
Aesthetic surgery services		
Number of procedures performed	**1,800**	2,900
Average spending per procedure[1] (RMB)	**5,700**	5,800
Number of active clients	**1,600**	2,900
Average spending per active client[2] (RMB)	**6,500**	5,900
Minimally-invasive aesthetic services		
Number of procedures performed	**42,800**	56,000
Average spending per procedure[1] (RMB)	**1,700**	1,400
Number of active clients	**15,700**	20,300
Average spending per active client[2] (RMB)	**4,700**	3,800
Aesthetic dermatology services		
Number of procedures performed[3]	**227,500**	462,100
Average spending per procedure[1] (RMB)	**300**	200
Number of active clients	**32,600**	42,000
Average spending per active client[2] (RMB)	**2,000**	1,900

Notes:

(1) We calculate the average spending per procedure by dividing the revenue of each type of aesthetic medical services by the relevant number of procedures performed during the Year.

(2) We calculate the average spending per active client by dividing the revenue of each type of aesthetic medical services by their relevant number of active clients during the Year.

(3) The number of procedures performed includes trial procedures, retouch procedures and procedures performed as promotional gifts.

OUR SUPPLIERS

During the Year, the supplies required in our operations primarily include implants, injection materials, pharmaceuticals, other medical consumables and aesthetic medical skincare products. Our five largest suppliers include suppliers of injection materials, implants and medical consumables. We have established good relationships with our five largest suppliers with an average term of over five years in 2022.

FINANCIAL REVIEW

Revenue

The following table sets forth our revenue by service offerings in 2022:

	Year ended 31 December				
	2022		2021		
	Revenue RMB'000	**% of total revenue %**	Revenue RMB'000	% of total revenue %	Change %
Aesthetic medical services	**151,661**	**92.2**	183,712	97.5	(17.4)
Aesthetic surgery services	**10,394**	**6.3**	16,934	9.0	(38.6)
Minimally-invasive aesthetic services	**73,860**	**44.9**	76,423	40.6	(3.4)
Aesthetic dermatology services	**63,692**	**38.7**	81,759	43.4	(22.1)
Others *(Note)*	**3,715**	**2.3**	8,596	4.5	(56.8)
Aesthetic medical management consulting services	**27**	**–**	3,173	1.7	(99.1)
Sales of aesthetic medical equipment products	**12,834**	**7.8**	1,482	0.8	766.0
	164,522	**100.0**	188,367	100.0	(12.7)

Note: Others primarily consist of aesthetic dental services and ancillary services such as anesthesiology services, nursing services for inpatients and physical examination services.

We generated revenue primarily from the provision of aesthetic medical services which principally include (i) aesthetic surgery services, which are invasive and are performed to alter the appearance of various parts of the face or body, such as eyes, nose, face and breast; (ii) minimally-invasive aesthetic services, which involve minimal penetration into the body tissue with no surgical incisions. Such procedures primarily comprise injection of botulinum toxin type A and dermal fillers into different parts of the body and face in order to reduce wrinkles and/or to achieve body and facial contouring; and (iii) aesthetic dermatology services, which primarily comprise aesthetic energy-based procedures performed with equipment that utilize various forms of energy such as laser, radiofrequency and intense pulsed light for various purposes such as acne and pigments removal, skin rejuvenation, skin lifting and tightening, and hair removal.

In 2022, our total revenue was approximately RMB164.5 million, representing a decrease of 12.7% from approximately RMB188.4 million in 2021. For the Year, our gross revenue from the aesthetic medical services and the sales of aesthetic medical equipment products was approximately RMB151.7 million and RMB12.8 million respectively, representing a decrease and an increase of 17.4% and 766.0% from approximately RMB183.7 million and RMB1.5 million of the gross revenue from aesthetic medical services and sales of aesthetic medical equipment products in 2021, respectively.

In 2022, our revenue from the minimally-invasive aesthetic services and the aesthetic dermatology services was approximately RMB73.9 million and RMB63.7 million respectively, representing a decrease of 3.4% and 22.1% from approximately RMB76.4 million and RMB81.8 million of the revenue from minimally-invasive aesthetic services and the aesthetic dermatology services in 2021, respectively. In 2022, our revenue from the aesthetic surgery services was approximately RMB10.4 million, representing a decrease of 38.6% from approximately RMB16.9 million of the revenue from the aesthetic surgery services in 2021. The decrease in revenue was primarily due to the fact that in the last month of the Year, the medical institutions business in Zhejiang and Anhui were affected by the large-scale outbreak of the COVID-19 pandemic, resulting in customers being unable to visit the Group's medical institutions, and the Group's medical institutions have been closed for nearly one month, which affected the Company's performance in the fourth quarter.

COST OF SALES

Our cost of sales mainly includes cost of supplies consumed and staff costs. In 2022, our cost of sales was approximately RMB97.7 million, representing a decrease of about 17.6% from approximately RMB118.7 million of the cost of sales in 2021.

Our cost of sales by nature is as follows:

	Year ended 31 December				
	2022		2021		Change
	RMB'000	**%**	RMB'000	%	%
Cost of supplies consumed	**55,018**	**56.3**	66,199	55.8	(16.9)
Cost of inventories sold	**2,008**	**2.1**	322	0.3	523.6
Staff costs	**28,056**	**28.7**	39,769	33.5	(29.5)
Others	**12,657**	**12.9**	12,385	10.4	2.2
	97,739	**100.0**	118,675	100.0	(17.6)

Cost of supplies consumed was the largest component of cost of sales in 2022, which included the cost of our medical consumables which mainly represents implants and auxiliary materials used in our aesthetic surgery services, hyaluronic acid used in our minimally-invasive aesthetic services, laser consumables and auxiliary materials and aesthetic medical equipment products used in our aesthetic dermatology services. Cost of inventories sold is the main cost of the new business of aesthetic medical equipment products sales.

Staff costs were the second largest component of our cost of sales in 2022, which mainly represent salaries and bonuses paid to our physicians and medical staff. All our aesthetic surgery services, minimally-invasive aesthetic services and aesthetic dermatology procedures are performed by qualified physicians with necessary clinical work experience in accordance with the relevant PRC laws and regulations.

Other cost of sales mainly includes rental, depreciation and travelling expenses.

GROSS PROFIT

In 2022, our gross profit amounted to approximately RMB66.8 million, representing a decrease of 4.2% from approximately RMB69.7 million of the gross profit in 2021. During the Year, our gross profit margin was approximately 40.6%, representing an increase of 3.6 percentage points from approximately 37.0% of the gross profit margin in 2021, which is mainly due to the significant increase in revenue from the sales of aesthetic medical equipment products.

The following table sets forth our gross profit and gross profit margin by service offered in 2022:

	Year ended 31 December					
	2022		2021			
	Gross profit RMB'000	**Gross profit margin %**	Gross profit RMB'000	Gross profit margin %	Change in gross profit %	Change in gross profit margin %
Aesthetic medical services	**56,933**	**37.5**	66,860	36.4	(14.8)	1.1
Aesthetic surgery services	**3,580**	**34.4**	3,803	22.5	(5.9)	11.9
Minimally-invasive aesthetic services	**29,490**	**39.9**	26,642	34.9	10.7	5.0
Aesthetic dermatology services	**27,904**	**43.8**	38,908	47.6	(28.3)	(3.8)
Others (Note)	**(4,041**	**(108.8)**	(2,493)	(29.0)	62.1	(79.8)
Aesthetic medical management consulting services	**(84)**	**(311.1)**	1,827	57.6	(104.6)	(368.7)
Sales of aesthetic medical equipment products	**9,934**	**77.4**	1,005	67.8	888.5	9.6
	66,783	**40.6**	69,692	37.0	(4.2)	3.6

Note: Others primarily consist of aesthetic dental services and ancillary services such as anesthesiology services, nursing services for inpatients and physical examination services.

In 2022, the total gross profit of the aesthetic medical services was approximately RMB56.9 million, representing a decrease of approximately 14.8% from RMB66.9 million of the total gross profit in 2021. In 2022, the gross profit of the sales business of aesthetic medical equipment products was approximately RMB9.9 million, representing an increase of approximately 888.5% from approximately RMB1.0 million of the gross profit of sales business of aesthetic medical equipment products.

OTHER INCOME AND GAINS

In 2022, our other income and gains amounted to approximately RMB8.1 million, representing an increase of approximately 200.0% from approximately RMB2.7 million in 2021. Such increase was mainly attributable to the increase in exchange gain and the decrease in contingent consideration.

SELLING AND DISTRIBUTION EXPENSES

Our selling and distribution expenses primarily comprised promotion and marketing expenses, and staff costs. In 2022, our selling and distribution expenses amounted to approximately RMB49.3 million, representing a decrease of approximately 9.6% from RMB54.5 million in 2021. The decrease of expenses was mainly due to the adverse impact of the pandemic in the last month of the Year, which led to the closure of aesthetic medical institutions, and the decrease in the corresponding promotion expenses and personnel expenses.

In 2022, our online advertisements were generally displayed in the forms of videos, advertorials, banners and live broadcast on websites and applications on e-commerce online platforms. In addition, we promoted our brand and services through out-of-home advertising channels, such as billboards.

ADMINISTRATIVE EXPENSES

In 2022, our administrative expenses amounted to approximately RMB35.9 million, representing an increase of approximately RMB1.2 million from RMB34.7 million in 2021, which remained relatively stable. Our administrative expenses primarily comprised professional fees, staff costs, rental related expenses, utility, depreciation expenses and other administrative office expenses.

FINANCE COSTS

In 2022, our finance cost amounted to approximately RMB2.8 million (2021: RMB2.4 million). Our finance costs primarily comprised interest on lease liabilities and interest on bank borrowings.

INCOME TAX CREDIT

Our income tax expenses/credit represented our total current income tax and deferred tax expenses/credit under the relevant PRC income tax policies and regulations. We recorded an income tax credit of approximately RMB1.9 million in 2022 (2021: RMB4.7 million), and our effective tax rate was approximately 8.4% (2021: 20.4%).

TOTAL COMPREHENSIVE LOSS FOR THE YEAR

We recorded a loss of approximately RMB20.2 million in 2022 (2021: RMB18.3 million). Among them, two non-recurring items of the impairment of goodwill and share option expense in total in 2022 amounted to approximately RMB10.2 million (2021: RMB1.0 million). Save for these factors, the adjusted net loss in 2022 were approximately RMB10.0 million (2021: RMB17.3 million).

LIQUIDITY AND CAPITAL RESOURCES

Our cash and bank balance and time deposits amounted to approximately RMB78.8 million as at 31 December 2022 (31 December 2021: RMB121.7 million). The decrease was mainly attributable to the increase in decoration expenses for the expanded area of aesthetic medical institutions, the decrease in bank loans and the increase in investment in Suzhou Yonglan. Our net current assets were approximately RMB36.1 million as at 31 December 2022 (31 December 2021: RMB35.7 million). Taking into account the financial resources available to the Group, including cash and cash equivalents on hand, cash generated from operations and available facilities of the Group, and the net proceeds from the issuance of ordinary shares relating to the initial public offering, and after diligent and careful investigation, the Directors are of the view that the Group has sufficient working capital required for the Group's operations at present. As at 31 December 2022, our Group has unutilised banking facilities of approximately RMB10.0 million (31 December 2021: RMB20.0 million) for working capital purposes.

LEASE LIABILITIES

As at 31 December 2022, the Group had lease liabilities of approximately RMB43.2 million (31 December 2021: RMB47.5 million).

COMMITMENTS

As at 31 December 2022, the Group's contracted, but not provided for commitments amounting to approximately RMB1.1 million, mainly for leasehold improvements, plant and machinery (31 December 2021: RMB4.7 million).

CAPITAL EXPENDITURES

During the Year, the Group purchased long-term asset amounting to approximately RMB18.9 million (2021: RMB45.8 million).

* *For identification purposes only*

INDEBTEDNESS

Interest-bearing Bank Borrowings

As at 31 December 2022, our Group had approximately RMB5.0 million outstanding interest-bearing bank borrowings (31 December 2021: RMB20.0 million), of which RMB5.0 million are at fixed interest rates (31 December 2021: RMB20.0 million).

As at 31 December 2021 and 2022, all the bank borrowings are repayable within one year and there was no other borrowing as at 31 December 2021 and 2022. All the borrowings are denominated in RMB.

Contingent Liabilities and Guarantees

As at 31 December 2022, our Group had no significant contingent liabilities and guarantees (31 December 2021: Nil).

PLEDGE OF ASSETS

As at 31 December 2022, the lease arrangements were secured by the Group's pledged deposits of RMB1.5 million (31 December 2021: bank loans and lease arrangements secured by the Group's pledged deposits of RMB10.5 million and RMB1.5 million respectively).

GEARING RATIO

Gearing ratio is calculated by dividing total liabilities by total equity as at 31 December 2022 and multiplying the result by 100%. As at 31 December 2022, the Group had total debt of approximately RMB136.8 million (31 December 2021: RMB162.4 million) and the gearing ratio is about 82.5% (31 December 2021: 89.0%).

INTEREST RATE RISK

The Group has no significant interest rate risk.

EXCHANGE RATE FLUCTUATION RISK

As we have deposited with licensed banks certain financial assets that are denominated in Hong Kong dollars, we may be exposed to the risk of exchange rate fluctuations between Hong Kong dollars and Renminbi. The Group currently does not have a foreign currency hedging policy. However, the management will monitor foreign exchange exposure closely and will consider to adopt a proactive but prudent approach to minimize the relevant exposure when necessary.

Treasury Policies

The Group adopts a prudent approach towards its treasury policies. The Group strives to reduce exposure to credit risk by performing ongoing credit evaluations of the financial conditions of its customers. To manage liquidity risk, the Board closely monitors the Group's liquidity position to ensure that the liquidity structure of the Group's assets, liabilities and commitments can meet its funding requirements.

SIGNIFICANT INVESTMENTS AND MATERIAL ACQUISITION AND DISPOSAL OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

Saved as disclosed in this report, the Group did not have any significant investments, material acquisitions and disposals of subsidiaries, associates or joint ventures during the Year.

PROFIT GUARANTEE

Reference is made to the discloseable and share transaction announcement of the Company dated 20 August 2021 in relation to the acquisition of 90% equity interest in Jiumei Xinhe (the "**Announcement**") and the supplemental announcement of the Company dated 25 August 2021 in relation to the same matter. Unless otherwise specified, all capitalised terms used herein shall have the same meanings as those defined in the Announcement.

Requirements of the Profit Guarantee

As disclosed in the Announcement, the Vendors had offered guarantees to the Purchaser that the Actual Net Profit of Jiumei Xinhe for each of the years ending 31 December 2022, 2023 and 2024 shall not be less than the following Guaranteed Net Profit:

Relevant Period(s)	Guaranteed Net Profit (RMB) for the Relevant Period(s)
1st Relevant Period	8,000,000
2nd Relevant Period	11,000,000
3rd Relevant Period	14,500,000
The Relevant Periods	33,500,000

If the Actual Net Profit for each of the Relevant Periods is lower than the Guaranteed Net Profit for that Relevant Period, the Consideration will be adjusted in accordance with the following formula (the "**Adjustment Mechanism**"):

$$\frac{\text{Actual Net Profit for the Relevant Period}}{\text{Guaranteed Net Profit for the Relevant Period}} \times \text{Consideration payable for the Relevant Period}$$

Financial performance of Jiumei Xinhe

Based on the audited financial statements of Jiumei Xinhe for the year ending 31 December 2022, the Actual Net Profit of Jiumei Xinhe for the year ending 31 December 2022 is less than the Guaranteed Net Profit for the 1st Relevant Period of approximately RMB4.9 million (the "Shortfall").

Reasons for the Shortfall

The Board has communicated with the Vendors and understands that the Vendors breach of the Profit Guarantee was primarily attributable to the COVID-19 pandemic which has adversely impacted the PRC economy. In particular, under the pandemic, Jiumei Xinhe faced difficulties in meeting the Profit Guarantee for 2022 due to the following reasons:

(a) the continual threat and resurgence of the COVID-19 pandemic and the resulting preventive measures (such as lockdowns, quarantines and travel restrictions) imposed in the PRC during 2022 had led to material impediments to the sales activities of Jiumei Xinhe, such as delays in product delivery and difficulties for sales personnel to meet and follow up with sales leads with a view to securing new orders; and

(b) as the majority of Jiumei Xinhe's customers are located in the PRC, the aforesaid preventive measures in the PRC which may have the same adverse impact on the business of these customers (including aesthetic medical institutions) has also affected the demand for and thus sales of the products provided by Jiumei Xinhe.

Supplemental agreement in relation to extension of Profit Guarantee period

Given that the reasons for the Shortfall are mainly attributable to the extraordinary and unexpected circumstances caused by the COVID-19 pandemic which are beyond the control of the Vendors, and in view of the business prospect of Jiumei Xinhe in light of the gradual relaxation of restrictive COVID-19 measures, the Group and the Vendors (who have remained in the core management team of Jiumei Xinhe) have agreed that Jiumei Xinhe may fulfill the outstanding Profit Guarantee requirement within a period of three months and the Board is of the view that there is no material adverse impact on the Group arising from the extension of the Profit Guarantee period for three months. Accordingly, the Company and the Vendors have entered into an agreement supplemental to the SP Agreement (the "**Supplemental Agreement**") on 10 March 2023 to extend the Profit Guarantee period (the "**Extension**"):

	Original period under the SP Agreement	Extended period under the Supplemental Agreement
1st Relevant Period	1/1/2022 to 31/12/2022	1/1/2022 to 31/3/2023
2nd Relevant Period	1/1/2023 to 31/12/2023	1/4/2023 to 31/3/2024
3rd Relevant Period	1/1/2024 to 31/12/2024	1/4/2024 to 31/3/2025
The Relevant Periods	1/1/2022 to 31/12/2024	1/1/2022 to 31/3/2025

The payment schedule of Post-Completion Considerations will therefore be deferred accordingly and thus no adjustment thereof in accordance with the Adjustment Mechanism has yet been made.

In the event the Actual Net Profit of Jiumei Xinhe for any of the extended Relevant Periods still fails to meet the Guaranteed Net Profit for that extended Relevant Period, the relevant Post-Completion Consideration may be adjusted in accordance with the Adjustment Mechanism.

Reasons for the Extension

Considering (i) that the reasons for the Shortfall are mainly attributable to the extraordinary and unexpected circumstances caused by the COVID-19 pandemic which are beyond the control of the Vendors; (ii) the business prospect of Jiumei Xinhe in light of the gradual relaxation of restrictive COVID-19 measures; (iii) that the Extension can serve as an incentive for the Vendors, who have remained in the core management team of Jiumei Xinhe, to commit more time and effort to improving the performance of Jiumei Xinhe; (iv) the relatively short period of extension of three months which will not materially affect the business development of the Group's aesthetic medical equipment product sales; and (v) that the obligation of the Group to pay the Post-Completion Considerations will also be deferred accordingly and still subject to fulfillment of the same amount of guaranteed profit and the Adjustment Mechanism, the Board considers that the Extension and the decision not to exercise the Adjustment Mechanism for the time being are fair and reasonable and in the interests of the Company and the shareholders of the Company as a whole. The Board will continue to review the performance of Jiumei Xinhe and take appropriate actions as and when necessary.

For details, please refer to the Company's announcements dated 20 August 2021, 25 August 2021 and 10 March 2023.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this report and in the prospectus of the Company dated 15 December 2020 (the "**Prospectus**"), the Group did not have plans for making material investments or acquiring capital assets as at 31 December 2022.

EMPLOYEES AND REMUNERATION POLICIES

As at 31 December 2022, we had 322 employees in the PRC.

Function	Number of Employees
Management	7
Physicians and medical staff	131
Sales, marketing, client service and other business staff	153
Finance and administration staff	31
Total	322

During the Year, our staff costs amounted to approximately RMB60.0 million, the share option expenses amounted to approximately RMB3.8 million, and the total staff costs amounted to approximately RMB63.8 million, representing a decrease of RMB12.5 million as compared to the total staff costs of approximately RMB76.3 million in 2021, accounting for approximately 38.8% of the total revenue in 2022 (2021: 40.5%).

We believe that we provide our physicians and medical staff with competitive compensation packages, continued medical education opportunities and a professional work environment. We review the performance of our physicians and medical staff at least once a year. According to our internal control policy, the results of such reviews will later be taken into consideration in the determination of salary, bonus awards and promotion. The Human Resource Department at our headquarters maintains the license records of our physicians and medical staff and regularly reviews their profile to ensure compliance with relevant laws and regulations in the PRC. Our Directors' remuneration will be reviewed by our Remuneration Committee once a year to ensure that it is comparable to the market.

Remuneration of our employees is determined based on factors such as comparable market salaries, work performance, time investment and the individual responsibilities. The Company provides employees with relevant internal and/or external training from time to time. In addition to basic salaries, the Company also provides year-end bonuses to outstanding employees in order to attract and retain qualified employees, so that they can contribute to the Group.

The employees of the Group in PRC are required to participate in a central pension scheme operated by local municipal government. The Group is required to contribute a certain percentage of their payroll costs to the central pension scheme. The contributions vest fully once made and are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme.

During the year ended 31 December 2022, there were no forfeited contributions (by the Group on behalf of employees who leave the pension scheme prior to vesting fully in such contributions) which has been utilised by the Group to reduce the existing level of contributions. At 31 December 2022, there were no forfeited contributions available to reduce the level of contributions to the pension schemes in future years.

USE OF PROCEEDS

The Company was successfully listed on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 28 December 2020 (the "**Listing**"). The net proceeds from the Global Offering including exercise of over-allotment options were approximately HK$81.7 million (the "**Net Proceeds**"), which was based on the issuing price of HK$0.4 per share and the actual expenses related to the Listing. As at the date of this report, there was no change in the intended use of Net Proceeds as previously disclosed in the section headed "Future Plans and Use of Proceeds" in the Prospectus. However, the net proceeds planned to be used for renovation and expansion of our aesthetic medical institutions and promotion of our brands have been utilised in advance by HK$5.7 million and HK$1.6 million, respectively.

The following table sets forth a summary of the utilization of the Net Proceeds as at 31 December 2022:

Purpose	Percentage to total amount	Planned use of net proceeds HK$'million	Actual use of proceeds up to 31 December 2022 HK$'million	Unutilised amount as at 31 December 2022 HK$'million	Expected timeline of full utilisation of the remaining proceeds
Expanding our aesthetic medical institutions network	**71.0%**	**58.0**	**24.5**	**33.5**	**31 December 2023**
– Renovation and expansion of existing aesthetic medical institutions	28.0%	22.9	22.9	–	31 December 2023
– Organic growth	28.0%	22.9	1.6	21.3	31 December 2023
– Strategic acquisitions	15.0%	12.2	–	12.2	31 December 2023
Acquire new aesthetic medical service equipment and treatment consumables to extend the spectrum of our treatment services offered in our current aesthetic medical institutions	**11.0%**	**9.0**	**9.0**	**–**	**31 December 2023**
Actively promote our brand	**8.0%**	**6.5**	**6.5**	**–**	**31 December 2023**
General working capital	**10.0%**	**8.2**	**4.7**	**3.5**	**31 December 2023**
Total	**100.0%**	**81.7**	**44.7**	**37.0**	

SUBSEQUENT EVENTS

On 10 January 2023, the Group entered into a legally binding letter of intent (the "LOI") with Hangzhou Tianxin Aesthetic Medical Hospital Co., Ltd.* (杭州天鑫醫療美容醫院有限公司) (the "Target Company") and the shareholders of the Target Company. Pursuant to the LOI, the Group conditionally agreed to subscribe for an equity interest in the Target Company of up to 9.0% of the registered capital of the Target Company, at the consideration of up to RMB25.0 million. As at the date of this report, a refundable earnest money of RMB20.0 million was paid to the Target Company.

For details, please refer to the Company's announcements dated 10 January 2023 and 18 January 2023.

PROSPECTS

With the relaxation of the national epidemic prevention measures and the growth of the social economy, the aesthetic medical industry in China will go through the trough, and the market will start to show a rebound trend. Aesthetic medical consumption is characterized by high viscosity and a large room for development in the industry.

Driven by the strengthened regulation of aesthetic medical policies, the advancement of science and technology and the change of consumption concept, the aesthetic medical industry in China has entered a new stage of compliance development, especially non-surgical aesthetic medical projects. The aesthetic medical brand with higher quality value can transform the trust of beauty seekers into consumption behavior more efficiently. We will continue to build our brand value, attach importance to medical safety and quality, and increase investment in non-surgical aesthetic medical service products and technologies.

While accelerating the expansion of the Chinese aesthetic medical industry, the space for the demand side is increasing, and the market share of upstream products is also increasing. The sales revenue of our aesthetic medical equipment products maintains a steady growth. The Group plans to expand its product portfolio and to increase its market share through domestic and overseas mergers and acquisitions and product agency.

Since 2021, the Group has started to expand into the field of upstream medical equipment and materials, actively optimized business models and explored new businesses. In the future, in addition to developing the traditional aesthetic medical business, we will gradually develop into an integrated minimally-invasive aesthetic medical center with self-developed and manufactured products and international advanced technologies, and become a professional minimally-invasive aesthetic medical institution to provide customers with diversified, high-quality and efficient aesthetic medical solutions.

CORPORATE CULTURE, VALUE AND STRATEGY

The Group has clear business cultures and corporate values to maintain high standards of business ethics and corporate governance and to act lawfully, ethically and responsibly. Integrity is the guiding principle for the Group's employees to behave and act without compromising its stringent standards. In addition, the Group treasures and practices the vision of commitment to workforce development, workplace safety and health, diversity, and sustainability, which serves to attract, develop and retain talents and bring about quality services. Through these, the Group strives to achieve long-term, steady and sustainable growth, while having due considerations from environmental, social and governance aspects. The Group's culture also aligns with its strategy and forms one of its strategic focuses. Adequate training in relation to the above will be provided to new employees, and regular update training will be provided to existing employees.

Meanwhile, it is the Group's rigorous and ongoing strategic planning process to identify short-term and long-term opportunities and challenges which the Group may face and to deliver due and timely responses in order to generate sustainable value for shareholders.

Ongoing management efforts will continue to be made to achieve the above and to assess the effectiveness of and level of compliance with the Group's corporate cultures, principles and values by, for instance, evaluating the impact of the same on the business developments of the Group and monitoring the status of employees' compliance with applicable laws, regulations and internal policies. The management of the Company will measure the success of the implementation of corporate cultures, principles and values based on various factors, including the number of non-compliance incidents of employees and the overall improvement of business performance. The Group also provides whistle-blowing channels for all stakeholders of the Group to share concerns on any misconduct or non-compliance with applicable laws, regulations and internal policies, upon receipt of which the Group will conduct investigation and take remedial measures, if needed, in a timely manner.

As an incentive to support the implementation of the Group's cultures, principles and values, the Group encourages its employees to act with integrity and strictly follow its standards and internal policies, and will specifically consider an employee's compliance record and performance in this regard when considering his/her promotion and salary adjustment.

DIVIDEND

The Board resolved not to declare any final dividend for 2022 (2021: Nil).

INVESTOR RELATIONS AND FINANCIAL JOURNALS

We highly support our investor relations activities. We have appointed a professional investor relations team to be responsible for investor relations affairs, to establish a communication bridge between the Company and investors, and to ensure that shareholders, investors, financial media and potential investors can maintain stable and smooth communications. We attach great importance to the opinions and feedback of investors on the Company, which helps us to better formulate the Company's development strategies to enhance shareholders' value.

In 2022, due to the inability to visit Hong Kong caused by the continuation of the pandemic, we organized an online public offering roadshow through the arrangement by the investor relations team, so that investors can have a deep and accurate understanding to the Company's business and ensure that the Company's shareholders have access to us the latest information. With the development of our business, we will continue to update and improve the investor relations system and strive to maintain a high level of investor relations.

Investors can access to the Company's website (http://www.raily.com) to obtain the Company's latest developments, or communicate with us via email investor.relationship@raily.com.

INFORMATION ABOUT SHARES

Company name	Raily Aesthetic Medicine International Holdings Limited （瑞麗醫美國際控股有限公司）
Place of listing	Main Board of The Stock Exchange of Hong Kong Limited
Stock code	2135.HK
Listing date	28 December 2020
Whole board lot	10,000 shares
Number of issued shares	2,089,040,000 shares

FINANCIAL JOURNALS

The last day of the transfer of registration for 2023 annual general meeting	12 June 2023
Closure of register of members for 2023 annual general meeting	13 to 16 June 2023 (both days inclusive)
2023 annual general meeting	16 June 2023

BIOGRAPHIES OF DIRECTORS AND SENIOR MANAGEMENT

EXECUTIVE DIRECTORS

Mr. Fu Haishu (傅海曙), aged 49, is the founder of our Group, Executive Director and Chairman. Mr. Fu is also the chairman of the nomination committee of the Board (the "Nomination Committee") and a member of the remuneration committee of the Board (the "Remuneration Committee"). Mr. Fu is responsible for the overall management, decision-making and strategic planning of our Group. He was appointed as our Director on 2 January 2018 and redesignated as our Executive Director and Chairman on 30 May 2019. Mr. Fu is currently a director of Hangzhou Raily Beauty Consultation Co., Ltd. ("Raily Beauty Consultation"), Wuhu Raily Aesthetic Medical Out-patient Department Co., Ltd. ("Wuhu Raily"), Ningbo Zhuerli Beauty Consulting Service Co., Ltd. ("Ningbo Zhuerli"), Wuhu Raily Medical Equipment Trading Co., Ltd. ("Raily Equipment"), Suzhou Yonglan, Jiumei Xinhe and Shenzhen Ruiquan Management Consulting Co., Ltd. ("Shenzhen Ruiquan").

Mr. Fu graduated from the Shanghai Medical College (上海醫科大學) (currently known as Shanghai Medical College of Fudan University (復旦大學上海醫學院)) major in Clinical Medicine in July 1999.

Being the founder of our Group, Mr. Fu has more than 14 years of experience in the aesthetic medical industry. Prior to founding our Group, he had served as a surgeon in Ruian Red Cross Hospital (瑞安市紅十字醫院) from December 1996 to December 2007.

Mr. Fu became a member of the First Minimally Invasive and Anti-ageing Expert Committee of the Beauty and Plastic Surgeons Branch of the Chinese Medical Doctor Association (中國醫師協會美容與整形醫師分會) in July 2007. He was a special member of the 6th and 7th editorial board of the Chinese Journal of Aesthetic and Plastic Surgery (中國美容整形外科雜誌) from May 2009 to August 2016. He became the managing director of the Translational Medicine Association of Zhejiang (浙江省轉化醫學學會) from April 2015 to June 2018. He was appointed as the chairman of the Financial Investment Branch of the CAPA in September 2016 and was appointed as the managing director of the Standing Council of the CAPA in October 2016. Since November 2017, he was appointed as the deputy director of the Brand Construction and Hospital Operation Management Subcommittee (品牌建設與醫院運營管理分委會) of the Plastics and Aesthetics Professional Committee (整形與美容專業委員會) of the Association of China Non-Public Medical Institutions (中國非公立醫療機構協會). As at 31 May 2021, he was appointed as the supervisor of Board of the Chinese Association of Plastic and Aesthetics (中國整形美容協會).

Mr. Song Jianliang (宋建良), aged 68, is the Chief Executive Officer of the Company, Executive Director and the Dean of our four aesthetic medical institutions. Mr. Song is responsible for assisting in the overall management and strategic planning of our Group as well as managing our four aesthetic medical institutions. He was appointed as our Executive Director on 30 May 2019. He is currently a supervisor of Raily Beauty Consultation, Hangzhou Raily and the Dean of our four aesthetic medical institutions.

Mr. Song obtained his Bachelor's Degree in Medicine from the Suzhou Medical College (蘇州醫學院) (currently known as the Medical College of Soochow University (蘇州大學醫學部)) in January 1978.

Mr. Song has over 36 years of experience in aesthetic medical clinical work and hospital management. Prior to joining our Group, he had served as a combat medic in the Wuhan Military Region General Hospital (武漢軍區總醫院) (currently known as the People's Liberation Army Central Military Region General Hospital (中國人民解放軍中部戰區總醫院)) from January 1985. He then worked at the Hangzhou Plastic Surgery Hospital (杭州整形醫院) from January 1987 to September 2005 with his last position being the Dean of the hospital, where he was responsible for its overall management. He joined our Group in January 2008 and has been working as the Dean of our four aesthetic medical institutions.

Mr. Song was awarded the title of Outstanding Young and Middle-aged Science and Technology Worker of Zhejiang Province (浙江省醫學傑出中青年科技人員) in June 1995, and 1995–1996 Outstanding Contribution Science and Technology Worker of Hangzhou (杭州市有突出貢獻的優秀科技工作者). He received special allowance from the State Council of PRC in December 1998 in reward for his contribution to the healthcare industry. He was appointed as a member of the Hand Surgery Subcommittee of the Chinese Medical Association (中華醫學會手外科分會) in October 1997 and May 2000, respectively. He was also appointed as a member of the Aesthetics Medical and Cosmetology Subcommittee of the Chinese Medical Association (中華醫學會) in September 2000. In addition, he was a member of the Reparative and Reconstructive Surgery Committee of the Chinese Association of Rehabilitation Medicine (中國康復醫學會) from October 1996 to September 2000 and from May 2004 to April 2008, respectively. He was appointed as the vice-chairperson of the Plastic Surgery Subcommittee of the Zhejiang Medical Association in July 2000. He was also appointed as the vice chairperson of the Aesthetics Medical and Cosmetology Subcommittee of Zhejiang Medical Association in August 2009, Anti-aging Subcommittee of CAPA in October 2014, and Aesthetics and Plastics Medical Doctors Subcommittee of the ZAPA in June 2014, respectively. He was appointed as the managing director of the first council of the ZAPA in May 2017, the vice president of the first council of Rhinoplasty Subcommittee of the ZAPA in April 2018, and the vice president of the first council of the ZAPA in September 2018, respectively. He became a member of the first session of the Standardization Committee of the CAPA in September 2019. He was also appointed as the vice president of the second committee of the Aesthetics and Plastics Medical Doctors Subcommittee of the Zhejiang Medical Doctors Association in October 2019. He was appointed as the vice president of the Anti-aging Subcommittee of CAPA in April 2021. He was also awarded as the Advanced Individual of the ZAPA in December 2021.

Mr. Wang Ying（王瀛）, aged 46, was appointed as our Executive Director on 28 December 2021. He joined the Group in October 2008 and had over 14 years of experiences in the aesthetic medical industry. From October 2008 to March 2015, Mr. Wang was an executive manager of Hangzhou Bellafill Aesthetic Medical Outpatient Department Co., Ltd. (formerly "Hangzhou Raily Tiange Plastic Surgery Outpatient Department Co., Ltd. ") ("Hangzhou Bellafill")（杭州貝麗菲爾醫療美容門診部有限公司, formerly 杭州瑞麗天鴿整形外科門診部有限公司）, during which he was responsible for overseeing the construction of Hangzhou Raily Aesthetic Medical Hospital*（杭州瑞麗醫療美容醫院）between October 2012 and October 2013. From April 2015 to July 2019, Mr. Wang was the general manager and executive manager of Ruian Raily Aesthetic Medical Outpatient Department Co., Ltd. (formerly "Ruian Raily Aesthetic Medical Hospital Co., Ltd.") ("Ruian Raily")（瑞安瑞麗醫療美容門診部有限公司, formerly 瑞安瑞麗醫療美容醫院有限公司）. Mr. Wang then worked as the general manager of Hangzhou Desi Medical Technology Co., Ltd*（杭州德斯醫療科技有限公司）and Hangzhou Feihong Investment Management Co., Ltd.*（杭州妃弘投資管理有限公司）between August 2019 and October 2019 and between November 2019 and June 2020, respectively. From July 2020 to December 2020, he was appointed as a manager of Hangzhou Lingmao Cloud Technology Co., Ltd.*（杭州靈貓雲科技有限公司）. From January 2021, he acts as the general manager of the Business Development Department of Raily Beauty Consultation, our wholly owned subsidiary. Mr. Wang also holds several positions within our Group, including (a) general manager and legal representative of Jiumei Xinhe; (b) executive director, general manager and legal representative of Hangzhou Raily, Hangzhou Bellafill, Ruian Raily and Hainan Bellafill Medical Center Co., Ltd. （海南貝麗菲爾醫學中心有限公司）respectively; and (c) director of Biotrisse.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Cao Dequan（曹德全）, aged 46, was appointed as our Independent Non-executive Director on 4 December 2020. Mr. Cao is also the chairman of the Remuneration Committee and a member of each of the audit committee of the Board (the "Audit Committee") and Nomination Committee. Mr. Cao is responsible for supervising and providing independent advice to our Board.

Mr. Cao obtained a Bachelor's Degree of Health Management from the Anhui Medical University in July 2001. He then obtained a Master of Public Health from Chinese Centre for Disease Control and Prevention（中國疾病預防控制中心） in July 2008. He completed the Public Health Leadership Professional Development Program offered by the Griffith University in June 2010.

Mr. Cao has over 13 years of experience in the aesthetic medical industry. He worked as an assistant researcher in Chinese Centre for Disease Control and Prevention（中國疾病預防控制中心）from May 2003. From September 2009 to August 2014, Mr. Cao became the director of the office of the Chinese Association of Plastic and Aesthetics（中國整形美容協會）. He was then appointed as a full-time deputy secretary general of the association in January 2015 and the executive deputy secretary general of the association in May 2021.

Mr. Liu Teng（劉騰）, aged 53, was appointed as our Independent Non-executive Director on 4 December 2020. Mr. Liu is also the chairman of the Audit Committee and a member of Remuneration Committee. He is primarily responsible for supervising and providing independent advice to our Board.

* *For identification purposes only*

Mr. Liu obtained a Master of Arts in Professional Accounting and Information Systems from the City University of Hong Kong in November 2004. He was admitted as a member of the Association of Chartered Certified Accountants in October 2006, and became a certified public accountant of the Hong Kong Institute of Certified Public Accountants in February 2007.

Mr. Liu has extensive experience in financial management and investment banking. He worked in Taikang Asset Management (Hong Kong) Company Limited as executive director from August 2008 to October 2010. He then worked as an executive general manager in China Orient International Asset Management Limited from February 2012 to March 2015. From October 2015 to September 2018, he worked in China Universal Asset Management (Hong Kong) Company Limited as a deputy chief executive officer. He is currently the chairman of China Eagle Asset Management Co., Ltd.

Mr. Liu is currently an independent non-executive director of Beauty Farm Medical and Health Industry Inc. (stock code: 2373), the shares of which are listed on the Main Board of the Stock Exchange.

Ms. Yang Xiaofen（楊小芬）, aged 45, was appointed as our Independent Non-executive Director on 4 December 2020. Ms. Yang is also a member of each of the Audit Committee and Nomination Committee. She is responsible for supervising and providing independent advice to our Board.

Ms. Yang obtained a Master of Law from the Tongji University in June 2013. Ms. Yang has over 16 years of experience in the PRC legal industry. She worked in Zhe Jiang Zhehang Law Firm（浙江浙杭律師事務所）from August 2006 to August 2014 with her last position held as a lawyer. She then worked as a lawyer in Zhejiang Dingya Law Firm（浙江鼎亞律師事務所）from August 2014 to March 2018. Since March 2018, she has been a lawyer and the executive head of Zhejiang Zhong Xin Da Law Firm（浙江眾信達律師事務所）.

SENIOR MANAGEMENT

Our senior management is responsible for the day-to-day management and operation of our business. The following table sets forth certain information on our senior management members.

Name	Age	Position(s)	Roles and responsibilities	Date of joining our Group	Relationship with other Directors and senior management
Mr. Fu Haishu（傅海曙）	49	Chairman and Executive Director	Overall management, decision-making and strategic planning	7 August 2008	N/A
Mr. Song Jianliang（宋建良）	68	Chief Executive Officer, Executive Director and Dean of our four aesthetic medical institutions	Assist in overall management, strategic planning and managing our four aesthetic medical institutions	1 January 2008	N/A
Ms. Zhang Chunxiu（章春秀）	42	Chief Financial Officer	Oversee our Group's financial matters	1 January 2006	N/A

Ms. Zhang Chunxiu (章春秀), aged 42, is the Chief Financial Officer of our Group. Ms. Zhang is primarily responsible for overseeing our Group's financial matters.

Ms. Zhang obtained a Diploma in Finance from Shanghai Normal University (上海師範大學) in June 2000 and subsequently obtained a Bachelor in Accounting from the Hangzhou Dianzi University (杭州電子科技大學) in January 2009.

Ms. Zhang has over 16 years of experience in financial management. She joined Raily Beauty Consultation as a financial officer from January 2006 to December 2007. Since January 2008, she has been the financial director of Raily Beauty Consultation, Hangzhou Raily, Hangzhou Bellafill, Ruian Raily, Wuhu Raily, Ningbo Zhuerli, Raily Equipment, Hangzhou Ruiquan, Suzhou Yonglan, Jiumei Xinhe and Shenzhen Ruiquan, where she is responsible for overseeing the financial matters.

For biographical details of Mr. Fu Haishu and Mr. Song Jianliang, see the paragraph headed "Executive Directors" above.

COMPANY SECRETARY

Mr. Chan Oi Fat (陳愛發), aged 44, was appointed as our Company Secretary on 27 November 2020. Mr. Chan obtained his Bachelor's Degree of Business Administration (Accountancy) from the City University of Hong Kong in November 2000. He is a member of the Association of Chartered Certified Accountants. He is also a member of the Hong Kong Institute of Certified Public Accountants and a life member of the Hong Kong Independent Non-Executive Director Association.

Mr. Chan has over 14 years of experience in providing professional corporate secretarial services and financial advice to listed companies. From September 2000 to January 2008, Mr. Chan worked in Deloitte Touche Tohmatsu with his last position as audit manager. From January 2008 to March 2018, he served as financial controller and was responsible for the financial and accounting management and company secretarial affairs in Ta Yang Group Holdings Limited (大洋集團控股有限公司), a company whose shares are listed on the Hong Kong Stock Exchange (stock code: 1991.HK). From June 2014 to January 2021, he serves as the independent non-executive director of Shanghai Prime Machinery Company Limited (上海集優機械股份有限公司), a company whose shares are listed on the Hong Kong Stock Exchange (stock code: 2345.HK). Since February 2018, he serves as the company secretary of China Leon Inspection Holding Limited (中國力鴻檢驗控股有限公司), a company whose shares are listed on the Hong Kong Stock Exchange (stock code: 1586.HK). In April 2018, he joined SML (Hong Kong) Limited, and served as its financial controller and was later promoted to the position of chief financial officer in April 2019. From July 2020 to now, he serves as the independent non-executive director of China Saftower International Holding Group Limited (中國蜀塔國際控股集團有限公司), a company whose shares are listed on the Hong Kong Stock Exchange (stock code: 8623.HK).

CORPORATE GOVERNANCE REPORT

CORPORATE GOVERNANCE PRACTICES

The Company is committed to principles of good corporate governance consistent with prudent management and enhancement of shareholder value, which emphasise transparency, accountability and independence.

The Company has adopted the code provisions set out in the Corporate Governance Code (the "CG Code") as set out in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules").

During the Year, the Company has complied with all applicable code provisions in the CG Code.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") set out in Appendix 10 to the Listing Rules as the code of conduct for securities transactions by the Directors.

The Company has made specific enquiries with all Directors, and all Directors have confirmed that they have complied with the required standards as set out in the Model Code during the Year.

BOARD OF DIRECTORS

Composition of the Board of Directors

The composition of the Board during 2022 and up to the date of this report is as follows:

Executive Directors
Mr. Fu Haishu *(chairman)*
Mr. Song Jianliang *(chief executive officer)*
Mr. Wang Ying

Non-executive Director
Ms. Fan Qirui *(resigned on 19 September 2022)*

Independent Non-executive Directors
Mr. Cao Dequan
Ms. Yang Xiaofen
Mr. Liu Teng

The Board currently consists of three Executive Directors and three Independent Non-executive Directors. The Board considers this composition to be balanced and to reinforce a stronger independent review and monitoring function on overall management practices. The Company has adopted a board diversity policy (the "Board Diversity Policy"), the purpose of which is to enhance the effectiveness of the Board and maintain the highest standards of corporate governance and to recognize and maintain the benefits of diversity of the Board. The biographical details and relevant relationships of the Directors are set out in the section headed "Biographies of Directors and Senior Management" on pages 28 to 31 of this report.

BOARD MEETINGS

The Board conducts meeting on a regular basis and also as and when required. Board meetings are scheduled in advance to facilitate maximum attendance by Directors. The Company Secretary assists the Chairman in preparing the meeting agenda, and each Director may request inclusion of items in the agenda. Senior management members may be invited to attend all board meetings to enhance communications between the Board and management. Meeting agendas and other relevant information are provided to the Directors in advance of Board or Board committee meetings. During the Year, save for meetings held between Executive Directors during the normal course of business of the Company, the Board held four board meetings. Directors who have conflicts of interest in a resolution are required to abstain from voting.

DIRECTORS' ATTENDANCE AT BOARD/BOARD COMMITTEE/GENERAL MEETINGS

During the Year, the attendance of each member of the Board committee meetings, the Board meeting and general meeting are recorded as below:

	Number of meetings attended/Number of meetings entitled to attend				
Name of Directors	**Board Meetings**	**Audit Committee Meetings**	**Remuneration Committee Meetings**	**Nomination Committee Meeting**	**General Meeting**
Executive Directors					
Mr. Fu Haishu	4/4	–	2/2	1/1	1/1
Mr. Song Jianliang	4/4	–	–	–	1/1
Mr. Wang Ying	4/4	–	–	–	1/1
Non-executive Director					
Ms. Fan Qirui *(resigned on 19 September 2022)*	3/3	–	–	–	1/1
Independent Non-executive Directors					
Mr. Cao Dequan	4/4	2/2	2/2	1/1	1/1
Mr. Liu Teng	4/4	2/2	2/2	–	1/1
Ms. Yang Xiaofen	4/4	2/2	–	1/1	1/1

RESPONSIBILITIES, ACCOUNTABILITIES AND CONTRIBUTIONS OF THE BOARD AND MANAGEMENT

The Board is responsible for the leadership and control of the Group (comprising the Company and its subsidiaries) and overseeing the Group's business, strategic decisions and performance. The Board has the functions of considering and approving the strategies, financial objectives, annual budget and investment proposals of the Group. The Independent Non-executive Directors, who offer diverse industry expertise, serve the important function of advising the management on strategy and ensuring that the Board maintains high standards of financial and other mandatory reporting requirements as well as providing adequate checks and balances for safeguarding the interests of the shareholders and the Company as a whole. Significant transactions are approved by the Board.

The members of the Board have no financial, business, family or other material/relevant relationship with each other.

The Board also performs its corporate governance functions in accordance with the CG Code. A summary of the works performed by the Board on corporate governance functions during the Year is as follows:

(a) Develop and review the corporate governance policies and practices;

(b) Review and monitor the training and continuous professional development of the Directors and senior management;

(c) Review and monitor the policies and practices related to compliance with statutory and regulatory requirements;

(d) Review and monitor the code of conduct and compliance manual (if any) applicable to employees and Directors; and

(e) Review whether the Company has complied with the disclosure requirements of the CG Code and the corporate governance report.

Delegation to Management

Day-to-day operational responsibilities are specifically delegated by the Board to the management under the leadership of the chief executive officer (the "CEO"). The main duties of the management include implementation of the strategies and decisions approved by the Board, and the management assumes full responsibility to the Board for the business operations of the Group.

Participation of Directors in Continuous Professional Training

Code Provision C.1.4 of the CG Code stipulates that all Directors must participate in continuous professional development to develop and refresh their knowledge and skills, with the purpose of ensuring that they can continue to make informed and relevant contributions to the Board. The Company is responsible for arranging and funding appropriate training, and placing an appropriate emphasis on the roles, functions and responsibilities of directors of listed companies. All Directors are provided with necessary training and information to ensure that they have a proper understanding of the Company's operations, businesses and market in which it operates as well as his responsibilities under relevant statues, laws, rules and regulations. The Directors are also provided with regular updates on the Company's performance, position and prospects to enable the Board as a whole to discharge their duties. The Directors and senior management also meet on a regular basis or as necessary to discuss issues such as operation of the Company, corporate governance policies, and regulatory compliance. Directors are encouraged to participate in continuous professional development to develop and refresh their knowledge and skills. The Company Secretary of the Company has from time to time updated and provided written training materials relating to the roles, functions and duties of a Director. During the Year, all Directors have participated in continuous professional development by attending seminars or reading materials on the following topics to develop and refresh their knowledge and skills and provided a record of training to the Company.

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

During the Year, Mr. Fu Haishu is the chairman of the Company and Mr. Song Jianliang is the CEO. Code Provision C.2.1 of the CG Code stipulates that the roles of chairman and CEO shall be separated and shall not be performed by the same individual. The Company has complied with such code provision and the power of management is not concentrated in any one individual.

INDEPENDENCE OF INDEPENDENT NON-EXECUTIVE DIRECTORS ("INEDS")

All INEDs, Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng, have each entered into an appointment letter dated 4 December 2020, with a term of three years commencing from 4 December 2020, subject to, among others, re-election in accordance with the Company's Articles of Association.

Each INED is required to give a written annual confirmation of his/her independence and to inform the Company as soon as practicable if there is any change that may affect his/her independence. The Company confirms that it has received from each INED the annual confirmation of independence in accordance with Rule 3.13 of the Listing Rules, and the Company still considers each INED to be an independent person.

APPOINTMENT AND RE-ELECTION OF DIRECTORS

All Directors are appointed for a specific term, subject to renewal upon expiry of the existing term. Each of the Executive Directors has entered into a service contract with the Company for a term of three years, and each of the INEDs has signed an appointment letter with the Company for a term of three years.

The procedures and process of appointment, re-election and removal of Directors are set out in the Articles of Association (the "Articles"). The Nomination Committee is responsible for reviewing Board composition, monitoring the appointment of Directors and assessing the INEDs.

According to the Articles, one-third of the Directors for the time being (if their number is not a multiple of three, the number nearest to but not less than one-third) shall retire from office by rotation at each annual general meeting provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. In addition, any Director appointed by the Board to fill a casual vacancy in the Board shall hold office only until the first general meeting after his appointment, and any Director appointed by the Board as an addition to the existing Board shall hold office until the next following annual general meeting of the Company. The retiring Directors are eligible for re-election by the shareholders at the respective general meetings.

BOARD COMMITTEES

The Board has established the following committees with defined terms of reference, which are on no less exacting terms than those set out in the CG Code:

- Remuneration Committee
- Nomination Committee
- Audit Committee

Each committee has authority to engage outside consultants or experts as it considers necessary to discharge the committee's responsibilities. Minutes of all committees meetings are circulated to their members.

REMUNERATION COMMITTEE

The composition of the Remuneration Committee is as follows:

Independent Non-executive Directors
Mr. Cao Dequan *(Chairman)*
Mr. Liu Teng

Executive Director
Mr. Fu Haishu

The Board has established the Remuneration Committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and the paragraph E.1.2 of the CG Code. The primary duties of the Remuneration Committee are to make recommendations to the Board regarding our policy and structure for the remuneration of our Directors and senior management and on the establishment of a formal and transparent procedure for developing remuneration policies, and to make recommendations to the Board on the remuneration packages of our Directors and senior management and on the employee benefit arrangement.

During the Year, the Remuneration Committee held two meetings. Details of the attendance of members of the Remuneration Committee at the above-mentioned meetings are set out in the sub-section headed "Directors' Attendance at Board/Board Committee/General Meetings" above.

A summary of the work performed by the Remuneration Committee is as follows:

a. Reviewed the remuneration policy, organizational structure and human resources deployment;

b. Reviewed the performance, remuneration and benefits of the Directors and senior management;

c. reviewed the grant of options during the year ended 31 December 2022. The Remuneration Committee considers that the grant of options is fair and reasonable and in the interests of the Group as a whole. It is noted that the vesting period of the share options granted on 29 August 2022 is less than 12 months. As the amendments on the Listing Rules regarding the vesting period of the share options became effective on 1 January 2023, the share options to be granted in the future would comply with the relevant Listing Rules.

NOMINATION COMMITTEE

The composition of the Nomination Committee is as follows:

Executive Director
Mr. Fu Haishu *(Chairman)*

Independent Non-executive Directors
Mr. Cao Dequan
Ms. Yang Xiaofen

The Board has established the Nomination Committee with written terms of reference in compliance with the paragraph B.3.1 of the CG Code. The primary duties of the Nomination Committee are mainly reviewing the structure, size and composition of the Board, identifying individuals who are suitably qualified to become a member of the Board, assessing the independence of the INEDs, selecting or making recommendations on the selection of individuals nominated for directorships and succession planning for the Directors, in particular, the chairman of the Company and the CEO.

During the Year, the Nomination Committee held one meeting. Details of the attendance of members of the Nomination Committee at the above-mentioned meetings are set out in the subsection headed "Directors' Attendance at Board/Board Committee/General Meetings" above.

A summary of the work performed by the Nomination Committee is as follows:

a. reviewed the structure, size and composition of the Board;

b. assessed the independence of INEDs;

c. made recommendation to the Board on the re-election of the retiring Directors.

AUDIT COMMITTEE

The composition of the Audit Committee is as follows:

Independent Non-executive Directors
Mr. Liu Teng *(Chairman)*
Mr. Cao Dequan
Ms. Yang Xiaofen

The Board has established the Audit Committee with written terms of reference in compliance with the Rule 3.22 of the Listing Rules and paragraph D.3 of the CG Code. The primary duties of the Audit Committee are to provide oversight of the financial reporting process, the audit process, the mechanism of internal control and compliance with laws and regulations, appointment of external auditors and perform further duties and responsibilities as assigned by our Board from time to time.

During the Year, the Audit Committee held two meetings. Details of the attendance of members of the Audit Committee at the above-mentioned meetings are set out in the sub-section headed "Directors' Attendance at Board/Board Committee/General Meetings" above.

A summary of the work performed by the Audit Committee is as follows:

a. Financial Reporting

- Reviewed and approved the audited consolidated financial statements for the year ended 31 December 2022 in conjunction with the Company's external auditors, Ernst & Young, and the unaudited financial statements for 6 months ended 30 June 2022 prior to approval by the Board;

- Reviewed the accounting principles and practices adopted by the Group;

- Reviewed the auditing and financial reporting matters, including the key audit matters of the consolidated financial statements for the year ended 31 December 2022 which are set out in the annual report of the Company for the year ended 31 December 2022;

- Reviewed the audit planning for the year ended 31 December 2022 in conjunction with the Company's external auditors;

b. External Auditors

- Approved the remuneration and terms of engagement of the Company's external auditors;

- Reviewed the independence and objectivity of the Company's external auditors and the effectiveness of audit procedures according to applicable standards;

- Reviewed the re-appointment of Company's external auditors and was satisfied with their work, their independence, and their objectivity, and therefore recommended the re-appointment of Ernst & Young (which had indicated their willingness to continue in office) as the Company's external auditors for Shareholders' approval in the annual general meeting which was held on 10 June 2022;

- Met with the Company's external auditors without the attendance from the executive Directors;

c. Internal Audit

- Reviewed the audit procedures and risk management and internal control systems of the internal audit department; and

d. Risk Management and Internal Controls

- Reviewed the effectiveness of risk management and internal control systems.

The Audit Committee has reviewed and approved the annual results of the Group for the year ended 31 December 2022 prior to approval by the Board, which was of the view that the preparation of such annual results have complied with the requirements of the applicable accounting standards, the Listing Rules and other applicable legal requirements, and that adequate disclosures have been made.

The Audit Committee has recommended to the Board the re-appointment of Ernst and Young, Certified Public Accountants, as auditors of the Company and the Company will propose a resolution for the re-appointment of Ernst & Young as the Company's auditor at the forthcoming annual general meeting of the Company.

AUDITORS' REMUNERATION

During the Year, the remuneration paid/payable to Ernst & Young, the Company's external auditors, for the provision of audit and other services is set out below:

	Fees paid/payable RMB'000
Audit services	1,600.0
Non-audit services	650.0

REMUNERATION OF DIRECTORS AND SENIOR MANAGEMENT

During the Year, the remuneration of senior management members by band is set out below:

Remuneration Band (HK$)	Number of individuals
HK$nil to HK$1,000,000	4
HK$1,000,001 to HK$2,000,000	–

Further particulars regarding the Directors' remuneration and the five highest paid employees are set out in Note 8 and Note 9 to the financial statements, respectively.

DIRECTORS' RESPONSIBILITIES ON FINANCIAL STATEMENTS

The Directors acknowledge their responsibilities for preparing the financial statements of the Group for the Year, which give a true and fair view. The Directors are not aware of any material uncertainties relating to events or conditions which may cast significant doubt upon the Group's ability to continue as a going concern.

The statement by the auditors of the Company regarding their reporting responsibilities on the consolidated financial statements of the Company is set out in the Independent Auditor's Report on pages 93 to 183 of this report.

INTERNAL CONTROL AND RISK MANAGEMENT

The Board has reviewed the effectiveness of the risk management and internal control systems of the Company and its subsidiaries, and believes that the systems are effective and adequate.

The Board is responsible for ensuring that the Group maintains a sound and effective risk management and internal control system and reviewing its effectiveness through the Audit Committee. The system is used to manage (rather than eliminate) the risk of failing to achieve the Company's goals, and aims to provide reasonable but not absolute guarantees about avoiding major misstatements, losses or frauds.

The Company has established an Internal Audit Department, and reviewed the risk management and internal control system at least once during the Year.

The Internal Audit Department at our headquarters is generally responsible for approving all the risk management procedures and internal control systems. Our departments at the headquarters oversee the implementation of such procedures and systems by our aesthetic medical institutions, while the respective departments of our aesthetic medical institutions are responsible for daily affairs in respect of implementation of such procedures and systems. Our employees receive mandatory training on relevant policies, standards, protocols and procedures from time to time and are required to strictly follow them in daily operations. The Audit Department at our headquarters is overseen by the Audit Committee.

The Board has adopted an enterprise risk management framework for the Company. If any significant risks are noticed in daily operations, the Group's business units, support functions and individuals will review, share experiences and report to senior management. The Internal Audit Department communicates and assesses the Group's risk portfolio and significant risks at the group level. The Board authorizes the executive management to design, implement and continuously assess these risk management and internal control systems; at the same time, the Board, through the Audit Committee, monitors and reviews the adequacy and effectiveness of established procedures for the monitoring and risk management of financial, operational and compliance matters.

Based on the assessment results and statements made by senior management, the Audit Committee is satisfied that:

- there is an ongoing process for identifying, evaluating and managing the significant risks faced by the Group that threaten the achievement of its business objectives; and
- appropriate systems of internal control and risk management have been in place for the Year and up to the date of this report.

Procedures and Internal Controls for Handling and Dissemination of Inside Information

In handling and dissemination of inside information, the Group:

– requires the inside information to be reported to the Board and the Company Secretary of the Company;

– will conduct immediate dissemination once inside information is available and/or respective decision is made, except the inside information falling into the Safe Harbours of Securities and Futures Ordinance that allow non-disclosure;

– complies with applicable laws, rules and Guidelines on Disclosure of Inside Information issued by Securities and Futures Commission; and

– communicates with relevant persons about corporate information disclosure practices with respective training.

BOARD DIVERSITY POLICY

In recognition of the particular importance of gender diversity, we are committed to promote gender diversity at the Company at all levels, including but without limitation, at the Board and senior management levels, to enhance the effectiveness of the corporate governance. We have taken and will continue to take steps to promote gender diversity of the Company, including the appointment of one female Non-executive Director, INED and senior management member. Subject to availability of experienced management personnel in the industry, we have also adopted measures to promote gender diversity in developing a pipeline of female senior management and potential successors to the Board, including putting gender diversity as a strategic priority when sourcing for the Director candidates, leveraging the community resources including relevant associations, networking groups and publications, and forging and keeping relationship with the potential candidates, as well as engaging more resources in training female staff who have long and relevant experience in our business, with the aim of promoting them to the senior management or directorship of the Group.

The Company believes that the diversity of Board members will be immensely beneficial for the enhancement of the Company's performance. Therefore, the Company has adopted a Board Diversity Policy to ensure that the Company will, when determining the composition of the Board, consider Board diversity in terms of, among other things, age, gender, cultural and educational background, professional and industry experience, skills and knowledge, insight, and the potential contributions that such candidate could bring to the Board. All Board appointments are made on merit, in the context of the skills and experience the Board as a whole requires being effective. The structure, size and composition (including, for example, gender, age, and length of service) of the Board will be reviewed from time to time by the Nomination Committee to ensure that the Board has a balance of skills, expertise and diversity of perspective for providing effective leadership to the Company and meeting the needs of the Group.

The Company recognizes and embraces the benefits of having a diverse Board, and considers diversity at Board level as an essential element in maintaining a competitive advantage. The Company also recognizes the importance of being able to attract, retain and motivate employees from the widest pool of available talent, and is committed to diversity at all levels, including gender, age, cultural and educational background, and professional experience. A truly diverse Board will include and make good use of differences in the talents, skills, regional and industry experience, background, gender and other qualities of the members of the Board. These differences will be considered in determining the optimum composition of the Board and when possible should be balanced appropriately.

At present, the Nomination Committee considered that the Board is sufficiently diverse and the Board has not set any measurable objective.

The Nomination Committee reviews and assesses the composition of the Board and makes recommendations to the Board on appointment of new Directors of the Company. The Nomination Committee also oversees the conduct of the annual review of the effectiveness of the Board.

In reviewing and assessing the composition of the Board, the Nomination Committee considers the benefits of all aspects of diversity, including without limitation, those described above, in order to maintain an appropriate range and balance of talents, skills, experience and diversity of perspectives on the Board. Factors to be taken into account include: gender, age, ethnicity, cultural and educational background, professional skills, experience and knowledge. Due regard is to be given to the business model and specific needs of the Company.

Principles

The Board believes in the benefits of diversity and recognizes that diversified thinking can create prudent business ideas. The Board is composed of individuals with different skills, experiences, backgrounds and opinions, namely:

- Have competitive advantages;
- Really understand the opportunities, problems and risks;
- Include different opinions, ideas and relationships;
- Strengthen decision-making and exchange of opinions; and
- Improve the ability to supervise the Company and its governance.

Factors and Reasons Behind

In terms of achieving diversity of board members, factors to be considered include but not limited to:

(1) Business and practical experiences;

(2) Professional skills and expertise;

(3) Gender;

(4) Age; and

(5) Cultural and educational background.

The principal business of the Group is the provision of aesthetic medical services, which are highly competitive businesses and activities. Experiences in business or activities or other businesses or activities are essential for understanding and operating the business and activities of the Group. Professional (such as law, accounting) skills and professional knowledge are particularly important to minimize the risks of the Group's business and activities. In terms of customers' requirements and feedback on the services provided by the Group and the needs of shareholders and investors, gender and age diversity and cultural and educational diversity will generate different opinions.

PROGRESS ON AND STATUS OF GENDER DIVERSITY

As at the date of this annual report, the Board comprises five male Directors and one female Director. The Nomination Committee considered that the Board had achieved gender diversity and possessed skill and expertise and a diverse mix appropriate for the business of the Company and will review the composition and diversity of the Board annually to ensure its continued effectiveness.

The details of workforce composition were disclosed under Environmental, Social and Governance Report in this report.

From the perspective of sociology, female's cognition of beauty is relatively higher than that of male. From the perspective of marketing, female representatives with better external performance are also a consumption implication. Combined with the characteristics of the aesthetic medical industry, the gender ratio of employees of the Company is relatively imbalanced, and the proportion of female employees is higher. With the rise of internet celebrity economy, better external performance men are also more popular, and the impressions of men and women are no longer solidified, especially the potential of male consumption is huge. The Company plans to increase the number of male employees to recruit, strengthen the cultivation of professional quality of male employees, and promote gender diversity of employees. With increasingly fierce market competition, corporate organizations are facing the impact of rapid changes in the environment. The gender diversity of employees can promote information exchange within the organization and become the key to the organization's competitive advantage. The Group is able to properly address gender issues and has a wider range of talent choices and a competitive advantage.

NOMINATION POLICY

The Board has adopted a Director Nomination Policy, which sets out the criteria, procedures and processes for selecting and recommending candidates to serve on the Board of the Company.

Selection Criteria

A number of factors should be considered when selecting and recommending candidates for the Directors of the Company, including but not limited to:

(1) Personal ability: Each candidate must abide by the highest ethical standards, demonstrate solid business judgment, and possess strong interpersonal skills.

(2) Comply with the Company's policy on diversity of board members.

(3) Comply with the Company's Memorandum and Articles of Association and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

(4) Specific skills and experiences:

- (a) Leadership experience in an organization or company of similar size and complexity to the Company;
- (b) Past board experience;
- (c) Able to read and interpret financial statements;
- (d) Experience in legal affairs;
- (e) Experience or expertise in the beauty industry or beauty service field;
- (f) Understand and share the Company's vision;
- (g) Able to invest necessary time and energy for the Company's good governance and improvement.

Procedures and Processes

(1) Any board member may nominate a candidate for new appointment as a Director of the Company or re-appoint any existing Director.

(2) The Nomination Committee may convene a meeting to review the nomination of relevant candidates.

(3) The Nomination Committee shall conduct due diligence on the candidates and make recommendations for the Board to consider and approve.

(4) The shareholders of the Company may elect any individual to serve as a Director of the Company through ordinary resolutions.

This policy will be reviewed from time to time.

DIVIDEND POLICY

In determining whether to propose the payment of dividends and the amount of dividends, the Company will consider the Group's future operations and strategies, financial performance, cash flow, market conditions, capital requirements and any other factors deemed relevant by the Board.

The declaration and payment of dividends by the Company are subject to the sole discretion of the Board from time to time, and shall also comply with any restrictions imposed by the Cayman Islands Company Law and the Company's Articles of Association.

This policy will be reviewed from time to time.

INDEPENDENT VIEWS MECHANISM

The Company attaches great importance to the independence of Directors and believes that independence is the key to fairness and impartiality. The Independent Non-executive Directors play a significant role in balancing the interests of the public and the Company, and the diverse background of the Independent Non-executive Directors can bring a broader mix of experience and broader perspectives to the Board. Therefore, the Group has adopted various methods to assess the independence of the Independent Non-executive Directors and is committed to fair and transparent methods in selecting suitable Directors.

In assessing the independence and suitability of a candidate for the position of Independent Non-executive Directors, the candidate nominated as an Independent Non-executive Director must satisfy the independence criteria set out in Rule 3.13 of the Listing Rules. Where applicable, the Nomination Committee should also evaluate the candidate's education background, qualifications and experience in order to consider whether he/she has the appropriate professional qualifications or accounting or related financial management expertise to meet the office of an Independent Non-executive Director.

If the proposed Independent Non-executive Director fails to meet any of the independence guidelines set out in Rule 3.13 of the Listing Rules, the Group must first demonstrate that the individual is independent before the proposed appointment. The Group must also disclose in its announcement of the appointment of such Director and in its first annual report thereafter the reasons why it considers such Director to be independent.

Each Independent Non-executive Director is required to inform the Group and the Stock Exchange as soon as practicable if there is any subsequent change of circumstances which may affect his./her independence and to confirm his/her independence to the Group on an annual basis. The Group is required to confirm in its annual report whether it has received such confirmation and whether it still considers the independent non-executive Directors to be independent. Each person who has any financial or other interest in the business of the Group in the past or present or is connected with any connected person (as defined in the Listing Rules) must make a true disclosure. The Nomination Committee is responsible for assessing the independence of all Independent Non-executive Directors on an annual basis and confirming whether each of them meets the independence criteria as set out in the Listing Rules and that there are no relationships or circumstances which are likely to affect or appear to affect their independent judgment. Each member of the Nomination Committee will not be involved in assessing his/her own independence. In assessing the independence of Independent Non-executive Directors on an annual basis, the Company will in particular ascertain the character and judgment required from such Director to remain as an Independent Non-executive Director and continue to bring independent, objective and constructive judgment and advice to the assumptions and opinions made by the management and the Board.

Where the Board proposes a resolution to elect an individual as an Independent Non-executive Director at the general meeting, it should set out in the circular to shareholders and/or explanatory statement accompanying the notice of the relevant general meeting why the Board believes he/she should be elected and the reasons why they consider him/her to be independent.

Independent Non-executive Directors can share their views and opinions by holding meetings with the head of a core department. Specific business departments shall also attend the meetings at the request of the Independent Non-executive Directors. Where necessary, the Chairman of the Board can hold meetings with the Independent Non-executive Directors without the presence of other Directors to provide a useful platform for the Chairman to obtain independent advice on various issues of the Group. Upon reasonable request of the Independent Non-executive Directors, the Company will provide them with independent professional advice to assist them in performing their duties.

The Independent Non-executive Directors are required to submit a written confirmation of independence to the Stock Exchange in accordance with the independence guidelines set out in Rule 3.13 of the Listing Rules.

The Board is satisfied with the implementation and effectiveness of the Independent View Policy for the Year.

DIRECTORS' REMUNERATION POLICY

The remuneration policy of the Directors of the Company (the "Policy") aims to set out the Group's criteria and guidelines in determining the remuneration packages of individual Directors and employees. High-quality and dedicated employees are one of the valuable assets contributing to the success of the Group. To ensure the ability to attract and retain talents, the Group's Remuneration Policy aims to provide fair and market-competitive, adequate but not excessive remuneration packages to support performance culture and achieve strategic business goals.

The Remuneration Committee is responsible for formulating the Group's remuneration policy for the Board's approval, and making recommendations to the Board on the annual salary adjustment and annual performance bonus of the Group. The appropriate remuneration offered to the Directors is mainly to ensure that an appropriate level of remuneration is maintained so as to attract and retain experienced and high-caliber talent to assist and manage the business and development of the Company. The remuneration will be reviewed annually with reference to factors such as the Company's performance and market trends.

The remuneration of Independent Non-executive Directors, subject to shareholders' approval, should be fixed by the Board and should be commensurate with their contribution and contribution to the Company. The Remuneration Committee should conduct regular reviews of the remuneration policies of the Executive directors and senior management independently from executive management.

In approving and determining the remuneration package, the Remuneration Committee shall consider and evaluate the performance of the Group and the key financial and operational performance targets of the Group. The remuneration package and structure should be based on a fair reward system to all participants and include the following key components:

Consideration of fixed remuneration

Basic salaries and allowances	• Level of remuneration in line with general norms and/or market trends in the industry in which the Group operates
	• Market benchmarks relevant to the function and scope of work of the relevant directors or employees
	• Company performance and financial performance
	• Individual performance and contribution (which can be measured by the achievement of individual annual financial and operating targets)
	• Other factors considered by the Remuneration Committee

Consideration of variable remuneration

Performance bonus (if any)	• Company performance and financial performance
	• Individual performance and contribution (which can be measured by the achievement of individual annual financial and operating targets)
	• Other factors considered by the Remuneration Committee

SHAREHOLDERS COMMUNICATION POLICY

The Company attaches great importance to communication with Shareholders and recognizes its responsibility to create maximum value for Shareholders. To ensure a two-way communication channel between the senior management of the Company and the Shareholders and investors, the Group has adopted various means to enhance communication and dialog with each other. The Group is committed to enhancing investor relations through timely, fair and transparent communication with shareholders and investors. The Company is committed to maintaining effective and transparent communication with its shareholders and investors in a proactive manner and ensuring that information is disseminated to shareholders and potential investors in an accurate, consistent and timely manner.

The Company has established different communication channels to ensure that all stakeholders have public access to corporate information. The Company will issue corporate communications (which include to financial reports, results announcements, announcements and circulars) containing regulatory disclosures and notices of the Company in accordance with applicable laws and regulatory requirements.

The annual general meeting (the "AGM") and the extraordinary general meeting (the "EGM") of the Company provide an important and open platform for shareholders to discuss and communicate with the management of the Group. Shareholders are encouraged to attend the general meetings or to appoint proxies to attend and vote at the meetings for and on their behalf if they are unable to attend the meetings. The chairman of the general meeting will provide reasonable time for shareholders to raise questions and express their opinions.

The senior management of the Group may answer questions raised by shareholders at the AGM/EGM, at which separate resolutions are proposed on significant matters. An explanation of the detailed procedures of conducting a poll will be provided to shareholders at the commencement of the AGM/EGM to ensure that shareholders are familiar with the procedures. The poll results in respect of the resolutions proposed at the meeting will be published on the websites of the Company and the Stock Exchange after the conclusion of the AGM/EGM.

In order to improve the accuracy and transparency of public disclosure, the Group attaches great importance to the preparation of interim and annual reports. The Group's report provides in-depth analysis and discussion of key areas, including financial and operating results. On the other hand, the Group will keep the Shareholders informed of any material events or inside information by way of announcement. For any matters requiring shareholders' approval, the Group will convene an extraordinary general meeting and publish a circular in accordance with the requirements of the Stock Exchange before a specified date to inform the shareholders so that they have sufficient time to prepare for the voting.

All published annual reports, interim reports, announcements and circulars have been uploaded to the Stock Exchange's website and the Company's corporate website.

The Company maintains a dedicated investor relations section on its corporate website. The Group regularly provides investors, shareholders and the media with the latest information through press releases, financial statements and company announcements, in order to provide the latest business progress, financial and operational information to the market and enhance corporate interaction, communication and transparency. In order to protect the environment and maintain effective communication with shareholders, all shareholders are encouraged to visit the Group's corporate website for up-to-date information.

Shareholders may at any time make a request for the Company's information to the extent that such information is publicly available. Shareholders should direct their questions about their shareholdings to the Company's branch share registrar, whose contact details are set out below:

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

The Board has reviewed the Shareholders' Communication Policy and its effectiveness for the Year. The Company has provided appropriate communication channels to the Shareholders in accordance with the Shareholders' Communication Policy and therefore the existing Shareholders' Communication Policy is appropriate to the Company.

COMPANY SECRETARY

Mr. Chan Oi Fat has been appointed as the Company Secretary of the Company on 27 November 2020. During the Year, Mr. Chan Oi Fat has taken not less than 15 hours of relevant professional training in accordance with Rule 3.29 of the Listing Rules.

PROCEDURES FOR SHAREHOLDERS TO PUT FORWARD PROPOSALS AT SHAREHOLDERS' MEETING

If a shareholder wishes to put forward proposals at a shareholders' meeting, the shareholder, who has satisfied the shareholding requirements set out in the following paragraph headed "SHAREHOLDERS' RIGHTS", may follow the same procedures by sending a written requisition to the Board. The shareholder should state his/her proposals in the written requisition and submit the written requisition as early as practicable to enable the Company to make necessary arrangement.

SHAREHOLDERS' RIGHTS

The Way by Which Shareholders Can Convene Extraordinary General Meeting

According to Article 64 of the Company's Articles of Association, the Board may, whenever it thinks fit, convene an extraordinary general meeting. Extraordinary general meetings shall also be convened on the requisition of one or more Shareholders holding, as at the date of deposit of the requisition, not less than one-tenth of the paid up capital of the Company having the right of voting at general meetings. Such requisition shall be made in writing to the Board or the Secretary for the purpose of requiring an extraordinary general meeting to be called by the Board for the transaction of any business specified in such requisition. Such meeting shall be held within two Months after the deposit of such requisition. If within 21 days of such deposit, the Board fails to proceed to convene such meeting, the requisitionist(s) himself (themselves) may do so in the same manner, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to the requisitionist(s) by the Company.

PROCEDURES FOR MAKING ENQUIRIES TO THE BOARD

Any enquiries to be put to the Board are welcomed and can be addressed to the Company's Securities Affairs Department via email (investor.relationship@raily.com) or by mail to the following address:

Raily Aesthetic Medicine International Holdings Limited
5/F, Minhang Tower
No. 290 North Zhongshan Road
Gongshu District
Hangzhou PRC

Attn: Securities Affairs Department

AMENDMENTS TO CONSTITUTIONAL DOCUMENT

On 7 April 2022, the Board proposed to amend the Memorandum and Articles of Association of the Company to conform with the core shareholder protection standards set out in Appendix 3 to the Listing Rules and to provide flexibility to the Company in relation to the conduct of general meetings, and to allow general meetings to be held as a hybrid meeting where shareholders of the Company (the "Shareholders") may attend by electronic means in addition to as a physical meeting where Shareholders attend in person. The amendments also explicitly set out other related powers of the Board and the chairman of the general meetings, including making arrangements for attendance as well as ensuring the security and orderly conduct of such general meetings. The new Memorandum and Articles of Association in substitution for, and to the exclusion of, the preceding Memorandum and Articles of Association of the Company was approved by way of special resolution at the annual general meeting of the Company held on 10 June 2022.

For details, please refer to the Company's announcements dated 7 April 2022, 19 April 2022 and 10 June 2022 and Company's circular dated 19 April 2022.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

1. ABOUT THIS REPORT

Raily Aesthetic Medicine International Holdings Limited (the "Company") is pleased to present the Environmental, Social and Governance ("ESG") Report (the "Report"). This ESG Report describes the performance, policies and strategies of the Company and its subsidiaries (collectively referred to as the "Group" or "we" or "us") in terms of sustainable development, environmental protection, employee care and corporate responsibility. We hope to demonstrate our concern for sustainable development and related issues through this ESG Report, listen to the opinions of various stakeholders, and establish a long-term and close relationship with them.

1.1 Reporting Scope

This ESG Report covers the environmental and social performance of the Group from 1 January 2022 to 31 December 2022 (the "Year"). Regarding the key performance indicators (KPIs) in environmental and social aspects. The Group focuses on the performance of i) aesthetic medical services (including two aesthetic medical hospitals in Hangzhou and Ruian, and two aesthetic medical out-patient departments in Hangzhou and Wuhu, respectively), ii) aesthetic medical management consulting services (including two offices in operation in Hangzhou and Shenzhen), and iii) medical equipment trading services operated in the People's Republic of China (the "PRC"). This scope is based on whether actual business premises and office premises have a significant impact on the Group.

1.2 Reporting Standard

This ESG Report is prepared by the Company in accordance with the Environmental, Social and Governance Reporting Guide set out in Appendix 27 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange"), and has been reported and disclosed according to the provisions of "Mandatory Disclosure" and "Comply or Explain" therein.

1.3 Reporting Principles

The content of this Report is determined through stakeholder engagement and materiality assessment process, which includes identifying ESG-related issues, collecting and reviewing the management and stakeholders' opinions, assessing the relevance and materiality of the issues and preparing and validating the information reported. This ESG Report covers all key issues that are concerned by different stakeholders.

This ESG Report discloses environmental and social KPIs in a quantitative manner to enable stakeholders to have a more comprehensive understanding of the Group's ESG performance. Information of the standards, methodologies, references and source of key emission and conversion factors used on these KPIs are stated wherever appropriate. In order to enhance and maintain comparability of ESG performances between years, the Group has strived to adopt consistent reporting and calculation methodologies as far as reasonably practicable. If there are any changes in the reporting and calculation methodologies or specific standards, the Group will explain in detail in this ESG Report.

1.4 Information and Feedback

The Group attaches great importance to your opinion on the ESG performance of the Group. If you have any comments or suggestions, please contact us through the following methods:

Address:	5/F, Minhang Tower, No. 290 North Zhongshan Road, Gongshu District, Hangzhou, PRC
Tel:	0571-8882 6555
Fax:	0571-8882 7555
Email:	service@raily.com

2. ESG GOVERNANCE

The Group understands the importance of ESG governance to our sustainable development, and believes that the opinions and participation of various stakeholders are particularly important to ESG governance. Therefore, the Group is committed to continuously improving its ESG governance and performance by understanding stakeholders' expectations and requirements for the Group and ESG issues of particular concern from various channels. The Group has established policies related to environmental, social and corporate governance responsibilities, and formulated appropriate ESG risk management measures and internal control systems to ensure that the Group can effectively respond to potential ESG risks and take corrective measures when necessary.

2.1 Statement from the Board

The Group believes that good ESG governance strategies and practices are essential to the long-term development of the business and help enhance the value and return of investment. To this end, the board of directors has established clear ESG duties and responsibilities, and the executive Directors are responsible for overseeing the implementation of the Group's ESG work. The Board pays attention to the ESG-related issues of the Group, conducts research, analysis and risk assessment on relevant issues in a timely manner, and makes recommendations on the sustainable development direction, policies and goals of the Group to ensure the Group's position and performance in responding to global sustainable development issues can meet the latest of international standards. The Board also regularly meets with department heads to understand the implementation of ESG work by each department in order to continuously improve the Group's ESG strategies and plans. In addition, the compliance department of the Group is responsible for reporting the preparation progress of a report to the Board on a regular basis, and the Board reviews the content and quality of a report to ensure that a report meets the requirements of the Board.

During the Year, the Group commissioned a third-party ESG professional consultant (the "ESG Consultant") to assist in stakeholder communication and materiality assessment, collect and analyze the opinions of various stakeholders on different ESG issues, and integrate material ESG issues in the industry to identify ESG issues that are important to the Group. At the same time, the Group reviews and discusses the results of the materiality assessment with the ESG consultant to ensure that the assessment results are in line with the Group's development direction.

In order to enable the Group to develop in an orderly manner in the ESG aspects, the Board will gradually set goals for various ESG issues of the Group. The Board will continue to follow up, coordinate and manage the progress of ESG work carried out by different departments in accordance with the goals set, and the management's performance compensation is also linked to the achievement of sustainability objectives to promote the effective implementation of ESG management by the Group.

2.2 Stakeholder Engagement

The Group understands the importance of stakeholders to business development. Therefore, the Group attaches great importance to the participation of stakeholders and takes the opinions of stakeholders as the core part of the preparation of this ESG Report to continuously improve ESG performance. During the Year, we have set up appropriate communication channels for stakeholders to maintain close communication with them and listen to their opinions and expectations. This will also help us determine potential risks in our business operations, identify ESG issues of concern to our stakeholders, and improve our ESG management standards at all levels.

Stakeholders	Expectations	Management response/ communication methods
Government and Regulators	• Comply with national policies and laws and regulations • Pay taxes on time	• Regular information reporting • Inspection and supervision
Shareholders	• Compliant operation • Enhance corporate value • Transparent information and efficient communication	• General meetings, announcements, circulars, interim reports and annual reports • Email, telephone communication and company website
Business Partners	• Operation with integrity • Performance of contracts • Mutual benefit	• Business communication • Engagement and cooperation
Customers	• Quality products and services • Operation with integrity	• Customer service center and hotline • Social media platforms
Environment	• Dispose of waste according to law	• Entrust qualified third-party institutions to recycle and process medical waste
Industry	• Promote industry development	• Participation in industry forums
Employees	• Occupational Health and Safety • Career development	• Staff communication meetings • Training and workshops • Intranet Employee Handbook
Community	• Information transparency	• Company website

2.3 Materiality Assessment

In order to clearly formulate the direction of ESG management and development, the ESG Consultant appointed by the Group has assisted in collecting and analyzing the opinions of the stakeholders on the Group's ESG issues. Through questionnaire, the Group scored and ranked the stakeholders' concern towards various ESG issues. At the same time, for a more comprehensive review of the ESG issues that are material to the Group's business, the ESG Consultant also assisted in reviewing internal and external documents and media reports, as well as referring to the materiality map provided by external authoritative agencies to identify the ESG issues that are of major concern to the industry.[1] Based on the above scoring and screening results, in conjunction with the professional opinions of the management and the ESG Consultant, the Group finally identified 12 major ESG issues, laying the foundation for the Group's future development in ESG.

[1] The materiality assessment has referred to the ESG industry materiality map provided by MSCI Inc and the materiality map provided by the Sustainability Accounting Standards Board (SASB).

ESG aspects	Material ESG issues	Corresponding section	
Environmental	Waste Management Energy Consumption Greenhouse Gas Emission	3.1 3.2 3.3	Pollution and Emission Control Resource Usage Addressing Climate Change
Employment and Labour Practices	Occupational Health and Safety Training and Education	4.3 4.4	Occupational Health and Safety Staff Development and Training
Operation Management	Operational Compliance Quality Management Customer Health and Safety Customer Service Management Information Security Customer Privacy Protection Responsible Sales and Marketing	5. 5.2 5.2 5.2 5.3 5.3 5.4	Operating Practices Quality Management Quality Management Quality Management Intellectual Property Rights and Customer Data Protection Intellectual Property Rights and Customer Data Protection Advertising and Marketing

3. ENVIRONMENTAL PROTECTION

The Group understands that environmental protection is an important part of promoting the sustainable development of the Group and the society. Therefore, the Group has spared no effort in environmental protection and is committed to incorporating environmental protection elements into the business management and decision-making process. The Group also strictly complies with national environmental laws and regulations, including but not limited to the Environmental Protection Law of the People's Republic of China (《中華人民共和國環境保護法》), the Water Pollution Prevention and Control Law of the People's Republic of China (《中華人民共和國水污染防治法》) and the Environmental Impact Assessment Law of the People's Republic of China (《中華人民共和國環境影響評價法》).

3.1 Pollution and Emission Control

The Group sets emission targets for different types of pollutants under the premise of complying with national and local laws and regulations. Our target is to reduce emissions of air pollutants, wastewater and waste, especially daily office and domestic waste, by 5% in 2025 when compared to those in 2021. The Group will take relevant measures to achieve the targets set by the Group in respect of the following different pollutants.

3.1.1 Air pollutant control

Since the business of the Group is mainly conducted in aesthetic medical institutions and offices, the Group does not generate any industrial gas emissions. There is a small amount of air pollutants generated from the Group's daily office vehicles. In order to reduce the vehicle's consumption of fuel and generation of additional air pollutants due to the reduced efficiency, the Group conducts regular maintenance and repairs for its vehicles to maintain vehicle efficiency. The Group also promotes the use of new energy vehicles. Electric vehicles do not generate any air pollutants and help improve roadside air pollution. In addition, the Group encourages its employees to take public transportation and share transportation to reduce the emissions of driving vehicles and related air pollutants during commuting.

During the Year, the air pollutant emissions generated by the Group when using vehicles are as follows:

Vehicle air pollutants *(Note 1)*	**2022**	2021
Nitrogen oxides (kg)	**6.90**	5.27
Sulfur oxides (kg)	**0.14**	0.10
Particulate matter (kg)	**0.51**	0.39

Note:

1. *Air pollutants generated by vehicles are calculated based on the Reporting Guidance on Environmental KPIs (《環境關鍵績效指標匯報指引》) published by the Hong Kong Stock Exchange.*

3.1.2 Wastewater control

As the Group operates aesthetic medical hospitals and out-patient departments, it is possible that wastewater containing pathogens may be generated during the operation, which will pollute the environment and endanger public health if the wastewater is not treated in a proper manner. Therefore, the Group strictly abides by laws and regulations related to sewage discharge, such as the Urban Drainage and Wastewater Treatment Regulations (《城鎮排水與污水處理條例》) and Discharge Standard of Water Pollutants for Medical Organization (《醫療機構水污染物排放標準》), and adopts the sewage discharge standards of relevant laws and regulations as the Group's discharge targets for water pollutants. The Group will ensure that the sewage discharged by its hospitals is disinfected at the internal sewage treatment station and meets the discharge standards before being discharged into the municipal sewage treatment system. To ensure that the sewage discharge has minimal adverse impact on the environment, we have a real-time sewage monitoring system in place and conduct regular pathogen testing to ensure that the pH value, residual chlorine content and bacterial content such as Salmonella and Shigella of the sewage discharged meet the emission standards. During the COVID-19 pandemic, the Group will increase the amount of sewage treatment disinfectants and strengthen the sewage detoxification treatment capacity. In addition, the Group provides annual wastewater treatment training for employees of the internal wastewater treatment stations to enhance wastewater treatment related knowledge, such as wastewater characteristics and hazards, disinfection knowledge, wastewater testing methods, equipment operation and daily maintenance, etc., to ensure the normal operation of the wastewater treatment process.

3.1.3 Waste management

Different non-hazardous wastes and hazardous wastes are generated in the aesthetic medical business of the Group, among which, we attach great importance to the proper treatment of medical waste, as improper treatment may seriously endanger public health and the environment. Therefore, the Group has adopted corresponding waste discharge management and control measures for different wastes to reduce the environmental impact caused by business operations.

For hazardous waste, the Group generates various types of medical waste in its aesthetic medical business which include used disposable medical supplies and instruments such as needles, suturing needles, cotton pads and other wound dressings, waste blood and serum, expired drugs and other discarded human tissues generated in the course of aesthetic surgical procedures, other procedures and medical examinations. In order to ensure proper disposal of medical waste, the Group strictly complies with relevant laws and regulations such as the Regulations on the Management of Medical Waste (《醫療廢物管理條例》) and the Administrative Measures for Medical Waste of Medical and Health Institutions (《醫療衛生機構醫療廢物管理辦法》) of the PRC, and has set up a Hospital Infection Management Committee to formulate clear management procedures for medical waste. In order to regulate the proper handling of medical waste by all our departments in accordance with the law, we have formulated the Medical Waste Management System (《醫療廢物管理制度》), the Medical Waste Recycling Registration System (《醫療廢物回收登記制度》) and the Medical Waste Storage Management System (《醫療廢物儲存管理制度》). We strictly require all the departments to correctly classify medical wastes according to the Medical Waste Classification Catalogue (《醫療廢物分類目錄》) and put them into corresponding special packaging bags or containers. Medical waste will be transferred to the temporary storage place for medical waste in the hospital by the prescribed route after registration. Finally, we will regularly transfer the collected medical waste to qualified third-party medical waste treatment companies for subsequent treatment. In order to prevent emergencies, the Group has formulated the Emergency Treatment Plan for the Loss, Leakage and Spread of Medical Waste and Accidents (《醫療廢物發生流失、洩露擴散和意外事故的應急處理預案》), which clarifies the procedures for various emergencies and the division of responsibilities of each department in emergencies, to ensure that effective control measures can be quickly taken in the event of medical waste leakage, proliferation, and other accidents and to report to relevant government departments in a timely manner. In addition, the Group's hazardous wastes include waste ink cartridges and waste batteries generated during daily office operations. The relevant hazardous wastes will be collected and recycled by qualified institutions.

In addition to hazardous waste, the Group generates non-hazardous waste, mainly general domestic waste. All non-hazardous wastes are properly disposed of by recycling, incineration or landfill.

During the Year, the amount of hazardous waste and non-hazardous waste generated by the Group is as follows:

Waste	**2022**	2021
Hazardous waste (tonnes) *(Note 1)*	**13**	12
Intensity of hazardous waste (tonnes/million RMB revenue)	**0.08**	0.07
Non-hazardous waste (tonnes)	**78**	77
Intensity of non-hazardous waste (tonnes/million RMB revenue)	**0.48**	0.41

Note:

1. *Hazardous waste includes medical waste generated during operations and the hazardous waste generated in offices.*

In order to ensure the effective classification and collection of hazardous waste and non-hazardous waste, the Group regularly trains all the employees to improve their understanding of the management of hazardous waste such as medical waste. We also post waste classification reminder tips in medical premises to promote to customers and their family members the correct classification of medical waste and domestic waste. In addition, the Group actively implements various waste reduction measures to reduce the generation of unnecessary waste. For example, the Group has set up waste sorting and recycling bins to recycle recyclable waste such as waste paper, scrap metal and waste plastics; encouraged employees to reuse stationery such as envelopes and folders; reduced the use of disposable and non-recyclable products, etc.

3.2 Resource Usage

The Group is fully aware of the scarcity of resources and its business operations are required to make the best use of resources as efficiently as possible to avoid unnecessary wastage. Therefore, the Group is committed to saving resources in different aspects. The Group has formulated the Energy Conservation and Emission Reduction Management Policy (節能減排管理制度) in accordance with the Energy Conservation Law of the People's Republic of China (《中華人民共和國節約能源法》) to ensure that the Group can carry out energy conservation and emission reduction work in a long-term and effective manner, improve the efficiency of resource utilization, and promote sustainable development.

In terms of electricity consumption, the Group has implemented various energy-saving measures in its daily operations from various aspects, such as making full use of natural light during daytime, minimizing the time for using lighting equipments and setting the temperature of air conditioners at appropriate level. In particular, the temperature of air conditioners in the office area shall be set at 26℃ or above in summer, and office equipment such as computers shall be configured to automatically enter low energy-consumption and hibernation modes when not in use. Lighting switches are set up in different lighting areas with independent control, to ensure that unused electronic equipment is turned off after office hours, and to regularly clean the lights and air-conditioner filters to maintain energy efficiency and reduce unnecessary energy use. The aesthetic medical hospitals and out-patient departments of the Group have also formulated their own energy-saving management systems, which include different electricity-saving measures to implement the Group's energy-saving philosophy. For example, using energy-efficient lamps and other electrical appliances, turning off lights when the employees are not in use in the office, and not using air conditioners during non-office hours. The Group also encourages all the departments to actively develop and apply new technologies, new processes and new equipment for energy conservation and emission reduction, as well as the conducting of major energy conservation and emission reduction technological transformation projects to gradually phase out technologies and equipment with high energy consumption and start energy conservation in the course of business operations.

In terms of water consumption, the Group regularly conducts leakage tests on concealed water pipes and checks water meter readings to check for hidden water leakage and check for overflowing water tanks to find out the cause of blockage. In addition, in order to reduce running, spraying, dripping and leaking of tap water and avoid wasting water, the Group uses infrared sensor and water-saving faucets, and posts water-saving slogans to remind employees to save water. During the Year, the Group did not have any issue in sourcing water that is fit for purpose.

While assuring the daily needs, the Group expects to achieve the goal of reducing 6% of electricity and water consumption by 2025 with 2021 as the base year through the above energy-saving and water-saving measures.

During the Year, the consumption of energy and water resources of the Group is as follows:

Resource usage	2022	2021
Energy		
Total energy consumption (MWh)	**1,574**	1,321
Vehicle fuel consumption (MWh) *(Note 1)*	**95**	65
Purchased electricity (MWh)	**1,477**	1,256
Energy consumption intensity (MWh/million RMB revenue)	**9.57**	7.01
Water resources		
Total water consumption (cubic meters)	**10,047**	11,814
Water consumption intensity (cubic meters/million RMB revenue)	**61.08**	62.72

Note:

1. *Calculated based on the fuel consumption, relevant national standards for vehicle fuel, and the conversion factors provided by the National Development and Reform Commission of the PRC.*

In terms of paper consumption, the Group makes good use of electronic communication to reduce paper consumption. We have changed the way of issuing financial reports to investors. Investors are informed that the Group's latest financial reports are available on the Company's website instead of distributing printed financial reports to each investor in the past. This measure significantly reduces the amount of printed financial reports, which not only reduces paper consumption, but also indirectly reduces carbon emissions and contributes to environmental protection. In addition, we require the employees to share and send documents by using WeChat groups and emails as much as possible to reduce the number of documents printed. Notices are also posted near the photocopiers to remind the employees to use double-sided photocopying or reuse paper to avoid wastage.

The Group will continue to strengthen propagation and education activities of energy conservation and emission reduction to raise the employees' awareness of electricity, water and office consumables conservation and cultivate conservation habits. The Group also regularly inspects the energy consumption of the office premises and the implementation of relevant energy conservation and emission reduction measures, and rewards departments with outstanding performance in energy conservation and emission reduction; At the same time, the departments that failed to comply with the principle of saving will be punished in accordance with relevant regulations.

3.3 Addressing Climate Change

Climate change has attracted international attention in recent years, and all the sectors of the society have to work together to reduce greenhouse gas emissions to mitigate the negative impact of climate change. The Group has conducted climate change-related risk assessment. Taking into account its business nature, the Group has not identified any significant physical risks and transitional risks caused by climate change to its business operations, and therefore will not have any significant adverse impact on its business operations. Nevertheless, the Group is well aware that greenhouse gas emissions will intensify climate change, and therefore is committed to adopting different emission reduction measures from the perspective of business operations, with the aim to maintain and minimize greenhouse gas emissions as much as possible. In order to reduce carbon emissions generated by daily office vehicles, the Group provides low-carbon driving training for drivers, such as avoiding sudden acceleration and ensuring no idling vehicles run the engine. In terms of business travel, the Group uses video conferences as much as possible to replace unnecessary overseas business trips. For unavoidable business trips, the Group gives priority to direct flights. The Group also encourages the employees to commute by public transportation and participate in environmental protection related activities, such as environmental protection activities organized by environmental protection organizations and different environmental protection training courses. The Group will lead its employees to participate in emission reduction and environmental protection related work to mitigate climate change.

During the Year, the Group's greenhouse gas emissions are as follows:

Greenhouse gas	2022	2021
Total greenhouse gas emissions (tonnes of carbon dioxide equivalent)	**1,074**	912
Direct greenhouse gas emissions (Scope 1) (tonnes of carbon dioxide equivalent) *(Note 1)*	**23**	16
Energy indirect greenhouse gas emissions (Scope 2) (tonnes of carbon dioxide equivalent) *(Note 2)*	**1,040**	883
Other indirect greenhouse gas emissions (Scope 3) (tonnes of carbon dioxide equivalent) *(Note 3)*	**11**	13
Greenhouse gas emissions intensity (tonnes of carbon dioxide equivalent/million RMB revenue)	**6.53**	4.84

Notes:

1. *Direct greenhouse gas emissions include vehicle fuel consumption. The data is calculated based on the accounting method of corporate greenhouse gas emissions and related emission factors provided by the National Development and Reform Commission of the PRC.*

2. *Energy indirect greenhouse emissions include purchased electricity. The data is calculated based on the average carbon dioxide emission factor of regional power grids in the PRC issued by the National Development and Reform Commission of the PRC, as well as the accounting method of corporate greenhouse gas emissions and related emission factors.*

3. *Other indirect greenhouse gas emissions include emissions from flying out on business trips, waste paper disposal, and energy consumption for treatment of water and wastewater. The data is calculated based on the International Civil Aviation Organization Carbon Emission Calculator and the Reporting Guidance on Environmental KPIs published by the Hong Kong Stock Exchange.*

4. TALENT MANAGEMENT

The Group regards its employees as the most valuable asset and an essential element for our development and success. Therefore, the Group is committed to creating a comfortable work environment and benefits for its employees, protecting the employees' rights and interests, work safety and physical and mental health, and providing diverse training and development opportunities.

4.1 Employment rights and benefits

The Group has always put the rights and benefits of the employees in first place. In order to protect the rights and interests of the employees, the Group strictly abides by the relevant labour laws and regulations, including but not limited to the Labour Law of the People's Republic of China (《中華人民共和國勞動法》) a and the Labour Contract Law of the People's Republic of China (《中華人民共和國勞動合同法》), in terms of employees' recruitment, promotion, remuneration and dismissal. The Group has also formulated a sound human resources system to regulate talent recruitment, employee promotion, compensation and dismissal.

When recruiting talents for the Group's business development, we will first advocate recruiting or deploying talents internally, and then recruiting externally, in order to give priority to the current employees. We adopt a fair and open recruitment principle, and will only arrange interviews for suitable candidates based on the requirements of relevant positions and the level of experience, professional knowledge and skills of the candidates, regardless of factors such as age, gender, nationality and religious belief. In order to prevent the misuse of child labour, the Group will check the applicant's identify card, education certificate and other documents to ensure that the applicant's age, identity, education background and appearance correspond with the documents provided, and meet the minimum legal working age required by the PRC labour laws. If any such case is found, the Group will immediately dismiss the relevant personnel who have made irregular recruitment, and properly handle the personnel recruited, and transfer them to the judicial authority if necessary.

As an equal opportunity and anti-discrimination employer, the Group has formulated the Equal Employment Policy (《平等僱傭政策》) to ensure that its employees are not discriminated against on the basis of gender, pregnancy, marital status, disability, family status or race in any way. The Group is committed to providing its employees with equal and fair promotion opportunities, training and treatment. In the event that an employee is being discriminated against, harassed or vilified during employment, he/she may bring the matter to the attention of the Group through the complaint channel. All complaints and related files and interview content are kept strictly confidential. The Group will handle the complaint in a a fair and impartial manner. In addition, the Group actively creates an inclusive employment environment and, where possible, we will make arrangements for persons with disabilities so that they can enjoy the same facilities as able-bodied persons.

In order to care for its employees and motivate them to work actively, the Group not only offers competitive remuneration to its employees, but also provides them with diversified benefits. We provide five basic social insurances, which cover pension, medical, maternity, unemployment and work-related injuries and housing provident fund for the employees, and provide regular employees with physical medical examinations every two years. The Group also provides free non-material medical treatments and surgeries to our regular employees, while material treatments and surgeries only charge the relevant employees the cost of materials. The Group provides lunch subsidies for the employees of its aesthetic medical hospitals and out-patient departments. The Group also provides its employees with sufficient rest time, as well as personal leave, sick leave, marriage leave, maternity leave, funeral leave and annual leave. In addition, the Group lists the weekly and daily work hours of the employees in the Employee Handbook, and pays overtime salaries to the employees who need to work overtime to avoid forced labour. In addition, we pay holiday fees to employees on important festivals and regularly organize group activities or dinners to enhance communication among the employees and their sense of belonging to the Company.

If an employee resigns, the Group will follow with the appropriate resignation procedures in accordance with the Management System for Employee Resignation (《員工離職管理制度》) and conduct an exit interview with the employee to understand his/her reasons for resignation and his/her comments and suggestions on the Group.

During the Year, the Group did not experience any major violations related to employment laws and regulations.

4.2 Employment Statistics

As at the end of the Year, the Group had a total of 322 employees. The detailed employment data by different categories are as follows:

Employment Information	2022 Number of employees (% of total employees)	2021 Number of employees (% of total employees)
Gender		
Male	**73 (23)**	99 (25)
Female	**249 (77)**	296 (75)
Age		
Below 30	**155 (48)**	174 (44)
30 to 50	**128 (40)**	168 (43)
Above 50	**39 (12)**	53 (13)
Geographical location		
The PRC	**322 (100)**	395 (100)
Hong Kong	**0 (0)**	0 (0)
Employment type		
Permanent employees	**322 (100)**	395 (100)
Temporary employees	**0 (0)**	0 (0)

During the Year, the Group's turnover of employees is as follows:

Turnover of employees *(Note 1)*	2022 (%)	2021 (%)
Gender		
Male	**16**	14
Female	**52**	42
Age		
Below 30	**36**	48
30 to 50	**27**	29
Above 50	**6**	10
Geographical location		
The PRC	**34**	35
Hong Kong	**0**	0

Note:

1. *The turnover rate is calculated with reference to Reporting Guidance on Social KPIs issued by the Hong Kong Stock Exchange. The calculation formula is: the number of resigned employees in the specified category/the total number of employees in the specified category × 100. Due to the Group's business nature, resigned employees include services staff who were unable to pass their probation periods, therefore resulting in a higher turnover rate.*

4.3 Occupational Health and Safety

The occupational safety of employees is essential to the operation of the Group. The Group has strictly abided by the Law of the People's Republic of China on the Prevention and Control of Occupational Diseases (《中華人民共和國職業病防治法》) and other occupational health and safety related laws and regulations, and has provided employees responsible for diagnosis and treatment and the use of treatment equipment, operating safety guidelines covering occupational safety issues such as personal protective equipment, emergency response procedures and disease prevention.

In order to reduce the risk of medical staff being infected by the patients during their work, the Group has formulated the Occupational Safety Protection Policy (《職業安全保護制度》) to strengthen the protective measures for medical staff to prevent and respond to occupational safety hazards. Medical staff are required to follow the standard prevention principle and take appropriate protective measures. For example, medical staff are required to wear personal protective equipment such as impervious gloves, masks, goggles and face shields when discharging their duties; ensure sufficient light in the treatment room to avoid being stabbed or scratched by sharp instruments such as needles and blades when performing invasive clinics and nursing care; put used sharp instruments directly into puncture-resistant and anti-leakage sharp boxes, or use needle handling equipment for safe disposal. In the event that a medical staff has accidentally polluted the skin or mucous membranes by the blood and body fluids of a virus-infected person in the course of work, or has been pierced by a sharp instrument which has been contaminated by blood and body fluids containing bacteria, the medical staff should immediately follow the internal guidelines to treat the wound or the contaminated part in order to reduce the virus infection and arrange for timely diagnosis and observation by professional medical institutions.

We understand that the process of processing medical waste will also bring potential safety hazards to employees. Therefore, we disinfect temporary storage sites of medical waste every day and provide the safety protection and emergency handling and other knowledge training for the personnel and management personnel engaged in the classified collection, transportation, temporary storage and disposal of medical waste. All the employees are required to wear personal protective equipment such as surgical masks, aprons and latex gloves when collecting medical waste to reduce the risk of infection. In addition to covering work links or activities with major safety risks and hazards, the Group also formulates corresponding contingency plans for all possible emergencies such as fires and explosions in its emergency response procedures. At the same time, the Group provides employees with detailed emergency handling procedures to minimize the losses caused by emergencies. We organize emergency drills on a regular basis to ensure that employees understand the escape routes when accidents occur and reduce casualties.

During the Year, the Group's number of working days lost due to work-related injuries is 0, and the data of the Group's work-related fatalities in the last three years is as follows:

Work-related fatalities	2022	2021	2020
Number of work-related deaths (person)	**0**	0	0
Rate of work-related deaths (%)	**0**	0	0

Response to COVID-19 pandemic

As the COVID-19 pandemic continues and the associated risk of transmission persists, the Group is determined to carry out pandemic prevention and anti-epidemic work. In order to protect the health and safety of its employees, the Group has implemented different levels of protection measures according to different locations. For example, disposable medical surgical masks and disinfectants are provided in the office, and disposable protective clothing, disposable medical gloves, protective masks and other equipment are provided in high-risk places such as operation rooms, and protective articles are required to be worn and removed according to specific procedures. In addition, the Group will inquire customers about their recent residence, travel and contact history, measured their body temperature, reviewed their nucleic acid test results and COVID-19 related antibody test reports during the diagnosis and treatment process to ensure that they were not infected with COVID-19. A separate emergency isolation room has also been set up in our hospitals. In the unlikely event that an inpatient is found to have suspected symptoms of COVID-19, an effective isolation and referral arrangement will be made immediately to prevent the spread of the virus within the Group.

In addition to formulating various preventive and preventive measures, the Group has posted pandemic-related posters in the office and provided employees with COVID-19-related learning and training to enhance their understanding of COVID-19 and their awareness of pandemic prevention.

4.4 Staff Development and Training

The Group believes that the career development of the employees is an important cornerstone for the success of its business. Therefore, the Group attaches great importance to the individual development of the employees. We not only create a clear career development path for all types of talents, but also encourage talents to grow and progress through performance evaluation, job selection and training, and contribute to the sustainable corporate development.

The Group has established the Performance Management Policy (《績效管理制度》) to set different performance targets for the employees based on their positions in the Group. We comprehensively assess the work performance of the employees based on the principles of "justice, openness, fairness", teamwork and objectivity, and provide guidance and assistance for the employees to improve their performance, while encouraging the employees to continue learning and progress. The results of the performance appraisal will serve as an important basis for promotion, position transfer, selection of annual outstanding employees, salary adjustments and year-end bonuses.

Employees who continuously failed to meet the performance appraisal requirements may be demoted or dismissed.

The Group provides the employees with diversified training opportunities which aimed at assisting their overall development, while improving their management capabilities and work efficiency and to enhance the competitiveness of the Group. Based on the six training principles of all-staff, pertinence, planning, whole process, comprehensiveness and follow-up, the Group has formulated and strictly implemented suitable training plans for all the employees to ensure that all the employees will successfully participate in the training and evaluate the training effect. The Group also provides professional training on aesthetic medical knowledge, medical safety management and safe use of medical supplies to the medical staff of its aesthetic medical hospitals and aesthetic medical out-patient departments to enhance their professional knowledge and skills.

The Group formulates training plans every year. Staff training is mainly divided into the following six categories:

1. New employee training: introduce information such as corporate background, corporate culture and relevant internal systems to new recruits.

2. All-employee training: provide training for all employees on quality and management capability improvement or popularization of development strategies, new systems, new policies, etc.

3. TTT training: provide training by external lecturers mainly for our internal trainer on training system construction, teaching skills, course development, courseware production, etc.

4. Talent echelon training: provide training mainly for college students and internal reserve cadres on career planning for the purpose of building the talent echelon, which consists of internal training and external training.

5. Department training: provide job skills improvement training by each department based on the actual work of the department.

6. External training: arrange external learning for the employees holding management positions or the employees recommended by departments, covering various forms of full-time learning, MBA programs, skill upgrading classes, etc.

During the Year, the time spent on training of the employees of the Group is as follows:

Training	2022 Average training hours for employees (% of employees trained)	2021 Average training hours for employees (% of employees trained)
Gender		
Male	**46 (100)**	48 (100)
Female	**48 (100)**	42 (100)
Employee Function		
Management	**40 (100)**	40 (100)
Physicians and medical staff	**60 (100)**	60 (100)
Sales, marketing and customer service staff	**40 (100)**	20 (100)
Finance, human resources and administration staff	**20 (100)**	20 (100)

Case sharing – CPR operation drill and training

During the Year, the Group's aesthetic medical hospital in Rui'an and the aesthetic medical out-patient departments in the Wuhu organized cardiopulmonary resuscitation ("CPR") operation drilled training for their staff, aiming to consolidate the safety of medical work and to equip medical staff with CPR operation skills and the knowledge to respond to emergency situations. In order to ensure that the trainees will receive adequate CPR training, in addition to providing CPR operation videos, the trainees have also used designated props for operation practice. After the completion of the training, all the trainees passed the training assessment and successfully mastered the CPR operating skills and methods.

5. OPERATING PRACTICES

The major business of the Group is the provision of aesthetic medical services, and the provision of quality services to customers is the Group's top priority. Therefore, the Group is committed to properly manage the supply chain, provide high-quality services and maintain good professional ethics.

5.1 Supply Chain Management

As the Group provides aesthetic medical services, which are closely related to the health and safety of its clients, the Group is extremely rigorous in managing its supply chain and has been looking for high-quality aesthetic medical equipment and supplies to ensure customer satisfaction in the process of diagnosis and treatment. Regarding the aesthetic medical equipment, implants, injection materials, medical materials, medicines and other medical consumables used, the Group has formulated the Procurement Management Policy (《採購管理制度》) to standardize the procurement of various materials to reduce potential risks in the procurement process, and improve the quality and economic efficiency of purchased materials.

In the process of selecting suppliers, the Group takes into account factors such as their product quality, product supply, pricing, reputation, service quality and delivery time, and requires suppliers to hold the requisite licenses and permits required for conducting business, including GMP certificate, GSP certificate, and authorization letter from the product agency manufacturer, etc. The Group also promotes green procurement by giving priority to products and services with energy-efficient labels or logos, higher recycling efficiency, less packaging, longer expiry dates and other products and services with minimum environmental adverse impacts. The Group also attaches great importance to the environmental and social risk management of suppliers. In terms of environment, the Group prefers to cooperate with suppliers with sustainable development, and gives priority to suppliers with ISO50001 energy management system certification, ISO14001 environmental management system certification and low-carbon product certification. In terms of social aspects, suppliers with well-established supply chain management system and international standards related to social risk management such as ISO26000 will be given priority. The Group regularly identifies, assesses and monitors the environmental and social risks of the suppliers, and removes suppliers that failed to meet the cooperation standards from the list of qualified suppliers. We only select suppliers that meet the selection criteria to ensure that the purchased materials are of good quality, can reduce the environmental and social risks and negative impacts brought by the supply chain to the Group, and provide customers with high-quality and safe services.

During the Year, the Group had a total of 38 suppliers and all the suppliers are required to comply with the Group's supplier management system. The Group purchases aesthetic medical equipment and supplies produced by foreign manufacturers from authorized distributors of foreign manufacturers in the PRC to ensure that the quality and legal supply sources of the purchased materials. For most medical supplies, the Group has multiple suppliers to choose from, and the Group closely monitors the performance of the suppliers to manage risks related to the quality and stability of the supply.

5.2 Quality Control

5.2.1 Material acceptance and storage

In order to ensure that the purchased aesthetic medical equipment and supplies can be used safely, the Group strictly abides by the Pharmaceutical Administration Law of the People's Republic of China (《中華人民共和國藥品管理法》) and other relevant laws and regulations on the quality control of medical drugs, and has formulated the Drugs and Inventory Management Policy (《藥品及庫存物資管理制度》). Strict acceptance procedures of medical supplies is carried out, checking on the medical supplies' variety, model, specification, quantity, quality, etc., and unqualified supplies is rejected. For materials that failed to pass the acceptance inspection, the Group will give feedback or arrange for return the materials to the relevant suppliers. For materials that have passed the acceptance inspection, we will take different storage and treatment methods according to the characteristics of each type of materials, and strictly limit unauthorized personnel to access drugs and inventory materials. The warehouse management personnel of the Group will conduct regular inventory of materials to verify the accuracy of the asset records, and closely monitor the expiry date of the materials to ensure that no expired materials will be used. If unqualified drugs are found during the work process or during the inventory of materials, the Group will immediately stop using the drugs, and the Group's quality management personnel will find out the reasons for the failure, and will take corrective and preventive measures in a timely manner. All the expired materials or aesthetic medical equipment with expired service life will be disposed of in a safe manner in accordance with applicable laws and regulations and will be revoked accordingly.

In addition, the Group's medical device trading companies have also formulated the Medical Device Quality Acceptance Procedures (《醫療器械質量驗收程序》) to standardize the acceptance operation procedures, carefully verify the appearance, packaging, labels, instructions and relevant supporting documents of the products, and entrust a third-party medical device testing center to take samples for quality inspection to ensure that the medical supplies accepted meet the requirements of relevant laws, regulations and statutory standards such as the Regulations on the Supervision and Administration of Medical Devices (《醫療器械監督管理條例》) and the Regulations on the Administration of Instructions and Labels for Medical Devices (《醫療器械說明書和標籤管理規定》). For medical supplies that do not meet the quality standards after the inspection, the Group will contact the suppliers to arrange for return of the medical supply.

5.2.2 Service quality control system

Quality is the foundation of the development of the Group, and high-quality medical services brings good social and economic benefits to the Group. Therefore, the Group strictly abides by the Administrative Measures for Aesthetic medical Services (《醫療美容服務管理辦法》), Basic Standards (Implementation) for Aesthetic Medical Institutions and Esthetic medical Departments (Rooms) (《美容醫療機構、醫療美容科基本標準(實行)》) and other laws and regulations related to the quality of esthetic medical services. To ensure the safety and quality of our esthetic medical services, our Group has established a comprehensive quality control system for our esthetic medical hospitals and out-patient departments, details of which are as follows:

– Formulate a set of quality control processes in accordance with the 18 core policies related to the quality of aesthetic medical diagnosis and treatment promulgated by the National Health and Family Planning Commission of the PRC, which includes initial diagnosis, ward inspections, consultations, discussions involving customers safety incidents, medical record preservation, preoperative discussion and shift system, etc., and fully implement the quality control process in our aesthetic medical hospitals and out-patient departments;

– unify the operation procedures of customer services, complaints and feedback in our aesthetic medical hospitals and out-patient departments;

- Recruit and retain qualified physicians and medical staff. When recruiting physicians and medical staff, we will evaluate their academic and professional qualifications, relevant work experience and integrity. We will review the performance of the physicians and medical staff every year to ensure that they have comprehensive professional knowledge, have passed the training and received recognition for diagnosis and treatment operations, and are able to provide customers with the necessary combination of diagnosis and treatment recommendations to achieve ideal cosmetic results. We will continue to closely monitor our qualification registration and licensing records to ensure that our physicians and medical staff comply with PRC laws and regulations;

- Each aesthetic medical hospital is required to conduct quality and safety self-examination, assessment and scoring on a regular basis. The Group conducts assessment from the quality of medical records kept by the medical procedures, operation safety, system and management of each medical room to improve the deficiencies in the service process, thereby improving the overall service quality of the Group.

In addition, the Group will formulate annual medical quality management and continuous improvement plans to implement standardized medical quality management in a more accurate and effective manner, so as to ensure that the Group maintains its competitive advantages in the aesthetic medical market, continues to develop, and provides customers with better services.

5.2.3 Customer feedback system

The Group operates in a service industry, which requires frequent communication with customers. The Group always strives for perfection and continuously improves service quality. Therefore, the Group implements a robust customer feedback management system to determine customer satisfaction with the Group's services, and actively manages and responds to customer feedback. Upon completion of the provision of services, each of the Group's aesthetic medical hospitals and out-patient departments will conduct telephone or WeChat follow-up visits through customer service personnel to understand the customers' opinions on the service.

In the process of actively soliciting customer feedback, the Group may encounter various customer concerns and questions, including customers who wish to refund all or part of the service fees before or after the provision of services due to various personal reasons. The Group will explain in detail to resolve customer concerns as much as possible. For customers who are not fully satisfied with all the aspects of the Group's services, such as employee attitude, waiting time before receiving services and discomfort after treatment, the Group has established a complaint management system and process to provide customers with three complaint channels: (i) online and telephone complaints; (ii) on-site complaints, which include medical department complaints and consulting department complaints; and (iii) third party complaints. After receiving medical complaints from customers, the Group will handle the complaints in a rigorous, open, fair, legal and effective manner and look for improvements. Medical safety meetings are held quarterly or when necessary to discuss major customer complaints and formulate improvement measures.

The main procedures of the Group's complaint management for medical service:



During the Year, the Group received a total of 58 customer complaints, mainly related to dissatisfaction with the results of the operation and treatment performance, and the occurrence of minor complications. After thorough investigation and communication with customers, the Group has made appropriate arrangements such as refund, free repair and complimentary treatment, and all customer complaints have been properly resolved.

For the Group's medical device trading business, we also provide the customers with high-quality after-sales services to answer their inquiries, and regularly visit customers to understand their evaluation of the quality of relevant medical supplies. When customers request is for product return due to quality problems of medical supplies, the Group's quality control inspectors will carefully check the product name, batch number, quantity and other data, and evaluate the damaged packaging or contamination of products. The Group will contact the suppliers to arrange for return if there are quality issues with the relevant medical supplies after verification. During the Year, there is no cases of recall of medical supplies sold by the Group due to safety and health reasons, and the Group did not receive any complaints about medical supplies.

5.3 Intellectual Property and Customer Data Protection

The Group's business does not involve any proprietary esthetic medical research and development. However, the Group is still aware of the importance of safeguarding intellectual property rights such as trademark rights and trade secrets, and protects and enforces the Group's intellectual property rights when any potential infringements are discovered. The Group strictly abides by the Tort Liability Law of the People's Republic of China (《中華人民共和國侵權責任法》) and other relevant laws and regulations on intellectual property rights, and has formulated and implemented a series of measures to protect intellectual property rights. For example, the establishment of a special management department for intellectual property rights, and special training to strengthen the employees' knowledge of intellectual property rights, and the use of legal litigation methods to protect our intellectual property rights and resolve intellectual property rights disputes. In addition, the Group undertakes to use authorised software and requires the employees to apply to the Company before installing any software to avoid infringing the intellectual property rights of others.

In addition, the Group's Customer Data Security Management Policy (《客戶資料安全管理制度》) aims to ensure that the security of the storage and the use of customer data such as customer personal data and medical records, and clearly sets out the precautions for proper handling of customer data and privacy-related data to reduce the risk of illegal use and leakage of customer data. The Group uses information technology systems to manage customer data, and access to these systems is controlled by security levels and requires authorization. The Group requires the employees to comply with the relevant regulations on confidentiality and file management when handling customer data, and takes encryption, encapsulation and other measures to ensure the security of data transmission process. If any customer information is found to be lost, damaged, leaked or tampered with, the Group will take immediate remedial measures and notify the customers in a timely manner.

5.4 Advertising and Marketing

In order to increase the Group's brand awareness and promote its esthetic medical services to more customers, the Group uses different media advertisements to promote its brand and services. The Group understands that medical advertising is strictly regulated in the PRC, therefore, it strictly complies with the Advertisement Law of the People's Republic of China (《中華人民共和國廣告法》) and the Measures for the Administration of Medical Advertising (《醫療廣告管理辦法》) and other advertising-related laws and regulations. In order to regulate and legally publish medical advertisements, the Group strictly implements the Release of Medical Advertisement Review Policy (《發佈醫療廣告審核制度》), which sets out the specifications and terms for publishing medical advertisements in detail. All advertising contents must undergo multiple audits to ensure that it complies with legal requirements and is not inaccurate or misleading. The Group also regularly arranges legal advisers to provide training on advertising-related legal knowledge to the employees to enhance their legal knowledge and ensure that the advertisements produced comply with the regulatory requirements.

The Group attaches great importance to its sales and marketing strategies. In order to better unify the Group's sales and marketing practices, in addition to regulating advertising, the Group has implemented the following internal control measures to regulate employees' sales and marketing activities:

- The price of the services in the marketing activities is determined with reference to the price list approved by the Group and the person in charge of each aesthetic medical hospital and out-patient department;

- The discounts offered to customers must be approved by the head of sales and marketing team;

- Sales and marketing activities must be approved by the Group in advance, and ensure that the services provided come from the service catalog approved by the head of the sales and marketing team;

- After an event organised by the Group, the remaining gifts and registration forms must be collected and returned to the warehouse after checking.

Managing Inappropriate and Excessive Sales Practices

The Group's remuneration package for our physicians, medical staff and client service personnel includes bonuses that is based on their performance and sales figures. As such, the Group is aware of its exposure to the risk of inappropriate and excessive sales practices, which includes advising clients to purchase unnecessary or unsuitable or inadequate aesthetic medical procedures, in order to boost sales figures. Such practice and behaviour could have a material adverse effect on the Group's market reputation and consumer perception, thereby weakening brand affinity and resulting in a decline in the trust of the Group's existing and potential customers in the Group's services. In order to avoid unscrupulous, inappropriate and excessive sales practices, the Group has adopted a series of control measures, including:

1. only providing aesthetic surgery services to adults over the age of 18 (for limited aesthetic surgical procedures preferentially conducted at a younger age such as orthodontics and cosmetic dentistry services, persons under the age of 18 are required to be accompanied by their guardians);

2. requiring customers to complete and sign a registration form to record their personal information as well as the reasons of accepting our aesthetic medical services;

3. verifying the identity of the client, explaining to the client the objective, process, medical risks, potential side effects, normal recovery period of the operation, and answering any questions that the client may raise and requiring the client to sign a consent letter prior to the performance of any procedure by the attending physician;

4. strictly prohibiting sales on credit or any kind of loans to clients in respect of the service fees, in order to avoid the sale of excessive and unnecessary aesthetic medical procedures to clients; and

5. providing trainings regarding proper sales practices to the Group's sales and marketing team from time to time.

5.5 Anti-corruption

In order to maintain the stability of corporate development and clients' confidence, the Group has cracked down on unethical behaviors such as corruption, and therefore has formulated the Anti-corruption and Other Fraud Policy (《反貪污腐敗等舞弊制度》) to provide the employees with a clear explanation of what constitutes corrupt practices and to provide prevention and control measures against corrupt practices. This Policy aims to regulate the conduct of the employees in the performance of their duties, to promote strict compliance with the Anti-Unfair Competition Law of the People's Republic of China (《中華人民共和國反不正當競爭法》), the Code of Conduct for Medical Institution Practitioners (《醫療機構從業人員行為規範》) and other anti-corruption laws, regulations and professional ethics standards, to establish a good culture of integrity and self-discipline, and to prevent occurrence of acts that are detrimental to the interests of the Group and its stakeholders. The Group has also designated a dedicated department to implement the Group's anti-fraud work and provide whistle-blowing channels for all stakeholders of the Group. Stakeholders can report suspicious or confirmed fraud anonymously or in their names. We will keep the reported information strictly confidential and effectively protect the legitimate rights and interests of real-name whistleblowers. Upon receipt of a report, the Group will form a joint investigation team to conduct investigations and to take remedial measures in a timely manner, and will review the loopholes in the original procedures, so as to improve the effectiveness of our internal controls and prevent the recurrence of corruption. Once an investigation is substantiated, any employee who violates the Group's anti-corruption policies will be subject to disciplinary punishment or even dismissal in accordance with the internal regulations. If necessary, the Group will seek assistance from local judicial authorities.

Although the Group did not provide anti-corruption training for employees during the Year, the Group's anti-fraud policy and business code of conduct have been published internally to ensure that the employees understand professional ethics and anti-fraud related policies. In the future, the Group will carry out various anti-corruption-related activities and trainings to strengthen internal anti-corruption awareness. During the Year, the Group did not experience any case of violation of laws and regulations on bribery, corruption, extortion, fraud and money laundering.

6. COMMUNITY INVESTMENT

As a community-caring corporate, the Group attaches great importance to the overall well-being of the surrounding communities where it operates, and hopes that the Group's business can grow together with the community. The Group actively participates in social welfare undertakings, fully fulfills its responsibilities and mission as a corporate citizen, and gives back to the society and the people.

The Group pays special attention to the rights and interests of disabled individuals, and hope to help them integrate into the society without discrimination. Therefore, the Group has formulated comprehensive management measures for the employment of disabled individuals to provide them with equal job opportunities, treatments and benefits. During the Year, the Group engaged a visual-impaired individual at its aesthetic medical hospital in Hangzhou for a 12-month work experience, and took this opportunity to listen to the feelings of the disabled individuals and improve relevant employment and welfare policies.

Looking ahead, the Group look forward to expanding into other areas of community investment to benefit more people in need in the community.

7. APPENDIX I: CONTENT INDEX OF THE "ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING GUIDE"

ESG Indicator	Description	Chapter		Page
A. ENVIRONMENT				
A1 Emissions				
General Disclosure	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste	3.	Environmental Protection	51-56
A1.1	The types of emissions and respective emissions data.	3.1	Pollution and Emission Control	51-54
A1.2	Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions and intensity.	3.3	Addressing Climate Change	57
A1.3	Total hazardous waste produced and intensity.	3.1	Pollution and Emission Control	51-54
A1.4	Total non-hazardous waste produced and intensity.	3.1	Pollution and Emission Control	51-54
A1.5	Description of emissions target(s) set and steps taken to achieve them.	3.1 3.2	Pollution and Emission Control Resource Usage	51-56
A1.6	Description of how hazardous and non-hazardous waste are handled, and a description of reduction target(s) set and the steps taken to achieve these goals.	3.1	Pollution and Emission Control	51-54
A2 Use of Resources				
General Disclosure	Policies on the effective use of resources.	3.2	Resource Usage	54-56
A2.1	Direct and/or indirect energy consumption by type in total and intensity.	3.2	Resource Usage	54-56
A2.2	Water consumption in total and intensity.	3.2	Resource Usage	54-56
A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	3.2	Resource Usage	54-56
A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target (s) set and steps taken to achieve them.	3.2	Resource Usage	54-56
A2.5	Total packaging material used for finished products and with reference to per unit produced.	Since the major business of the Group is to provide aesthetic-related services and related management consulting services, it does not involve the use of any packaging materials.		–

ESG Indicator	Description	Chapter		Page
A. ENVIRONMENT				
A3 The Environment and Natural Resources				
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	3.	Environmental Protection	51-56
A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	3.	Environmental Protection	51-56
A4 Climate Change				
General Disclosure	Policies on identification and mitigation of significant climate-related issues which have impacted, and those which may impact, the issuer.	3.3	Addressing Climate Change	57
A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	By conducting risk assessments related to climate change and considering the nature of the business of the Group, the Group has identified that climate change will not have a significant impact on business operations.		–
B. Social				
B1 Employment				
General Disclosure	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare	4.1	Employment and Benefits	58-59
B1.1	Total workforce by gender, employment type, age group and geographical region.	4.2	Employment Statistics	60
B1.2	Employee turnover by gender, age group and geographical region.	4.2	Employment Statistics	60

ESG Indicator	Description	Chapter		Page
B. Social				
B2 Health and Safety				
General Disclosure	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	4.3	Occupational Health and Safety	61-62
B2.1	Number and rate of work-related fatalities occurred in each of the past three years.	4.3	Occupational Health and Safety	61-62
B2.2	Lost days due to work injury.	4.3	Occupational Health and Safety	61-62
B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	4.3	Occupational Health and Safety	61-62
B3 Development and Training				
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	4.4	Staff Development and Training	62-64
B3.1	The percentage of employees trained by gender and employment category.	4.4	Staff Development and Training	62-64
B3.2	The average training hours completed per employee by gender and employee category.	4.4	Staff Development and Training	62-64
B4 Labour Standards				
General Disclosure	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child or forced labour.	4.1	Employment and Benefits	58-59
B4.1	Description of measures to review employment practices to avoid child and forced labour.	4.1	Employment and Benefits	58-59
B4.2	Description of steps taken to eliminate such practices when discovered.	4.1	Employment and Benefits	58-59

ESG Indicator	Description	Chapter		Page
B. Social				
B5 Supply Chain Management				
General Disclosure	Policies on managing environmental and social risks of the supply chain.	5.1	Supply Chain Management	64-65
B5.1	Number of suppliers by geographical region.	5.1	Supply Chain Management	64-65
B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, how they are implemented and monitored.	5.1	Supply Chain Management	64-65
B5.3	Description of practices to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	5.1	Supply Chain Management	64-65
B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	5.1	Supply Chain Management	64-65
B6 Product Responsibility				
General Disclosure	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labeling and privacy matters relating to products and services provided and methods of redress.	5. 5.2 5.3 5.4	Operating Practices; Quality Control; Intellectual Property Rights and Customer Data Protection; Advertising and Marketing	64-70
B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	5.2	Quality Control	65-69
B6.2	Number of products and service related complaints received and how they are dealt with.	5.2	Quality Control	65-69
B6.3	Description of practices relating to observing and protecting intellectual property rights.	5.3	Intellectual Property Rights and Customer Data Protection	69
B6.4	Description of quality assurance process and recall procedures.	5.2	Quality Control	65-69
B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	5.3	Intellectual Property Rights and Customer Data Protection	69

ESG Indicator	Description	Chapter		Page
B. Social				
B7 Anti-corruption				
General Disclosure	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	5.5	Anti-corruption	71-72
B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	5.5	Anti-corruption	71-72
B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	5.5	Anti-corruption	71-72
B7.3	Description of anti-corruption training provided to directors and staff.	The Group has not held anti-corruption related trainings during the Year		–
B8 Community Investment				
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	6.	Community Investment	72
B8.1	Focus areas of contribution.	6.	Community Investment	72
B8.2	Resources contributed to the focus area.	6.	Community Investment	72

DIRECTORS' REPORT

The Board is pleased to submit the Group's annual report and the audited consolidated financial statements for the Year.

PRINCIPAL ACTIVITIES

The Group is a leading aesthetic medical service provider in Zhejiang Province, the PRC, providing clients with a broad range of aesthetic medical services to meet their different aesthetic and anti-aging objectives. In 2022, the main business of the Group was the provision of aesthetic surgery services, minimally-invasive aesthetic services and aesthetic dermatology services. Details of the key subsidiaries of the Group in 2022 are set out in Note 1 to the financial statements.

SUMMARY OF RESULTS

The results of the Group in 2022 are set out in the consolidated statement of profit or loss on page 98 of this annual report.

The Group's revenue and results are mainly derived from the aesthetic medical services provided by 4 aesthetic medical institutions. A detailed review of the business development of the Group in 2022 and the possible future outlook are set out in the section "Management Discussion and Analysis" of this annual report.

FINANCIAL SUMMARY

The summary of the results, assets and liabilities of the Group is set out on page 184 of this annual report. This summary does not form part of the audited consolidated financial statements.

BUSINESS REVIEW

The business review of the Group for the Year is set out in the section headed "Management Discussion and Analysis" on pages 11 to 26 of this report.

COMPLIANCE WITH THE RELEVANT LAWS AND REGULATIONS

During the Year, the Group is not aware of material non-compliance with the relevant laws and regulations that have a significant impact on the business and operations of the Group.

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Company recognises its responsibility to protect the environment from its business activities. The Company is committed to the sustainable development of the environment and our society. The Group has endeavoured to comply with the laws and regulations regarding environmental protection and adopted effective environmental practices to ensure that our business meets the required standards and ethics in respect of environmental protection. Information on environmental policies and performance of the Group are set out in the Environment, Social and Governance Report on pages 48 to 77 of this annual report.

RELATIONSHIP WITH STAKEHOLDERS

The success of the Group relies on the support of key stakeholders, including the Directors and senior management members, employees, clients and suppliers.

Employees

As of 31 December 2022, the Group has 322 employees, all of whom are located in the PRC. Specifically, there are 7 management staff, 131 physicians and medical staff, 153 sales, marketing, client service and other business staff, 31 finance and administration staff. We believe we have a good relationship with our employees. Our employees are not represented by a labour union. During the Year, we have not experienced any material disruptions to our business operations due to labour disputes or strikes. We contribute to social security insurance and housing provident funds for our employees under relevant PRC laws, rules and regulations.

We value the importance of providing a safe, healthy and efficient work environment for all of our employees. We also place significant emphasis on employee trainings and development, and we invest in education and training programs for our employees with the purpose of upgrading their knowledge on the latest development of the aesthetic medical industry.

Customers

During the Year, all of our aesthetic medical service clients were individual retail clients, the clients of our aesthetic medical management consulting services were aesthetic medical institutions, and the clients of our sales of medical aesthetic equipment and products are sales agencies and individual retail clients. Our high quality services and stringent safety controls have translated into our low number of client complaints and high number of repeat clients.

Suppliers

The supplies required in our operations primarily include those who provide implants, injection materials, pharmaceuticals, other medical consumables and medical aesthetic skincare products.

MAJOR CUSTOMERS AND SUPPLIERS

In 2022, the total revenue or sales attributable to the five largest clients of the Group accounted for less than 30% of the total revenue of the Group.

In 2022, the purchase amount from the five largest suppliers of the Group accounted for approximately 47.3% of the Group's total purchase amount; and the purchase amount from the largest supplier of the Group accounted for approximately 24.5% of the Group's total purchase amount.

In 2022, to the best knowledge of the Directors, none of the Directors, their close associates, or any shareholder who owns more than 5% of our issued share capital had any interest in any of our five largest clients or suppliers.

PROPERTIES AND EQUIPMENT

Details of the changes in the properties and equipment of the Group for the year ended 31 December 2022 are set out in Note 13 to the financial statements.

ANNUAL GENERAL MEETING

The annual general meeting of the Company (the "2023 AGM") will be held on Friday, 16 June 2023. A notice convening the 2023 AGM will be published and dispatched to the shareholders of the Company in the manner required by the Listing Rules in due course.

CLOSURE OF THE REGISTER OF MEMBERS

The register of members of the Company will be closed from Tuesday, 13 June 2023 to Friday, 16 June 2023, both days inclusive, in order to determine the identity of the shareholders of the Company who are entitled to attend the forthcoming 2023 AGM to be held on Friday, 16 June 2023. To be eligible for attending and voting at the 2023 AGM, all transfers accompanied by the relevant share certificates and transfer forms must be lodged with the Company's Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong before 4:30 p.m. on Monday, 12 June 2023.

RESERVES

The changes in the Group's reserves during 2022 are set out in the consolidated statement of changes in equity on page 102.

DIVIDENDS

During the Year, the Board did not distribute dividends to the shareholders of the Company (2021: Nil).

SUBSIDIARIES

Details of the Company's subsidiaries are set out in Note 1 to the financial statements.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Year, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any listed securities of the Company.

SHARE CAPITAL

Details of the changes in the Company's share capital during the Year are set out in Note 29 to the financial statement.

EQUITY-LINKED AGREEMENTS

Save as disclosed in the section headed "Share Option Scheme" of this annual report, no equity-linked agreements have been entered into during the Year or subsisted at the end of the Year.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Company's Articles of Association or the laws of the Cayman Islands, which would oblige the Company to offer new shares on a pro-rata basis to its existing shareholders.

TAX RELIEF AND EXEMPTION

The Directors are not aware of any tax relief and exemption available to the shareholders of the Company by reason of their holding of the Company's securities.

PERMITTED INDEMNITY PROVISION

Pursuant to the Articles and subject to the applicable laws and regulations, every Director shall be entitled to be indemnified out of the assets of the Company against all losses or liabilities incurred or sustained by him as a Director in defending any proceedings, whether civil or criminal, in which judgment is given in his/her favour, or in which he/she is acquitted.

The Company has maintained appropriate liability insurance for its Directors and senior management.

USE OF NET PROCEEDS FROM THE GLOBAL OFFERING

The Group was listed on the Main Board of the Stock Exchange on 28 December 2020, and after exercising the over-allotment option, a total of 376,540,000 shares were issued. After deducting the underwriting commission and related expenses, the net proceeds raised from the listing was approximately HK$81.7 million (the "Net Proceeds"). We will gradually use the Net Proceeds from the global offering in the manner set out in the section "Future Plans and Use of Proceeds" in the Prospectus.

DIRECTORS

The Directors during the Year and up to the date of this report are as follows:

Executive Directors

Mr. Fu Haishu *(Chairman)*
Mr. Song Jianliang *(Chief Executive Officer)*
Mr. Wang Ying

Non-executive Director

Ms. Fan Qirui *(resigned on 19 September 2022)*

Independent Non-executive Directors

Mr. Cao Dequan
Ms. Yang Xiaofen
Mr. Liu Teng

DIRECTORS' SERVICE CONTRACTS

None of the Directors has entered into any service contract with the Company which is not determinable by the Company and any of its subsidiaries within one year without payment of compensation (other than statutory compensation).

EMOLUMENT POLICY

Our Remuneration Committee was established in compliance with the Listing Rules. The primary duties of the Remuneration Committee are to make recommendations to the Board regarding our policy and structure for the remuneration of our Directors and senior management and on the establishment of a formal and transparent procedure for developing remuneration policies, and to make recommendations to the Board on the remuneration packages of our Directors and senior management and on the employee benefit arrangement.

Under the Remuneration Policy of the Company, the Remuneration Committee will consider factors such as corporate and individual key performance, remuneration paid by comparable companies and other economic factors. Details of the Directors' remuneration and the five highest paid individuals are set out in notes 8 and 9 to the financial statements, respectively.

INDEPENDENCE CONFIRMATION LETTERS FORM INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received from all INEDs the annual independence confirmations on each of the factors mentioned in Rules 3.13(1) to (8) of the Listing Rules. The Company believes that all INEDs are independent.

MANAGEMENT CONTRACTS

In 2022, the Company did not enter into any contract, other than the service contracts with the Directors or any person engaged in the full-time employment of the Company, whereby any individual, firm or body corporate undertakes the management and administration of the whole, or any substantial part of any business of the Company.

DIRECTORS' AND CONTROLLING SHAREHOLDERS' MATERIAL INTERESTS IN TRANSACTIONS, ARRANGEMENTS AND CONTRACTS OF SIGNIFICANCE

Save as disclosed in this annual report, there were no transactions, arrangements or contracts of significance in relation to the Group's business, to which the Company or any of its subsidiaries was a party and in which any of the Directors or the controlling shareholders of the Company had a material interest, whether directly or indirectly during the Year.

DIRECTORS' INTERESTS IN COMPETING BUSINESS

None of the Directors had any interest in any business which competes or may compete, either directly or indirectly, with the business of the Group.

INTERESTS AND SHORT POSITIONS OF DIRECTORS AND CHIEF EXECUTIVES IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 31 December 2022, the interests and short positions of the Directors and chief executives of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (as defined in Section XV of the Securities and Futures Ordinance ("SFO")), as recorded in the register maintained by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

Long Positions in Shares, Underlying Shares and Debentures of the Company

Name	Capacity/Nature of interests	Number of shares held	Approximate percentage of the interest in the Company[1]
Mr. Fu Haishu[2]	Interest in a controlled corporation	1,109,283,463	53.10%
Mr. Song Jianliang[3]	Beneficial owner	2,000,000	0.10%
Mr. Wang Ying[3]	Beneficial owner	2,000,000	0.10%

Notes:

1. *The percentage is calculated based on the total number of issued shares of the Company as at 31 December 2022 (i.e. 2,089,040,000 shares).*

2. *These shares are held by Ruide Consultation Limited, a company wholly-owned by Mr. Fu Haishu.*

3. *These shares of the Company represent the share options granted by the Company on 23 August 2021 under the share option scheme adopted by the shareholders of the Company on 4 December 2020 (the "Share Option Scheme").*

Long Positions in Shares, Underlying Shares and Debentures in the associated corporation

Name of Director	Name of the associated corporation	Capacity/Nature of interests	Number of ordinary share(s) held	Approximate percentage of the total issued shares of the associated corporation
Mr. Fu Haishu	Ruide Consultation Limited	Beneficial owner	50,000	100%

Save as disclosed above, as at 31 December 2022, none of the Directors and chief executives of the Company or their respective associates had any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to be owned under the relevant provisions of the SFO), or which were required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein, or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

DIRECTORS' RIGHTS TO PURCHASE SHARES OR BONDS

Save as disclosed in this annual report and the Prospectus, none of the Company, any of its holding companies, subsidiaries or fellow subsidiaries have entered into any arrangement at any time during the Year, so that the Directors or chief executives of the Company or any of their respective spouses or children under the age of 18 may gain benefits by purchasing shares or bonds of the Company or any other corporate.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSON'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 31 December 2022, the interests or short positions of substantial shareholders of the Company and other persons in the shares or underlying shares of the Company as recorded in the register maintained by the Company under Section 336 of the SFO, or otherwise notified to the Company were as follows:

Substantial Shareholders' and Other Person's Long Positions in Shares and Underlying Shares of the Company

Name	Capacity/Nature of interests	Number of shares held	Approximate percentage of the interest in the Company[1]
Ruide Consultation Limited	Beneficial owner	1,109,283,463	53.10%
Jin Chunmiao[2]	Interest of spouse	1,109,283,463	53.10%
Beauty Milkway (HK) LIMITED	Beneficial owner	129,128,745	6.18%
China Orient Asset Management (International) Holding Limited[3]	Interest in a controlled corporation	112,244,454	5.37%
China Orient Asset Management Co., Ltd.[3]	Interest in a controlled corporation	112,244,454	5.37%
Dong Yin Development (Holdings) Limited[3]	Interest in a controlled corporation	112,244,454	5.37%
Wise Leader Assets Ltd.[3]	Interest in a controlled corporation	112,244,454	5.37%
上海東爐健康管理合夥企業（有限合夥）[3]	Beneficial owner	112,244,454	5.37%
東方資產管理（中國）控股有限公司[3]	Interest in a controlled corporation	112,244,454	5.37%
深圳東方創業投資有限公司[3]	Interest in a controlled corporation	112,244,454	5.37%
深圳前海財富東方股權投資基金管理有限公司[3]	Interest in a controlled corporation	112,244,454	5.37%
青海省東方藏醫藥產業發展基金（有限合夥）[3]	Interest in a controlled corporation	112,244,454	5.37%
青海省東方藏醫藥產業投資管理有限公司[3]	Interest in a controlled corporation	112,244,454	5.37%

Notes:

1. *The percentage is calculated based on the total number of issued shares of the Company as at 31 December 2022 (i.e. 2,089,040,000 shares).*

2. *Ms. Jin Chunmiao is the spouse of Mr. Fu Haishu, and is therefore deemed to be interested in the shares deemed or taken to be owned by Mr. Fu under the SFO.*

3. *According to information available to the Company, 112,244,454 Shares are held by 上海東爐健康管理合夥企業(有限合夥) in the capacity of beneficial owner. 上海東爐健康管理合夥企業(有限合夥) is owned as to approximately 99.81% and approximately 0.19% by 青海省東方藏醫藥產業發展基金(有限合夥) and 青海省東方藏醫藥產業投資管理有限公司 respectively. 青海省東方藏醫藥產業發展基金(有限合夥) is owned as to approximately 48.78% and approximately 2.44% by 深圳東方創業投資有限公司 and 青海省東方藏醫藥產業投資管理有限公司 respectively. 青海省東方藏醫藥產業投資管理有限公司 is owned as to approximately 51% by 深圳前海財富東方股權投資基金管理有限公司. 深圳東方創業投資有限公司 is wholly-owned by 東方資產管理(中國)控股有限公司. 深圳前海財富東方股權投資基金管理有限公司 and 東方資產管理(中國)控股有限公司 is wholly-owned by China Orient Asset Management (International) Holding Limited. Each of Dong Yin Development (Holdings) Limited and Wise Leader Assets Ltd. owns 50% of China Orient Asset Management (International) Holding Limited. Wise Leader Assets Ltd. is wholly-owned by Dong Yin Development (Holdings) Limited, which is wholly-owned by China Orient Asset Management Co., Ltd.*

   Each of 上海東爐健康管理合夥企業(有限合夥), 青海省東方藏醫藥產業發展基金(有限合夥), 青海省東方藏醫藥產業投資管理有限公司, 深圳東方創業投資有限公司, 東方資產管理(中國)控股有限公司, China Orient Asset Management (International) Holding Limited, Dong Yin Development (Holdings) Limited, Wise Leader Assets Ltd. and China Orient Asset Management Co., Ltd. is deemed to be interested in 112,244,454 Shares held by 上海東爐健康管理合夥企業(有限合夥) under the SFO.

Save as disclosed above, as at 31 December 2022, there are no other interests or short positions in the shares and underlying shares of the Company as recorded in the register required to be maintained under Section 336 of the SFO.

SHARE OPTION SCHEME

The Share Option Scheme was adopted by the shareholders of the Company on 4 December 2020. The Share Option Scheme is established to recognize and acknowledge the contributions that the Eligible Participants (as defined below) had or may have made to our Group. The Share Option Scheme will provide the Eligible Participants an opportunity to have a personal stake in our Company with the view to achieving the following objectives:

(i) motivate the Eligible Participants to optimise their performance efficiency for the benefit of our Group; and

(ii) attract and retain or otherwise maintain an on-going business relationship with the Eligible Participants whose contributions are or will be beneficial to the long-term growth of our Group.

The Board may, at its discretion, offer to grant an option to the following persons (collectively the "Eligible Participants") to subscribe for such number of new shares of the Company (the "Shares") as the Board may determine at an exercise price(Remark):

(i) any full-time or part-time employees, executives or officers of our Company or any of its subsidiaries;

(ii) any directors (including independent non-executive directors) of our Company or any of its subsidiaries; and

(iii) any advisers, consultants, agents, suppliers, clients, distributors and such other persons who in the sole opinion of the Board will contribute or have contributed to our Company and/or any of its subsidiaries.

Upon acceptance of the option, the grantee shall pay HK$1 to our Company by way of consideration for the grant. Any offer to grant an option to subscribe for Shares may be accepted in respect of less than the number of Shares for which it is offered provided that it is accepted in respect of a board lot of dealing in Shares on the Stock Exchange or an integral multiple thereof and such number is clearly stated in the duplicate offer document constituting the acceptance of the option. To the extent that the offer to grant an option is not accepted by any prescribed acceptance date, it shall be deemed to have been irrevocably declined.

The maximum number of Shares in respect of which options may be granted under the Share Option Scheme and under any other share option schemes of our Company must not in aggregate exceed 10% of the total number of Shares in issue immediately following the Listing, being 205,500,000 Shares, excluding for this purpose Shares which would have been issuable pursuant to options which have lapsed in accordance with the terms of the Share Option Scheme (or any other share option schemes of our Company). Subject to the issue of a circular by our Company and the approval of our Shareholders in general meeting and/or such other requirements prescribed under the Listing Rules from time to time, the Board may:

(i) renew this limit at any time to 10% of our Shares in issue as at the date of the approval by our Shareholders in general meeting; and/or

(ii) grant options beyond the 10% limit to Eligible Participants specifically identified by the Board.

The total number of shares available for issue upon exercise of the outstanding Share Options and the Share options to be granted under the Share Option Scheme is 205,500,000 shares of the Company, representing approximately 9.84% of the total number of shares of the Company in issue as at the date of this report.

The maximum number of Shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the Share Option Scheme and any other share option schemes of our Company at any time shall not exceed 30% of our Shares in issue from time to time. No options shall be granted under any schemes of our Company (including the Share Option Scheme) if this will result in the 30% limit being exceeded.

The total number of Shares issued and which may fall to be issued upon exercise of the options granted under the Share Option Scheme and any other share option schemes of our Company (including both exercised and outstanding options) to each Eligible Participant in any 12-month period up to the date of grant shall not exceed 1% of our Shares in issue as at the date of grant. Any further grant of options in excess of this 1% limit shall be subject to the approval of our Shareholders in general meeting with such Eligible Participant and his/her close associates (as defined in the Listing Rules) (or his/her associates if the Eligible Participant is a core connected person) abstaining from voting.

The exercise price of a Share in respect of any particular option granted under the Share Option Scheme shall be such price as the Board in its absolute discretion shall determine, save that such price must be at least the higher of:

(i) the official closing price of our Shares as stated in the Stock Exchange's daily quotation sheets on the date of grant, which must be a day on which the Stock Exchange is open for the business of dealing in securities;

(ii) the average of the official closing prices of our Shares as stated in the Stock Exchange's daily quotation sheets for the five business days immediately preceding the date of grant; and

(iii) the nominal value of a Share.

Any grant of options to a director, chief executive or substantial shareholder (as defined in the Listing Rules) of our Company or any of their respective associates (as defined in the Listing Rules) is required to be approved by the independent non-executive Directors (excluding any independent non-executive Director who is the grantee of the options). If the Board proposes to grant options to a substantial shareholder or any independent non-executive Director or their respective associates (as defined in the Listing Rules) which will result in the number of Shares issued and to be issued upon exercise of options granted and to be granted (including options exercised, cancelled and outstanding) to such person under the Share Option Scheme and any other share option schemes of our Company in the 12-month period up to and including the date of such grant:

(i) representing in aggregate over 0.1% or such other percentage as may be from time to time provided under the Listing Rules of our Shares in issue on the date of such grant; and

(ii) having an aggregate value in excess of HK$5 million or such other sum as may be from time to time provided under the Listing Rules, based on the official closing price of our Shares at the date of each grant,

such further grant of options will be subject to the issue of a circular by our Company and the approval of our Shareholders in general meeting on a poll at which the grantee, his/her associates and all core connected persons (as defined in the Listing Rules) of our Company shall abstain from voting in favour, and/or such other requirements prescribed under the Listing Rules from time to time[(Remark)].

An option may be exercised in accordance with the terms of the Share Option Scheme at any time commencing the date upon which the option is deemed to be granted and accepted and prior to the expiry of 10 years from that date. The period during which an option may be exercised will be determined by the Board in its absolute discretion, save that no option may be exercised more than 10 years after it has been granted. Subject to earlier termination by our Company in general meeting or by the Board, the Share Option Scheme shall be valid and effective for a period commencing on the Listing Date and ending on the tenth anniversary of the Listing Date (both dates inclusive), after which no further options shall be offered but the provisions of the Share Option Scheme shall in all other respects remain in full force and effect to the extent necessary to give effect to the exercise of any options granted prior thereto or otherwise as may be required in accordance with the provisions of the Share Option Scheme. Options granted prior thereto but not yet exercised shall continue to be valid and exercisable in accordance with the Share Option Scheme.

Name or category of grantees	Date of grant of share options	Exercise Price (HK$)	Vesting Period	Exercise Period	Balance as at 01.01.2022	Granted during the Year	Exercised during the Year	Lapsed during the Year	Cancelled during the Year	Balance as at 31.12.2022
					Number of share options					
Directors										
Song Jianliang	23/08/2021	0.492	23/08/2021-22/08/2022	23/08/2022-22/02/2023	1,000,000	–	–	–	–	1,000,000
	23/08/2021	0.492	23/08/2021-22/08/2023	23/08/2023-22/02/2024	1,000,000	–	–	–	–	1,000,000
Wang Ying	23/08/2021	0.492	23/08/2021-22/08/2022	23/08/2022-22/02/2023	1,000,000	–	–	–	–	1,000,000
	23/08/2021	0.492	23/08/2021-22/08/2023	23/08/2023-22/02/2024	1,000,000	–	–	–	–	1,000,000
Other employees										
In aggregate	23/08/2021	0.492	23/08/2021-22/08/2022	23/08/2022-22/02/2023	5,900,000	–	–	600,000	–	5,300,000
	23/08/2021	0.492	23/08/2021-22/08/2023	23/08/2023-22/02/2024	5,900,000	–	–	600,000	–	5,300,000
	29/08/2022	0.1678	29/08/2022-28/08/2023	29/08/2023-28/08/2032	–	287,814 *(Note)*	–	–	–	287,814
	29/08/2022	0.1678	29/08/2022-28/08/2024	29/08/2024-28/08/2032	–	287,814 *(Note)*	–	–	–	287,814
	29/08/2022	0.1678	29/08/2022-28/08/2025	29/08/2025-28/08/2032	–	431,722 *(Note)*	–	–	–	431,722
	29/08/2022	0.1678	29/08/2022-28/08/2026	29/08/2026-28/08/2032	–	431,722 *(Note)*	–	–	–	431,722
Service Providers										
In aggregate	23/08/2021	0.492	23/08/2021-22/08/2022	23/08/2022-22/02/2023	40,680,462	–	–	–	–	40,680,462
	23/08/2021	0.492	23/08/2021-22/08/2023	23/08/2023-22/02/2024	40,680,466	–	–	–	–	40,680,466
	29/08/2022	0.1678	29/08/2022-28/08/2023	29/08/2023-28/08/2032	–	21,600,000 *(Note)*	–	–	–	21,600,000
	29/08/2022	0.1678	29/08/2022-28/08/2024	29/08/2024-28/08/2032	–	21,600,000 *(Note)*	–	–	–	21,600,000
	29/08/2022	0.1678	29/08/2022-28/08/2025	29/08/2025-28/08/2032	–	32,400,000 *(Note)*	–	–	–	32,400,000
	29/08/2022	0.1678	29/08/2022-28/08/2026	29/08/2026-28/08/2032	–	32,400,000 *(Note)*	–	–	–	32,400,000
Total					**97,160,928**	**109,439,072**	**–**	**1,200,000**	**–**	**205,400,000**

Note: The closing price of the Shares immediately before 29 August 2022, the date on which those options were granted, was HK$0.167.

As at the beginning of the Year, the number of options available for grant under the Share Option Scheme is 108,339,072 Shares. As at the end of the Year, the number of options available for grant under the Share Option Scheme is 100,000 Shares. The number of Shares that may be issued in respect of options granted under all share option schemes of the Company during the Year divided by the weighted average number of issued Shares for the Year is 0.0641.

The model used to calculate the fair value of the options granted on 23 August 2021 and 29 August 2022 is binomial option pricing model. The model is one of the commonly used models to estimate the fair value of an option. The variables and assumptions used in computing the fair value of the options are based on the management's best estimate. The value of an option varies with different variables of a number of subjective assumptions. Any change in the variables so adopted may materially affect the estimation of the fair value of an option.

Remarks:

1. Pursuant to Rule 17.03A of the Listing Rules, the participants of a scheme shall only comprise directors and employees of the issuer or any of its subsidiaries and the persons who provide services to the issuer group on a continuing or recurring basis in its ordinary and usual course of business which are in the interests of the long term growth of the issuer group.

2. Pursuant to Rule 17.03F of the Listing Rules, the vesting period for options shall not be less than 12 months.

3. Pursuant to Rule 17.04(3) of the Listing Rules, where any grant of options or awards to an independent non-executive director or a substantial shareholder of the listed issuer, or any of their respective associates, would result in the shares issued and to be issued in respect of all options and awards granted (excluding any options and awards lapsed in accordance with the terms of the scheme) to such person in the 12-month period up to and including the date of such grant representing in aggregate over 0.1% of the relevant class of shares in issue, such further grant of options or awards must be approved by shareholders of the listed issuer in general meeting in the manner set out in rule 17.04(4). Pursuant to Rule 17.04(4) of the Listing Rules, the listed issuer must send a circular to the shareholders. The grantee, his/her associates and all core connected persons of the listed issuer must abstain from voting in favour at such general meeting. The listed issuer must comply with the requirements under rules 13.40, 13.41 and 13.42.

RELATED PARTY TRANSACTIONS

Details of related party transactions of the Group during the Year are set out in Note 35 to the financial statements. Such transactions were either (i) fully exempt from the reporting, annual review, announcement and independent Shareholders' approval requirements under Rule 14A.76(1) of the Listing Rules; or (ii) did not constitute connected transactions or continuing connected transactions under Chapter 14A of the Listing Rules.

NON-EXEMPT CONTINUING CONNECTED TRANSACTIONS

Contractual Arrangements

Background and Reasons

We are a leading aesthetic medical service provider in Zhejiang Province, the PRC. According to the Special Administrative Measures (Negative List) for the Access of Foreign Investment (2021) (the "2021 Negative List"), medical institutions may not be held 100% by foreign investments, and foreign investments are restricted to the form of sino-foreign equity joint venture. In view of the foreign ownership restriction, our provision of aesthetic medical services is subject to foreign investment restriction in accordance with the 2021 Negative List. The entities that we control certain percentage of their shareholding through the contractual arrangements (the "VIE Entities") are Hangzhou Bellafill, Hangzhou Raily and Ruian Raily, which were established under the laws of the PRC. We do not directly own 100% equity interest in the VIE Entities. Hangzhou Bellafill is currently held as to 70% by Raily Beauty Consultation and 30% by Mr. Fu Haishu while each of Hangzhou Raily and Ruian Raily is owned as to 70% by Raily Beauty Consultation and 30% by Ningbo Ruixuan Investment Management Partnership (LLP) ("Ningbo Ruixuan").

In light of the foreign investment restriction, in order to comply with PRC laws and regulations and maintain effective control over all of our operations as well as to obtain the maximum economic benefits of the VIE Entities, a series of contractual arrangements (the "Contractual Arrangements") have been entered into by, among others, Hangzhou Raily, Hangzhou Bellafill, Ruian Raily and the Registered Shareholders (as defined below) on 1 January 2019. Through shareholdings and the Contractual Arrangements, we have maintained effective control over the financial and operational policies of the VIE Entities and have become entitled to all the economic benefits from their operations.

The existing agreements underlying such Contractual Arrangements with each of the VIE Entities include: (1) Business Cooperation Agreements, (2) Exclusive Option Agreements, (3) Equity Pledge Agreements, and (4) Voting Rights Proxy Agreements. Our Directors believe that the Contractual Arrangements are fair and reasonable because: (i) the Contractual Arrangements were freely negotiated and entered into by and among Raily Beauty Consultation, the VIE Entities and the Registered Shareholders; (ii) by entering into the Business Operation Agreements (as defined below) with Raily Beauty Consultation, the VIE Entities will enjoy better management, consultancy and technical support from us as well as better market reputation after the Listing; and (iii) a number of other companies use similar arrangements to accomplish the same purpose.

The Contractual Arrangements shall continue to enable our Group to receive the economic benefits derived by the VIE Entities through: (i) our Group's right (if and when so allowed under the applicable PRC laws) to acquire, all or part of the entire equity interests in the VIE Entities at the minimum amount of consideration permitted by applicable PRC laws and regulations; (ii) the business structure under which the profit generated by the VIE Entities is substantially retained by our Group; and (iii) our Group's right to control the management and operation of, as well as, in substance, all of the voting rights of the VIE Entities.

We own 70% equity interest in each of the VIE Entities and as a result of the aforementioned Contractual Arrangements. We have obtained control of the remaining equity interest of the VIE Entities through Raily Beauty Consultation. As such, our Company can receive all of the economic interests returns generated by the VIE Entities.

Contractual Arrangements overview

1. Details of the VIE Entities and Registered Shareholders

VIE Entities:	Hangzhou Raily, Hangzhou Bellafill and Ruian Raily
Registered Share-holders:	the shareholders of Hangzhou Bellafill, Hangzhou Raily and Ruian Raily including Mr. Fu Haishu and Ningbo Ruixuan

2. Description of the VIE Entities' business

Our VIE Entities are aesthetic medical services provider in the PRC, according to the 2021 Negative List, medical institutions are restricted to the form of sino-foreign equity joint venture.

3. Summary of terms of contractual arrangements

The Contractual Arrangements which were in place during the Year are as follows:

(i) Pursuant to the business cooperation agreements dated 1 January 2019 entered into by each of the VIE Entities, its Registered Shareholders and Raily Beauty Consultation (each a "Business Cooperation Agreement", and collectively the "Business Cooperation Agreements"), each of the VIE Entities agreed to engage Raily Beauty Consultation as its exclusive provider of technical support, consultation and other services, including (1) asset and business management consultation; (2) human resources consultation; (3) marketing consultation; (4) advertising support; (5) technical support; (6) medical technical consultation; (7) product quality control support; (8) service quality control support; (9) system integration; (10) material contracts consultation; (11) mergers and acquisitions consultation; and (12) other relevant services requested by each of the VIE Entities from time to time to the extent permitted under PRC laws.

(ii) Pursuant to the Business Cooperation Agreements, Raily Beauty Consultation has the ownership of any and all intellectual property rights developed or created by the VIE Entities during the performance of the Business Cooperation Agreements.

(iii) Each of the VIE Entities, its Registered Shareholders and Raily Beauty Consultation entered into the voting rights proxy agreements (each a "Voting Rights Proxy Agreement", and collectively, the "Voting Rights Proxy Agreements") on 1 January 2019, pursuant to which, each Registered Shareholder, irrevocably appoints Raily Beauty Consultation or its designated directors and their successors (including a liquidator replacing our Directors) but excluding those who are non-independent or those who may give rise to conflict of interests, as his attorney-in-fact to exercise such shareholder's rights in the VIE Entities.

(iv) Raily Beauty Consultation, each of the VIE Entities and its Registered Shareholders entered into the exclusive option agreements (each an "Exclusive Option Agreement", and collectively the "Exclusive Option Agreements") on 1 January 2019, pursuant to which each of the Registered Shareholders agreed to grant Raily Beauty Consultation or its designated third party an exclusive option to transfer their equity interests and/or assets in the VIE Entities to Raily Beauty Consultation and/or a third party designated by it, in whole or in part at any time and from time to time, at the consideration of RMB1 or a minimum purchase price permitted under the PRC laws and regulations.

(v) Raily Beauty Consultation, each of the VIE Entities and its Registered Shareholders entered into the equity pledge agreements (each an "Equity Pledge Agreement", and collectively the "Equity Pledge Agreements") on 1 January 2019, pursuant to which each of the Registered Shareholders agreed to pledge all of their respective equity interests in the VIE Entities to Raily Beauty Consultation as a first priority security interest to guarantee the performance of contractual obligations and the payment of outstanding debts under the Contractual Arrangements.

For the Year, the VIE Entities paid the service fee of approximately RMB7.9 million to Raily Beauty Consultation under the Business Cooperation Agreements.

The revenue and net loss of the VIE Entities subject to the Contractual Arrangements amounted to approximately RMB128.8 million and RMB4.3 million for the Year, respectively. The total assets and total liabilities of the VIE Entities subject to the Contractual Arrangements amounted to approximately RMB120.2 million and RMB72.1 million as at 31 December 2022, respectively.

Please refer to the section headed "Contractual Arrangements" of the Prospectus for details. Up to the date of this report, there is no further update in relation to the foreign ownership restriction.

Risks associated with the Contractual Arrangements

For risks associated with the Contractual Arrangements, please see the section headed "Risk Factors" in the Prospectus for details.

Material change in relation to the Contractual Arrangements

During the Year, there is no material change in the Contractual Arrangements and/or the circumstances under which they were adopted.

Unwinding the Contractual Arrangements

As regards to the Contractual Arrangements, if and when the Ministry of Commerce, PRC ("MOFCOM") and/or other relevant governmental departments promulgate any measures for the administration of foreign-invested enterprises engaging in aesthetic medical services business or such entities invested by foreign investors, depending on the limit of the percentage equity interest permitted to be held by foreign investors (if any), we will partially unwind the Contractual Arrangements and hold (directly or indirectly) equity interest in the VIE Entities up to the percentage limit prescribed by such measures; and if there is no prescribed limit of the percentage equity interest permitted to be held by foreign investors and that our Company would be allowed to directly hold 100% of the equity interests in the VIE Entities, we will fully unwind the Contractual Arrangements and directly hold the entire equity interest in the VIE Entities.

However, for the Year, none of the Contractual Arrangements had been unwound as none of the restrictions that led to the adoption of the Contractual Arrangements had been removed.

Waiver from the Stock Exchange

The Stock Exchange has granted a waiver to the Company from strict compliance with the connected transactions requirements under Chapter 14A of the Listing Rules in respect of the Contractual Arrangements. For details, please refer to the section "Connected Transactions" in the Prospectus.

Confirmation from Independent Non-executive Directors

The Independent Non-executive Directors have reviewed the Contractual Arrangements and confirmed that during the Year that (i) the transactions carried out during such year have been entered into in accordance with the relevant provisions of the Contractual Arrangements; (ii) no dividends or other distributions have been made by the VIE Entities to the holders of its equity interests which are not otherwise subsequently assigned or transferred to our Group; and (iii) any new contracts entered into, renewed or reproduced between our Group and the VIE Entities during the relevant financial period are fair and reasonable, or advantageous, so far as our Group is concerned and in the interests of the Shareholders as a whole.

Confirmations from the Company's Independent Auditors

Ernst and Young, the Company's auditors, has carried out procedures annually to report on the Group's Continuing Connected Transactions in accordance with Hong Kong Standard on Assurance Engagements 3000 Assurance Engagements Other Than Audits or Reviews of Historical Financial Information and with reference to Practice Note 740 Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules issued by the Hong Kong Institute of Certified Public Accountants. For the purpose of Rule 14A.56 of the Listing Rules, Ernst and Young has confirmed in a letter to the Board that, with respect to the aforesaid continuing connected transactions entered into in 2022:

(a) nothing has come to their attention that causes the Company's auditors to believe that the disclosed continuing connected transactions have not been approved by the Board;

(b) nothing has come to their attention that causes the Company's auditors to believe that the disclosed continuing connected transactions were not entered into, in all material respects, in accordance with the relevant agreements under the Contractual Arrangements governing such transactions; and

(c) nothing has come to their attention that causes the Company's auditors to believe that any dividends or other distributions have been made by the VIE Entities to its registered equity shareholders which are not otherwise subsequently assigned or transferred to the Group.

PUBLIC FLOAT

Based on the information that is publicly available to the Company and within the knowledge of the Directors as at the date of this report, at least 25% of the Company's total number of issued shares were held by the public at all times since the Listing Date.

DONATION

During the Year, the Group did not make any donation.

AUDIT COMMITTEE

Before the Group's annual results for the Year were approved by the Board, the Audit Committee had reviewed and approved the relevant annual results. The work of the Audit Committee and its composition information are set out in the corporate governance report on page 38 of this annual report.

CORPORATE GOVERNANCE

The corporate governance practices of the Company are set out in the corporate governance report on page 33 of this annual report.

AUDITORS

Ernst & Young, Certified Public Accountants, has audited the financial statements for 2022 and will retire at the annual general meeting and is eligible for re-election. The Company will propose a resolution for the re-appointment of Ernst & Young as the Company's auditors at the forthcoming annual general meeting.

By order of the Board

Raily Aesthetic Medicine International Holdings Limited
Fu Haishu
Chairman and Executive Director

Hong Kong, 31 March 2023

INDEPENDENT AUDITOR'S REPORT

Ernst & Young
27/F, One Taikoo Place
979 King's Road,
Quarry Bay, Hong Kong

安永會計師事務所
香港鰂魚涌英皇道979號
太古坊一座27樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

To the shareholders of Raily Aesthetic Medicine International Holdings Limited
(Incorporated in the Cayman Islands with limited liability)

OPINION

We have audited the consolidated financial statements of Raily Aesthetic Medicine International Holdings Limited (the "Company") and its subsidiaries (the "Group") set out on pages 93 to 183, which comprise the consolidated statement of financial position as at 31 December 2022, and the consolidated statement of profit or loss, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2022, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards ("IFRSs") issued by the International Accounting Standards Board ("IASB") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the HKICPA's *Code of Ethics for Professional Accountants* (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the consolidated financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying consolidated financial statements.

KEY AUDIT MATTERS (CONTINUED)

Key audit matter	How our audit addressed the key audit matter
Impairment of goodwill	
As at 31 December 2022, the carrying value of goodwill in the consolidated financial statements amounted to RMB56,764,000. An impairment loss of RMB6,365,000 has been recognised during this year. In accordance with IAS 36 Impairment of Assets, the Group is required to perform impairment assessment for goodwill at least on an annual basis. In performing the impairment assessment, the goodwill has been allocated to the corresponding subsidiaries acquired as the acquired subsidiaries are the only cash-generating units that can benefit from synergy of the acquisition. The impairment assessment is based on the recoverable amount of the acquired subsidiaries to which the goodwill is allocated. The recoverable amount of the subsidiaries is their value in use using cash flow projections based on a financial budget covering a 5-year period. This matter was significant to our audit because the impairment assessment process included reviewing profit forecasts, growth rate and discount rate which was complex and involved significant judgements and estimates. The disclosures about impairment of goodwill are included in note 2.4 "Summary of Significant Accounting Policies", note 3 "Significant Accounting Judgement and Estimates" and note 15 "Goodwill", which specifically explain the key assumptions management used for the calculation of the recoverable amount.	Our audit procedures included, among others, considering the appropriateness of the allocation of the goodwill to the cash-generating units. With the assistance of our internal valuation specialists, we evaluated the assumptions and methodologies used by the Group, in particular, the discount rate and the growth rate beyond a 5-year period. We paid attention to the forecasts used with respect to future revenues and operating results by comparing the forecasts with the historical performance and the business development plan of the acquired subsidiaries to which the goodwill was allocated. We also focused on the adequacy of the disclosures in the consolidated financial statements.

KEY AUDIT MATTERS (CONTINUED)

Key audit matter	**How our audit addressed the key audit matter**
Valuation of contingent consideration payable for business acquisitions	
In 2021, the Group recognised contingent consideration payable of approximately RMB29,437,000 arising from the acquisition of Shenzhen Jiumei Xinhe Medical Equipment Co., Ltd. ("Shenzhen Jiumei"), which was measured at fair value through profit or loss. As at 31 December 2022, the total fair value of the contingent consideration amounted to RMB25,567,000. The fair value of the contingent consideration payable is remeasured at each reporting date by the management with the assistance of external valuer. We focused on this area as the assessment made by management involved significant estimates and judgements in relation to the post-acquisition performance of the acquired business and the discount rates applied, which may be affected by unexpected changes in future market or economic conditions. The disclosures about contingent consideration are included in note 2.4 "Summary of Significant Accounting Policies", note 3 "Significant Accounting Judgement and Estimates", and note 28 "Contingent consideration".	Our audit procedures, included among others, examining the terms of the purchase agreement relevant to the valuation of the contingent consideration payable. With the assistance of our internal valuation specialists, we evaluated the valuation methodologies and assumptions used by the Group, in particular, the discount rate and the expected future operating results. We paid specific attention to the forecasts used with respect to future operating results by comparing the forecasts with the historical performance and the business development plan of the acquired subsidiary. We also focused on the adequacy of the Group's disclosures of the contingent consideration payable in the consolidated financial statements.

OTHER INFORMATION INCLUDED IN THE ANNUAL REPORT

The directors of the Company are responsible for the other information. The other information comprises the information included in the Annual Report, other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF THE DIRECTORS FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with IFRSs issued by the IASB and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors of the Company either intend to liquidate the Group or to cease operations or have no realistic alternative but to do so.

The directors of the Company are assisted by the Audit Committee in discharging their responsibilities for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Our report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Siu Fung Terence Ho.

Ernst & Young
Certified Public Accountants

Hong Kong
31 March 2023

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

Year ended 31 December 2022

	Notes	2022 RMB'000	2021 RMB'000
REVENUE	*5*	**164,522**	188,367
Cost of sales		**(97,739)**	(118,675)
Gross profit		**66,783**	69,692
Other income and gains	*5*	**8,071**	2,681
Selling and distribution expenses		**(49,287)**	(54,533)
Administrative expenses		**(35,882)**	(34,724)
Other expenses		**(6,822)**	(3,493)
Research and development expenses		**(2,000)**	–
Finance costs	*7*	**(2,801)**	(2,419)
Share of loss of an associate		**(163)**	(152)
LOSS BEFORE TAX	*6*	**(22,101)**	(22,948)
Income tax credit	*10*	**1,854**	4,682
LOSS FOR THE YEAR		**(20,247)**	(18,266)
Attributable to:			
Owners of the parent		**(15,911)**	(17,691)
Non-controlling interests		**(4,336)**	(575)
		(20,247)	(18,266)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*12*		
Basic and diluted – For loss for the year (RMB)		**(0.76) cents**	(0.85) cents

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Year ended 31 December 2022

	2022 RMB'000	2021 RMB'000
LOSS FOR THE YEAR	**(20,247)**	(18,266)
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:		
Equity investment designated at fair value through other comprehensive income:		
Changes in fair value	**–**	32
Income tax effect	**–**	(8)
Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods	**–**	24
OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX	**–**	24
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	**(20,247)**	(18,242)
Attributable to:		
Owners of the parent	**(15,911)**	(17,667)
Non-controlling interests	**(4,336)**	(575)
	(20,247)	(18,242)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

31 December 2022

	Notes	2022 RMB'000	2021 RMB'000
NON-CURRENT ASSETS			
Property, plant and equipment	*13*	**40,763**	32,200
Right-of-use assets	*14(a)*	**43,243**	47,859
Goodwill	*15*	**56,764**	63,129
Other intangible assets	*16*	**30,467**	34,008
Investment in an associate	*17*	**3,262**	3,348
Deferred tax assets	*27*	**12,716**	11,425
Pledged deposits	*21*	**1,543**	1,500
Other non-current assets		**1,333**	240
Total non-current assets		**190,091**	193,709
CURRENT ASSETS			
Inventories and supplies	*18*	**12,678**	13,266
Trade receivables	*19*	**5,341**	6,094
Prepayments, other receivables and other current assets	*20*	**15,762**	9,937
Cash and bank balances	*21*	**78,779**	121,719
Total current assets		**112,560**	151,016
CURRENT LIABILITIES			
Trade payables	*22*	**9,169**	12,565
Other payables and accruals	*23*	**18,562**	17,824
Amount due to an independent director		**466**	147
Interest-bearing bank borrowings	*24*	**5,000**	20,000
Contract liabilities	*25*	**16,608**	14,686
Refund liabilities	*26*	**4,076**	5,580
Contingent consideration	*28*	**6,386**	29,437
Lease liabilities	*14(b)*	**8,666**	7,760
Tax payable		**7,480**	7,303
Total current liabilities		**76,413**	115,302
NET CURRENT ASSETS		**36,147**	35,714
TOTAL ASSETS LESS CURRENT LIABILITIES		**226,238**	229,423

Consolidated Statement of Financial Position

31 December 2022

	Notes	2022 RMB'000	2021 RMB'000
NON-CURRENT LIABILITIES			
Lease liabilities	*14(b)*	**34,555**	39,694
Deferred tax liabilities	*27*	**6,625**	7,375
Contingent consideration	*28*	**19,181**	–
Total non-current liabilities		**60,361**	47,069
Net assets		**165,877**	182,354
EQUITY			
Equity attributable to owners of the parent			
Share capital	*29*	**136,267**	136,267
Other reserves	*31*	**29,813**	41,954
		166,080	178,221
Non-controlling interests		**(203)**	4,133
Total equity		**165,877**	182,354

Fu Haishu
Director

Song Jianliang
Director

Wang Ying
Director

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Year ended 31 December 2022

		Attributable to owners of the parent								
	Notes	**Share capital** RMB'000 *(note 29)*	**Capital reserves*** RMB'000 *(note 31)*	**Share option reserve*** RMB'000 *(note 30)*	**Fair value reserve of financial assets at fair value through other comprehensive income*** RMB'000	**Statutory surplus reserve*** RMB'000 *(note 31)*	**Retained earnings/ (accumulated loss)*** RMB'000	**Total** RMB'000	**Non-controlling interests** RMB'000	**Total equity** RMB'000
At 1 January 2021		134,060	22,017	–	(53)	9,646*	20,203*	185,873	877	186,750
Loss for the year		–	–	–	–	–	(17,691)	(17,691)	(575)	(18,266)
Change in fair value of equity investment at fair value through other comprehensive income, net of tax		–	–	–	24	–	–	24	–	24
Over-allotment of shares	*29(iii)*	2,207	9,181	–	–	–	–	11,388	–	11,388
Share issue expenses		–	(2,411)	–	–	–	–	(2,411)	–	(2,411)
Establishment of new subsidiaries		–	–	–	–	–	–	–	3,831	3,831
Equity-settled share option arrangements	*30*	–	–	1,038	–	–	–	1,038	–	1,038
Transfer from retained earnings		–	–	–	29	101	(130)	–	–	–
Deregistration of a subsidiary		–	–	–	–	(396)	396	–	–	–
At 31 December 2021		136,267	28,787	1,038	–	9,351*	2,778*	178,221	4,133	182,354
At 1 January 2022		**136,267**	**28,787**	**1,038**	**–**	**9,351***	**2,778***	**178,221**	**4,133**	**182,354**
Loss for the year		**–**	**–**	**–**	**–**	**–**	**(15,911)**	**(15,911)**	**(4,336)**	**(20,247)**
Equity-settled share option arrangements	*30*	**–**	**–**	**3,770**	**–**	**–**	**–**	**3,770**	**–**	**3,770**
At 31 December 2022		**136,267**	**28,787**	**4,808**	**–**	**9,351**	**(13,133)**	**166,080**	**(203)**	**165,877**

* *These reserve accounts comprise the consolidated reserves of RMB29,813,000 (2021: RMB41,954,000) in the consolidated statement of financial position.*

CONSOLIDATED STATEMENT OF CASH FLOWS

Year ended 31 December 2022

	Notes	2022 RMB'000	2021 RMB'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before tax		**(22,101)**	(22,948)
Adjustments for:			
Finance costs	*7*	**2,801**	2,419
Share of loss of an associate		**163**	152
Loss on disposal of items of property, plant and equipment		**33**	329
Investment income	*5*	**(139)**	(246)
Interest received		**(433)**	(287)
Depreciation of right-of-use assets	*6, 14*	**9,339**	6,023
Depreciation of property, plant and equipment	*6, 13*	**10,313**	7,461
Provision for impairment of trade receivables and other receivables	*6*	**13**	591
Provision for goodwill	*15*	**6,365**	–
Amortisation of intangible assets	*6, 16*	**3,541**	1,044
Lease payments waived	*14*	**(1,127)**	–
Equity-settled share option expense	*30*	**3,770**	1,038
Fair value change in contingent consideration	*5*	**(3,870)**	–
(Gain)/loss on foreign exchange differences		**(2,790)**	1,936
		5,878	(2,488)
Decrease/(increase) in inventories and supplies		**511**	(99)
Decrease in trade receivables		**269**	975
(Increase)/decrease in prepayments, other receivables and other assets		**(7,206)**	2,200
(Decrease)/increase in trade payables		**(3,397)**	408
Increase in amount due to a director		**319**	147
Increase in contract liabilities		**1,922**	6,672
(Decrease)/increase in refund liabilities		**(1,504)**	228
Increase/(decrease) in other payables and accruals		**1,143**	(7,258)
Cash (used in)/generated from operations		**(2,065)**	785
Income tax paid		**(210)**	(3,251)
Net cash flow used in operating activities		**(2,275)**	(2,466)

Consolidated Statement of Cash Flows

Year ended 31 December 2022

	Notes	**2022** **RMB'000**	2021 RMB'000
CASH FLOWS FROM INVESTING ACTIVITIES			
Interest received		**433**	287
Purchases of items of property, plant and equipment		**(18,853)**	(15,768)
Purchases of items of intangible assets		**–**	(11)
Purchase of financial investments		**(25,030)**	(33,500)
Proceeds from disposal of financial investments		**25,169**	33,746
Purchase of pledged deposits		**–**	(12,000)
Redemption of pledged deposits		**–**	10,500
Redemption/(purchase) of time deposits		**18,839**	(37,704)
Acquisition of a subsidiary		**–**	(24,588)
Injection of capital into an associate		**–**	(3,500)
Proceeds from disposal of items of property, plant and equipment		**–**	86
Net cash flows generated from/(used in) investing activities		**558**	(82,452)
CASH FLOWS FROM FINANCING ACTIVITIES			
Capital injections from non-controlling shareholders of a subsidiary		**–**	3,831
New bank loans		**5,100**	20,000
Repayments of bank loans		**(20,100)**	(13,000)
Interest paid		**(240)**	(659)
Net proceeds from issue of shares		**–**	9,452
Payments of lease liabilities	*14(b)*	**(10,411)**	(7,653)
Net cash flows (used in)/generated from financing activities		**(25,651)**	11,971
NET DECREASE IN CASH AND CASH EQUIVALENTS		**(27,368)**	(72,947)
Effect of foreign exchange rate changes, net		**2,790**	(1,936)
Cash and cash equivalents at beginning of the year		**68,515**	143,398
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	*21*	**43,937**	68,515
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balances	*21*	**78,779**	121,719
Less: Pledged deposits for bank facilities		**–**	(10,500)
Time deposit with maturity of more than 3 months		**(34,842)**	(42,704)
Cash and cash equivalents as stated in the statement of cash flows		**43,937**	68,515

1. CORPORATE AND GROUP INFORMATION

Raily Aesthetic Medicine International Holdings Limited is a limited liability company incorporated in the Cayman Islands on 2 January 2018. The registered office address of the Company is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands.

The Company is an investment holding company. During the year, the Company's subsidiaries were principally engaged in the provision of aesthetic medical services, sale of aesthetic medical equipment products and consulting services. The Company was listed on the Hong Kong Stock Exchange on 28 December 2020.

In the opinion of the directors, the holding company and the ultimate holding company of the Company is Ruide Consultation Limited, which is incorporated in the British Virgin Islands.

Information about subsidiaries

Particulars of the Company's subsidiaries are as follows:

Name[1]	Place of incorporation/ registration and business	Issued ordinary/ registered share capital	Percentage of equity attributable to the Company Direct	Indirect	Principal activities
Raily Medical Management Limited ("Raily BVI") 瑞麗醫療管理有限公司	British Virgin Islands	USD50,000	100%	–	Investment holding
Raily Medical Limited ("Raily HK") 瑞麗醫療有限公司	Hong Kong	HK$10,000	–	100%	Consulting service
Hangzhou Raily Beauty Cosmetology Consulting Service Co., Ltd. ("Raily Beauty Consultation")[5] 杭州瑞麗美容諮詢服務有限公司	PRC/Mainland China	RMB20,000,000	–	100%	Investment holding
Hangzhou Raily Aesthetic Medical Hospital Co., Ltd. ("Hangzhou Raily")[5] 杭州瑞麗醫療美容醫院有限公司	PRC/Mainland China	RMB20,000,000	–	100%[2]	Aesthetic medical service
Hangzhou Bellafill Aesthetic Medical Out-patient Department Co., Ltd. ("Hangzhou Bellafill")[5] 杭州貝麗菲爾醫療美容門診部有限公司	PRC/Mainland China	RMB3,333,300	–	100%[2]	Aesthetic medical service

1. CORPORATE AND GROUP INFORMATION (CONTINUED)

Information about subsidiaries (Continued)

Name[1]	Place of incorporation/ registration and business	Issued ordinary/ registered share capital	Percentage of equity attributable to the Company Direct	Indirect	Principal activities
Ruian Raily Aesthetic Medical Out-patient Department Co., Ltd. ("Ruian Raily")[5] 瑞安瑞麗醫療美容門診部有限公司	PRC/Mainland China	RMB20,000,000	–	100%[2]	Aesthetic medical service
Wuhu Raily Aesthetic Medical Out-patient Department Co., Ltd ("Wuhu Raily")[5] 蕪湖瑞麗醫療美容門診部有限公司	PRC/Mainland China	RMB685,800	–	70%[3]	Aesthetic medical service
Ningbo Zhuerli Beauty Consulting Service Co., Ltd. ("Ningbo Zhuerli")[5] 寧波珠兒麗美容諮詢服務有限公司	PRC/Mainland China	RMB1,000,000	–	100%	Consulting service
Wuhu Raily Medical Equipment Trade Co., Ltd. ("Raily Equipment")[5] 蕪湖瑞麗醫療器械貿易有限公司	PRC/Mainland China	RMB1,000,000	–	100%	Medical equipment trading
Hainan Bellafill Medical Center Co., Ltd. ("Hainan Bellafill ")[5] 海南貝麗菲爾醫學中心有限公司	PRC/Mainland China	RMB5,000,000	–	100%[4]	Aesthetic medical service
Shenzhen Ruiquan Management Consulting Co., Ltd. ("Shenzhen Ruiquan")[5] 深圳瑞泉管理諮詢有限公司	PRC/Mainland China	RMB10,000,000	–	100%	Consulting service
Hangzhou Ruiquan Medical Equipment Co., Ltd. ("Hangzhou Ruiquan")[5] 杭州瑞泉醫療器械有限公司	PRC/Mainland China	RMB10,000,000	–	100%	Medical equipment trading
Shenzhen Jiumei Xinhe Medical Equipment Co., Ltd. ("Shenzhen Jiumei")[5] 深圳市九美信禾醫療器械有限公司	PRC/Mainland China	RMB1,000,000	–	100%	Medical equipment trading
Suzhou Yonglan Biotechnology Science and Technology Co., Ltd. ("Suzhou Yonglan")[5] 蘇州詠藍生物醫藥科技有限公司	PRC/Mainland China	USD20,000,000	-	51%	Medical equipment manufacturing

1. CORPORATE AND GROUP INFORMATION (CONTINUED)

Information about subsidiaries (Continued)

[1] *The English names of these entities registered in the People's Republic of China ("PRC") represent the best efforts made by the management of the Company to directly translate their Chinese names as they did not register any official English names.*

[2] *Since 1 January 2019, the 30% equity interest in this entity is attributable to the Company through a variable interest entity ("VIE") agreement.*

[3] *Since 1 January 2019, the 30% equity interest in this entity is attributable to the non-controlling interests.*

[4] *Hainan Bellafill Medical Center Co., Ltd. was established by the Group on 24 June 2022.*

[5] *These subsidiaries are registered as limited liability companies under PRC law.*

2.1 BASIS OF PREPARATION

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRSs") (which include all International Financial Reporting Standards, International Accounting Standards ("IASs") and Interpretations) issued by the International Accounting Standards Board ("IASB"), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for contingent consideration which has been measured at fair value. These financial statements are presented in Renminbi ("RMB") and all values are rounded to the nearest thousand except when otherwise indicated.

Basis of consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries (collectively referred to as the "Group") for the year ended 31 December 2022. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

Generally, there is a presumption that a majority of voting rights results in control. When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

(a) the contractual arrangement with the other vote holders of the investee;

(b) rights arising from other contractual arrangements; and

(c) the Group's voting rights and potential voting rights.

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

2.1 BASIS OF PREPARATION (CONTINUED)

Basis of consolidation (Continued)

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it derecognises (i) the assets (including goodwill) and liabilities of the subsidiary, (ii) the carrying amount of any non-controlling interest and (iii) the cumulative translation differences recorded in equity; and recognises (i) the fair value of the consideration received; (ii) the fair value of any investment retained; and (iii) any resulting surplus or deficit in profit or loss. The Group's share of components previously recognised in other comprehensive income is reclassified to profit or loss or retained profits, as appropriate, on the same basis as would be required if the Group had directly disposed of the related assets or liabilities.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following revised IFRSs for the first time for the current year's financial statements.

Amendments to IFRS 3	*Reference to the Conceptual Framework*
Amendments to IAS 16	*Property, Plant and Equipment: Proceeds before Intended Use*
Amendments to IAS 37	*Onerous Contracts – Cost of Fulfilling a Contract*
Annual Improvements to IFRS Standards 2018–2020	Amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41

The nature and the impact of the revised IFRSs that are applicable to the Group are described below:

(a) Amendments to IFRS 3 replace a reference to the previous *Framework for the Preparation and Presentation of Financial Statements* with a reference to the *Conceptual Framework for Financial Reporting* (the "Conceptual Framework") issued in June 2018 without significantly changing its requirements. The amendments also add to IFRS 3 an exception to its recognition principle for an entity to refer to the Conceptual Framework to determine what constitutes an asset or a liability. The exception specifies that, for liabilities and contingent liabilities that would be within the scope of IAS 37 or IFRIC 21 if they were incurred separately rather than assumed in a business combination, an entity applying IFRS 3 should refer to IAS 37 or IFRIC 21 respectively instead of the Conceptual Framework. Furthermore, the amendments clarify that contingent assets do not qualify for recognition at the acquisition date. The Group has applied the amendments prospectively to business combinations that occurred on or after 1 January 2022. As there were no contingent assets, liabilities and contingent liabilities within the scope of the amendments arising in the business combination that occurred during the year, the amendments did not have any impact on the financial position and performance of the Group.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (CONTINUED)

(b) Amendments to IAS 16 prohibit an entity from deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling any such items, and the cost of those items as determined by IAS 2 *Inventories*, in profit or loss. The Group has applied the amendments retrospectively to items of property, plant and equipment made available for use on or after 1 January 2021. Since there was no sale of items produced prior to the property, plant and equipment being available for use, the amendments did not have any impact on the financial position or performance of the Group.

(c) Amendments to IAS 37 clarify that for the purpose of assessing whether a contract is onerous under IAS 37, the cost of fulfilling the contract comprises the costs that relate directly to the contract. Costs that relate directly to a contract include both the incremental costs of fulfilling that contract (e.g., direct labour and materials) and an allocation of other costs that relate directly to fulfilling that contract (e.g., an allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract as well as contract management and supervision costs). General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. The Group has applied the amendments prospectively to contracts for which it has not yet fulfilled all its obligations at 1 January 2022 and no onerous contracts were identified. Therefore, the amendments did not have any impact on the financial position or performance of the Group.

(d) *Annual Improvements to IFRS Standards 2018–2020* sets out amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41. Details of the amendment that are applicable to the Group are as follows:

- IFRS 9 *Financial Instruments*: clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either the borrower or lender on the other's behalf. The Group has applied the amendment prospectively from 1 January 2022. As there was no modification or exchange of the Group's financial liabilities during the year, the amendment did not have any impact on the financial position or performance of the Group.

2.3 ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS

The Group has not applied the following new and revised IFRSs, that have been issued but are not yet effective, in these financial statements.

Amendments to IFRS 10 and IAS 28	*Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*[3]
Amendments to IFRS 16	*Lease Liability in a Sale and Leaseback*[2]
IFRS 17	*Insurance Contracts*[1]
Amendments to IFRS 17	*Insurance Contracts*[1,5]
Amendment to IFRS 17	*Initial Application of IFRS 17 and IFRS 9 – Comparative Information*[6]
Amendments to IAS 1	*Classification of Liabilities as Current or Non-current* (the "2020 Amendments")[2, 4]
Amendments to IAS 1	*Non-current Liabilities with Covenants* (the "2022 Amendments")[2]
Amendments to IAS 1 and IFRS Practice Statement 2	*Disclosure of Accounting Policies*[1]
Amendments to IAS 8	*Definition of Accounting Estimates*[1]
Amendments to IAS 12	*Deferred Tax related to Assets and Liabilities arising from a Single Transaction*[1]

1 Effective for annual periods beginning on or after 1 January 2023

2 Effective for annual periods beginning on or after 1 January 2024

3 No mandatory effective date yet determined but available for adoption

4 As a consequence of the 2022 Amendments, the effective date of the 2020 Amendments was deferred to annual periods beginning on or after 1 January 2024

5 As a consequence of the amendments to IFRS 17 issued in October 2020, IFRS 4 was amended to extend the temporary exemption that permits insurers to apply IAS 39 rather than IFRS 9 for annual periods beginning before 1 January 2023

6 An entity that chooses to apply the transition option relating to the classification overlay set out in this amendment shall apply it on initial application of IFRS 17

Further information about those IFRSs that are expected to be applicable to the Group is described below.

Amendments to IFRS 10 and IAS 28 address an inconsistency between the requirements in IFRS 10 and in IAS 28 in dealing with the sale or contribution of assets between an investor and its associate or joint venture. The amendments require a full recognition of a gain or loss resulting from a downstream transaction when the sale or contribution of assets between an investor and its associate or joint venture constitutes a business. For a transaction involving assets that do not constitute a business, a gain or loss resulting from the transaction is recognised in the investor's profit or loss only to the extent of the unrelated investor's interest in that associate or joint venture. The amendments are to be applied prospectively. The previous mandatory effective date of amendments to IFRS 10 and IAS 28 was removed by the IASB in January 2016 and a new mandatory effective date will be determined after the completion of a broader review of accounting for associates and joint ventures. However, the amendments are available for adoption now.

2.3 ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS (CONTINUED)

Amendments to IFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. The amendments are effective for annual periods beginning on or after 1 January 2024 and shall be applied retrospectively to sale and leaseback transactions entered into after the date of initial application of IFRS 16 (i.e., 1 January 2019). Earlier application is permitted. The amendments are not expected to have any significant impact on the Group's financial statements. In respect of sale and leaseback transactions with variable lease payments that do not depend on an index or a rate, the Group will develop an accounting policy for such transactions.

Amendments to IAS 1 *Classification of Liabilities as Current or Non-current* clarify the requirements for classifying liabilities as current or non-current, in particular the determination over whether an entity has a right to defer settlement of the liabilities for at least 12 months after the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement of the liability. The amendments also clarify the situations that are considered a settlement of a liability. In 2022, the IASB issued the 2022 Amendments to further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. In addition, the 2022 Amendments require additional disclosures by an entity that classifies liabilities arising from loan arrangements as non-current when it has a right to defer settlement of those liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period. The amendments are effective for annual periods beginning on or after 1 January 2024 and shall be applied retrospectively. Earlier application is permitted. An entity that applies the 2020 Amendments early is required to apply simultaneously the 2022 Amendments, and vice versa. The Group is currently assessing the impact of the amendments and whether existing loan agreements may require revision. Based on a preliminary assessment, the amendments are not expected to have any significant impact on the Group's financial statements.

Amendments to IAS 1 *Disclosure of Accounting Policies* require entities to disclose their material accounting policy information rather than their significant accounting policies. Accounting policy information is material if, when considered together with other information included in an entity's financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. Amendments to IFRS Practice Statement 2 provide non-mandatory guidance on how to apply the concept of materiality to accounting policy disclosures. Amendments to IAS 1 are effective for annual periods beginning on or after 1 January 2023 and earlier application is permitted. Since the guidance provided in the amendments to IFRS Practice Statement 2 is non-mandatory, an effective date for these amendments is not necessary. The Group is currently revisiting the accounting policy disclosures to ensure consistency with the amendments.

Amendments to IAS 8 clarify the distinction between changes in accounting estimates and changes in accounting policies. Accounting estimates are defined as monetary amounts in financial statements that are subject to measurement uncertainty. The amendments also clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted. The amendments are not expected to have any significant impact on the Group's financial statements.

2.3 ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS (CONTINUED)

Amendments to IAS 12 narrow the scope of the initial recognition exception in IAS 12 so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences, such as leases and decommissioning obligations. Therefore, entities are required to recognise a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability for temporary differences arising from these transactions. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and shall be applied to transactions related to leases and decommissioning obligations at the beginning of the earliest comparative period presented, with any cumulative effect recognised as an adjustment to the opening balance of retained profits or other component of equity as appropriate at that date. In addition, the amendments shall be applied prospectively to transactions other than leases and decommissioning obligations. Earlier application is permitted. The amendments are not expected to have any significant impact on the Group's financial statements.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investments in associates

An associate is an entity in which the Group has a long term interest of generally not less than 20% of the equity voting rights and over which it is in a position to exercise significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies.

The Group's investments in associates are stated in the consolidated statement of financial position at the Group's share of net assets under the equity method of accounting, less any impairment losses. Adjustments are made to bring into line any dissimilar accounting policies that may exist.

The Group's share of the post-acquisition results and other comprehensive income of associates is included in the consolidated statement of profit or loss and consolidated other comprehensive income, respectively. In addition, when there has been a change recognised directly in the equity of the associate, the Group recognises its share of any changes, when applicable, in the consolidated statement of changes in equity. Unrealised gains and losses resulting from transactions between the Group and its associates are eliminated to the extent of the Group's investments in the associates, except where unrealised losses provide evidence of an impairment of the assets transferred. Goodwill arising from the acquisition of associates is included as part of the Group's investments in associates.

If an investment in an associate becomes an investment in a joint venture or vice versa, the retained interest is not remeasured. Instead, the investment continues to be accounted for under the equity method. In all other cases, upon loss of significant influence over the associate, the Group measures and recognises any retained investment at its fair value. Any difference between the carrying amount of the associate upon loss of significant influence and the fair value of the retained investment and proceeds from disposal is recognised in profit or loss.

When an investment in an associate is classified as held for sale, it is accounted for in accordance with *IFRS 5 Non-current Assets Held for Sale and Discontinued Operations*.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The consideration transferred is measured at the acquisition date fair value which is the sum of the acquisition date fair values of assets transferred by the Group, liabilities assumed by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange for control of the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of net assets in the event of liquidation at fair value or at the proportionate share of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at fair value. Acquisition-related costs are expensed as incurred.

The Group determines that it has acquired a business when the acquired set of activities and assets includes an input and a substantive process that together significantly contribute to the ability to create outputs.

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts of the acquiree.

If the business combination is achieved in stages, the previously held equity interest is remeasured at its acquisition date fair value and any resulting gain or loss is recognised in profit or loss.

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability is measured at fair value with changes in fair value recognised in profit or loss. Contingent consideration that is classified as equity is not remeasured and subsequent settlement is accounted for within equity.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred, the amount recognised for non-controlling interests and any fair value of the Group's previously held equity interest in the acquiree over the identifiable assets acquired and liabilities assumed. If the sum of this consideration and other items is lower than the fair value of the net assets acquired, the difference is, after reassessment, recognised in profit or loss as a gain on bargain purchase.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. The Group performs its annual impairment test of goodwill as at the end of the year. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units, or groups of cash-generating units, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or groups of units.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Business combinations and goodwill (Continued)

Impairment is determined by assessing the recoverable amount of the cash-generating unit (group of cash-generating units) to which the goodwill relates. Where the recoverable amount of the cash-generating unit (group of cash-generating units) is less than the carrying amount, an impairment loss is recognised. An impairment loss recognised for goodwill is not reversed in a subsequent period.

Where goodwill has been allocated to a cash-generating unit (or group of cash-generating units) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on the disposal. Goodwill disposed of in these circumstances is measured based on the relative value of the operation disposed of and the portion of the cash-generating unit retained.

Fair value measurement

The Group measures its equity investments and non-principal-protected investments at fair value at the end of the year. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 – based on quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly.

Level 3 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than inventories and supplies, deferred tax assets and financial assets), the asset's recoverable amount is estimated. An asset's recoverable amount is the higher of the asset's or cash-generating unit's value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs. In testing a cash-generating unit for impairment, a portion of the carrying amount of a corporate asset is allocated to an individual cash-generating unit if it can be allocated on a reasonable and consistent basis or, otherwise, to the smallest group of cash-generating units.

An impairment loss is recognised only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

An assessment is made at the end of each reporting period as to whether there is an indication that previously recognised impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognised impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortisation) had no impairment loss been recognised for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises.

Related parties

A party is considered to be related to the Group if:

(a) the party is a person or a close member of that person's family and that person

(i) has control or joint control over the Group;

(ii) has significant influence over the Group; or

(iii) is a member of the key management personnel of the Group or of a parent of the Group;

or

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Related parties (Continued)

(b) the party is an entity where any of the following conditions applies:

(i) the entity and the Group are members of the same group;

(ii) one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);

(iii) the entity and the Group are joint ventures of the same third party;

(iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;

(v) the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;

(vi) the entity is controlled or jointly controlled by a person identified in (a);

(vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and

(viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

Property, plant and equipment and depreciation

Property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalised in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognises such parts as individual assets with specific useful lives and depreciates them accordingly.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Property, plant and equipment and depreciation (Continued)

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

Machinery equipment	19% to 33.33%
Office and other equipment	19% to 33.33%
Leasehold improvements	20% to 33.3%
Motor vehicles	19.00% to 23.75%

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each financial year end.

An item of property, plant and equipment including any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognised in profit or loss in the year the asset is derecognised is the difference between the net sales proceeds and the carrying amount of the relevant asset.

Construction in progress represents a building renovation project under construction, which is stated at cost less any impairment losses, and is not depreciated. Cost comprises the direct costs of construction and capitalised borrowing costs on related borrowed funds during the period of construction. Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

Intangible assets (other than goodwill)

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year end.

Intangible assets with definite useful lives are amortised on the straight-line basis over the following useful economic lives.

Software and others	5 to 10 years
Exclusive distribution agreement	10 years

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Research and development costs

All research costs are charged to the statement of profit or loss as incurred.

Expenditure incurred on projects to develop new products is capitalised and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred.

Deferred development costs are stated at cost less any impairment losses and are amortised using the straight-line basis over the commercial lives of the underlying products not exceeding five to seven years, commencing from the date when the products are put into commercial production.

Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Group as a lessee

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the rights to use the underlying assets.

(a) Right-of-use assets

Right-of-use assets are recognised at the commencement date of the lease (that is the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

Working spaces	3 to 10 years

If ownership of the leased asset transfers to the Group by the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Leases (Continued)

Group as a lessee (Continued)

(b) Lease liabilities

Lease liabilities are recognised at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognised as an expense in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.

(c) Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases of rental properties (that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the recognition exemption for leases of low-value assets to leases of office equipment that are considered to be of low value. Lease payments on short-term leases and leases of low-value assets are recognised as an expense on a straight-line basis over the lease term.

Investments and other financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income, and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient of not adjusting the effect of a significant financing component, the Group initially measures a financial asset at its fair value, plus in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under IFRS 15 in accordance with the policies set out for "Revenue recognition" below.

In order for a financial asset to be classified and measured at amortised cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Investments and other financial assets (Continued)

Initial recognition and measurement (Continued)

The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortised cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows, while financial assets classified and measured at fair value through other comprehensive income are held within a business model with the objective of both holding to collect contractual cash flows and selling. Financial assets which are not held within the aforementioned business models are classified and measured at fair value through profit or loss.

All regular way purchases and sales of financial assets are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as follows:

Financial assets at amortised cost (debt instruments)

Financial assets at amortised cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired.

Financial assets designated at fair value through other comprehensive income (equity investments)

Upon initial recognition, the Group can elect to classify irrevocably its equity investments as equity investments designated at fair value through other comprehensive income when they meet the definition of equity under IAS 32 *Financial Instruments*: *Presentation* and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to the statement of profit or loss. Dividends are recognised as other income in the statement of profit or loss when the right of payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably, except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in other comprehensive income. Equity investments designated at fair value through other comprehensive income are not subject to impairment assessment.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognised in the statement of profit or loss.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Group's consolidated statement of financial position) when:

– the rights to receive cash flows from the asset have expired; or

– the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Impairment of financial assets

The Group recognises an allowance for expected credit losses ("ECLs") for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

General approach

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECLs). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECLs).

At each reporting date, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information. The Group considers that there has been a significant increase in credit risk when contractual payments are more than 30 days past due.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Impairment of financial assets (Continued)

General approach (Continued)

Normally when contractual payments are 90 days past due, the Group performs analytical review and investigates the reason for the overdue to evaluate if it's in default or not. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Financial assets at amortised cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables which apply the simplified approach as detailed below.

Stage 1 – Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs

Stage 2 – Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs

Stage 3 – Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs

Simplified approach

For trade receivables that do not contain a significant financing component or when the Group applies the practical expedient of not adjusting the effect of a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as loans and borrowings, contingent consideration and payables, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings, contingent consideration and payables, net of directly attributable transaction costs.

The Group's financial liabilities include trade payables, lease liabilities, other payables and accruals, contingent consideration, amounts due to an independent director.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Financial liabilities (Continued)

Subsequent measurement

The subsequent measurement of financial liabilities depends on their classification as follows:

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities designated upon initial recognition as at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. Gains or losses on liabilities designated at fair value through profit or loss are recognised in the statement of profit or loss, except for the gains or losses arising from the Group's own credit risk which are presented in other comprehensive income with no subsequent reclassification to the statement of profit or loss. The net fair value gain or loss recognised in the statement of profit or loss does not include any interest charged on these financial liabilities.

Financial liabilities at amortised cost (loans and borrowings)

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in finance costs in the statement of profit or loss.

Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognised in profit or loss.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

Inventories and supplies

Supplies and inventories, consisting primarily of inventories of pharmaceutical, medical supplies and products, are stated at the lower of cost and net realisable value, which is based on estimated selling prices less any estimated costs to be incurred to completion and disposal.

Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired which are repayable on demand and form an integral part of the Group's cash management.

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including term deposits, and assets similar in nature to cash, which are not restricted as to use.

Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognised outside profit or loss is recognised outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Group operates.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Income tax (Continued)

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

– when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss;

– in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilised, except:

– when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

– in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at the end of the year and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at the end of each reporting period and are recognised to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Government grants

Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed.

Revenue recognition

Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of goods or services is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services.

When the consideration in a contract includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

(a) Rendering of aesthetic medical services

Revenue from outpatient aesthetic medical services is recognised at the point in time when services is rendered.

The Group provides certain outpatient aesthetic medical services in packages which are accounted for as multiple elements of services. The total transaction prices of the packages are allocated to each service by using its stand-alone selling price. The revenue from each service is recognised when the related service is rendered.

Revenue from inpatient aesthetic medical services is recognised over the period of the contract by reference to the progress towards complete satisfaction of the performance obligation. The progress towards the complete satisfaction of performance obligation is measured by direct measures of the value of individual service transferred to the customer.

When the consideration in a contract includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved. The Group adopts the most likely amount method to estimate the variable considerations.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue recognition (Continued)

Revenue from contracts with customers (Continued)

(b) Rendering of consulting services

Revenue from consulting service contracts with fixed terms is recognised over time by reference to the progress towards complete satisfaction of the performance obligation. Revenue from consulting service contracts for training courses, generally within one day, is recognised at the point in time when courses are delivered.

(c) Sales of aesthetic medical equipment products

Revenue from the sales of aesthetic medical equipment products is recognised at the points in time when control of asset is transferred to the customer, generally on the delivery of the aesthetic medical equipment products.

Other income

Interest income is recognised on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

Contract liabilities

A contract liability is recognised when a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services. Contract liabilities are recognised as revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer).

Refund liabilities

A refund liability is the constructive obligation to refund some or all of the consideration received (or receivable) from the customer and is measured at the amount the Group ultimately expects it will have to return to the customer. The Group updates its estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.

Employee benefits

The employees of the Group's subsidiaries which operate in Mainland China are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute a certain percentage of their payroll costs to the central pension scheme. The contributions are charged to the statement of profit or loss as they become payable in accordance with the rules of the central pension scheme.

Share-based payments

The Company operates a share option scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. Employees (including directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services in exchange for equity instruments ("equity-settled transactions").

The cost of equity-settled transactions with employees for grants is measured by reference to the fair value at the date at which they are granted. The fair value is determined by an external valuer using a binomial model, further details of which are given in note 30 to the financial statements.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Share-based payments (Continued)

The cost of equity-settled transactions is recognised in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognised for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the statement of profit or loss for a period represents the movement in the cumulative expense recognised as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

For awards that do not ultimately vest because non-market performance and/or service conditions have not been met, no expense is recognised. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

Where the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified, if the original terms of the award are met. In addition, an expense is recognised for any modification that increases the total fair value of the share-based payments, or is otherwise beneficial to the employee as measured at the date of modification.

Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. This includes any award where non-vesting conditions within the control of either the Group or the employee are not met. However, if a new award is substituted for the cancelled award, and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of earnings per share.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets. The capitalisation of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalised. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Dividends

Final dividends are recognised as a liability when they are approved by the shareholders in a general meeting.

Foreign currencies

These financial statements are presented in RMB, which is the Company's functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognised in the statement of profit or loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognised in other comprehensive income or profit or loss is also recognised in other comprehensive income or profit or loss, respectively).

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of initial transaction is the date on which the Group initially recognises the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

The preparation of the Group's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

3. SIGNIFICANT ACCOUNTING JUDGEMENT AND ESTIMATES

The preparation of the Group's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

3. SIGNIFICANT ACCOUNTING JUDGEMENT AND ESTIMATES (CONTINUED)

Judgement

In the process of applying the Group's accounting policies, management has made the following judgement, apart from those involving estimations, which has the most significant effect on the amounts recognised in the financial statements:

Lease commitments – Group as lessee

The Group has entered into property, plant and equipment leases with various lessors. The Group has determined the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised.

Estimation uncertainty

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the year, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

Variable consideration for refund to customers

The Group estimates variable considerations to be included in the transaction price for the refund to customers in respect of unsatisfactory services rendered.

The Group has developed a statistical model for estimating the refund which is based on the Group's past experience with various groups of customers. Any significant changes in experience as compared to historical patterns will impact the expected refund estimated by the Group. The Group updates its assessment of the expected refund on a regular basis and the refund liabilities are adjusted accordingly.

Impairment of goodwill

The Group determines whether goodwill is impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the goodwill is allocated. Estimating the value in use requires the Group to make an estimate of the expected future cash flows from the cash-generating units and also to choose a suitable discount rate in order to calculate the present value of those cash flows. The carrying amount of goodwill at 31 December 2022 was RMB56,764,000 (2021: RMB63,129,000). Further details are given in note 15.

Impairment of non-financial assets (other than goodwill)

The Group assesses whether there are any indicators of impairment for all non-financial assets (including the right-of-use assets) at the end of each reporting period. Other non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm's length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value in use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows.

3. SIGNIFICANT ACCOUNTING JUDGEMENT AND ESTIMATES (CONTINUED)

Estimation uncertainty (Continued)

Useful lives of intangible assets (other than goodwill)

The Group determines the estimated useful lives for its intangible assets. This estimate is based on the historical experience of the actual useful lives of intangible assets of similar nature and functions. It could change significantly as a result of technical innovations, or competitor actions in response to severe industry cycles. Management will increase the amortisation charge where useful lives are less than previously estimated lives, or it will write off or write down technically obsolete or non-strategic assets that have been abandoned or sold.

Deferred tax assets

Deferred tax assets are recognised for unused tax losses and deductible temporary differences to the extent that it is probable that taxable profit will be available against which the losses and the deductible temporary differences can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and level of future taxable profits together with future tax planning strategies. Further details are contained in note 27.

Fair value of contingent consideration

The contingent consideration is remeasured at its fair value at each reporting date as detailed in note 28 to the financial statements. The valuation requires the Group to forecast the future performance of the business acquired and determine the key parameters, such as volatility and discount rate, used in the valuation. The Group classifies the fair value of contingent consideration as Level 3. The fair value of the contingent consideration as at 31 December 2022 was RMB25,567,000 (2021: RMB29,437,000).

4. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their services and has three reportable operating segments as follows:

(a) Aesthetic medical services comprise principally inpatient services including surgical services and outpatient services including injection service, dermatology service and others.

(b) Consulting services comprise principally management consulting services.

(c) Aesthetic medical equipment products comprise principally sales of surgical implants and aesthetic medical skincare products.

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on reportable segment operating profit which is calculated based on gross profit less selling and marketing expenses and general and administrative expenses allocated excluding other income and gains, corporate and unallocated expenses, and finance costs (other than interest on lease liabilities).

Segment assets exclude deferred tax assets, pledged deposits, cash and cash equivalents, equity investment at fair value through profit or loss and other unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude contingent consideration, interest-bearing bank borrowings (other than lease liabilities), an amount due to an independent director, tax payable, deferred tax liabilities and other unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

Intersegment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

4. OPERATING SEGMENT INFORMATION (CONTINUED)

Year ended 31 December 2022	Aesthetic medical services RMB'000	Consulting services RMB'000	Aesthetic medical equipment products RMB'000	Total RMB'000
Segment revenue *(note 5)*:				
Sales to external customers	151,661	27	12,834	164,522
Intersegment sales	–	–	1,378	1,378
	151,661	27	14,212	165,900
Reconciliation:				
Elimination of intersegment sales				(1,378)
Revenue from continuing operations				164,522
Segment results	(10,067)	(796)	5,818	(5,045)
Reconciliation:				
Elimination of intersegment results				(94)
Other income and gains				4,201
Corporate and unallocated expenses				(20,945)
Finance costs (other than interest on lease liabilities)				(218)
Loss before income tax				(22,101)

4. OPERATING SEGMENT INFORMATION (CONTINUED)

Year ended 31 December 2022	Aesthetic medical services RMB'000	Consulting services RMB'000	Aesthetic medical equipment products RMB'000	Total RMB'000
Segment assets	109,388	455	93,421	203,264
Reconciliation:				
Corporate and other unallocated assets				99,387
Total assets				302,651
Segment liabilities	82,477	19	6,462	88,958
Reconciliation:				
Corporate and other unallocated liabilities				47,816
Total liabilities				136,774
Other segment information:				
Share of losses of an associate:	–	–	(163)	(163)
Impairment losses recognised in the statement of profit or loss, net	6,364	–	14	6,378
Depreciation and amortisation	19,220	15	3,958	23,193
Capital expenditure*	18,771	–	82	18,853

* *Capital expenditure consists of additions to property, plant and equipment, other non-current assets and intangible assets.*

4. OPERATING SEGMENT INFORMATION (CONTINUED)

Year ended 31 December 2021	Aesthetic medical services RMB'000	Consulting services RMB'000	Aesthetic medical equipment products RMB'000	Total RMB'000
Segment revenue *(note 5)*:				
Sales to external customers	183,712	3,173	1,482	188,367
Intersegment sales	–	–	172	172
	183,712	3,173	1,654	188,539
Reconciliation:				
Elimination of intersegment sales				(172)
Revenue from continuing operations				188,367
Segment results	(1,717)	(983)	709	(1,991)
Reconciliation:				
Elimination of intersegment results				(38)
Other income and gains				2,681
Corporate and unallocated expenses				(22,930)
Finance costs (other than interest on lease liabilities)				(670)
Loss before income tax				(22,948)
Segment assets	99,218	1,965	36,455	137,638
Reconciliation:				
Corporate and other unallocated assets				207,087
Total assets				344,725
Segment liabilities	92,594	305	3,256	96,155
Reconciliation:				
Corporate and other unallocated liabilities				66,216
Total liabilities				162,371
Other segment information:				
Share of losses of an associate:	–	–	(152)	(152)
Impairment losses recognised in the statement of profit or loss, net	(11)	603	(1)	591
Depreciation and amortisation	12,290	574	1,664	14,528
Capital expenditure*	15,426	10	30,343	45,779

* *Capital expenditure consists of additions to property, plant and equipment, other non-current assets and intangible assets from the acquisition of a subsidiary.*

4. OPERATING SEGMENT INFORMATION (CONTINUED)

Geographical information

All significant external customers and non-current assets of the Group are located in Mainland China. Accordingly, no geographical information of external customers or non-current assets is presented.

Information about a major customer

There was no single customer from whom the revenue amounting to 10% or more of the Group's revenue was derived for the years 2022 and 2021.

5. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	2022 **RMB'000**	2021 RMB'000
Revenue from contracts with customers		
Aesthetic medical services	**151,661**	183,712
Consulting services	**27**	3,173
Aesthetic medical equipment products	**12,834**	1,482
	164,522	188,367

5. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

Revenue from contracts with customers

(a) Disaggregated revenue information

For the year ended 31 December 2022

Segments	Aesthetic medical services RMB'000	Consulting services RMB'000	Aesthetic medical equipment products RMB'000	Total RMB'000
Types of goods or services				
Sale of products	–	–	12,834	12,834
Services	151,661	27	–	151,688
Total revenue from contracts with customers	151,661	27	12,834	164,522
Geographical market				
Mainland China	151,661	27	12,834	164,522
Timing of revenue recognition				
Goods transferred at a point in time	–	–	12,834	12,834
Services transferred at a point in time	106,870	–	–	106,870
Services transferred over time	44,791	27	–	44,818
Total revenue from contracts with customers	151,661	27	12,834	164,522

5. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

Revenue from contracts with customers (Continued)

(a) Disaggregated revenue information (Continued)

For the year ended 31 December 2021

Segments	Aesthetic medical services RMB'000	Consulting services RMB'000	Aesthetic medical equipment products RMB'000	Total RMB'000
Types of goods or services				
Sale of products	–	–	1,482	1,482
Services	183,712	3,173	–	186,885
Total revenue from contracts with customers	183,712	3,173	1,482	188,367
Geographical market				
Mainland China	183,712	3,173	1,482	188,367
Timing of revenue Recognition				
Goods transferred at a point in time	–	–	1,482	1,482
Services transferred at a point in time	49,179	–	–	49,179
Services transferred over time	134,533	3,173	–	137,706
Total revenue from contracts with customers	183,712	3,173	1,482	188,367

5. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

Revenue from contracts with customers (Continued)

(a) Disaggregated revenue information (Continued)

Set out below is the reconciliation of the revenue from contracts with customers to the amounts disclosed in the segment information:

For the year ended 31 December 2022

Segments	Aesthetic medical services RMB'000	Consulting services RMB'000	Aesthetic medical equipment products RMB'000	Total RMB'000
Revenue from contracts with customers				
External customers	**151,661**	**27**	**12,834**	**164,522**
Intersegment sales	**–**	**–**	**1,378**	**1,378**
Intersegment adjustments and eliminations	**–**	**–**	**(1,378)**	**(1,378)**
Total revenue form contracts with customers	**151,661**	**27**	**12,834**	**164,522**

For the year ended 31 December 2021

Segments	Aesthetic medical services RMB'000	Consulting services RMB'000	Aesthetic medical equipment products RMB'000	Total RMB'000
Revenue from contracts with customers				
External customers	183,712	3,173	1,482	188,367
Intersegment sales	–	–	172	172
	183,712	3,173	1,654	188,539
Intersegment adjustments and eliminations	–	–	(172)	(172)
Total revenue form contracts with customers	183,712	3,173	1,482	188,367

5. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

Revenue from contracts with customers (Continued)

(a) *Disaggregated revenue information (Continued)*

The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period and recognised from performance obligations satisfied in previous periods:

	2022 **RMB'000**	2021 RMB'000
Revenue recognised that was included in the contract liabilities at the beginning of the reporting period	**14,316**	8,014

	2022 **RMB'000**	2021 RMB'000
Revenue recognised from performance obligations satisfied in previous periods:		
Sale of services not previously recognised due to constraints on variable consideration	**4,249**	3,384

(b) *Performance obligations*

Information about the Group's performance obligations is summarised below:

Rendering of inpatient aesthetic medical services

According to the nature of service, the performance obligation is satisfied over time or satisfied upon completion of service and payment in advance is normally required.

Rendering of consulting services

The performance obligation of consulting contracts with fixed terms is satisfied over time when the services are rendered and payment is generally received in advance or due periodically with a credit term of 30 to 90 days. The performance obligation of other consulting contracts is satisfied when the services are rendered.

Sale of aesthetic medical equipment products

The performance obligation is satisfied upon delivery of the aesthetic medical equipment products and payment in advance is normally required. Some contracts provide customers with volume rebates which give rise to variable consideration subject to constraint.

5. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

Revenue from contracts with customers (Continued)

(b) Performance obligations (Continued)

The amount of transaction prices allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at 31 December is as follows:

	2022 **RMB'000**	2021 RMB'000
Within one year	**16,608**	14,686

All the amounts of transaction prices allocated to the remaining performance obligations are expected to be recognised as revenue within one year. The amounts disclosed above do not include variable consideration which is constrained.

An analysis of other income and gains is as follows:

	2022 **RMB'000**	2021 RMB'000
Other income		
Government subsidies	**221**	281
Investment income	**139**	246
Interest income	**590**	988
Others	**113**	92
	1,063	1,607
Gains		
Gains on derecognition of financial liabilities measured at amortised cost	**494**	1,074
Fair value gains on contingent consideration	**3,870**	–
Gains on foreign exchange differences	**2,644**	–
	7,008	1,074
	8,071	2,681

6. LOSS BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	Notes	2022 RMB'000	2021 RMB'000
Cost of supplies consumed		**55,018**	66,199
Cost of inventories sold		**2,008**	322
Amortisation of intangible assets	*16*	**3,541**	1,044
Depreciation of property, plant and equipment	*13*	**10,313**	7,461
Depreciation of right-of-use assets	*14*	**9,339**	6,023
Research and development costs		**2,000**	–
Lease payments not included in the measurement of lease liabilities		**709**	1,354
Auditor's remuneration		**2,250**	2,200
Employee benefit expense (excluding directors' and chief executive's remuneration *(note 8)*):			
Wages and salaries		**52,067**	65,040
Equity-settled share option expense		**3,645**	987
Pension scheme contributions		**4,226**	6,465
Staff welfare expenses		**1,816**	2,141
Impairment of trade receivables, net	*19*	**7**	596
Impairment of financial assets included in prepayments, other receivables and other assets	*20*	**6**	(5)
Impairment of goodwill	*15*	**6,365**	–
Loss on disposal of items of property, plant and equipment		**33**	329
Promotion and marketing expenses		**19,360**	26,849
Professional fee		**1,903**	8,856
Foreign exchange differences, net		**(2,644)**	2,403
Fair value gains on contingent consideration		**(3,870)**	–

7. FINANCE COSTS

An analysis of finance costs from continuing operations is as follows:

	2022 RMB'000	2021 RMB'000
Interest on lease liabilities	**2,583**	1,749
Interest on bank borrowings	**218**	670
	2,801	2,419

8. DIRECTORS' AND CHIEF EXECUTIVE'S REMUNERATION

Directors' and chief executive's remuneration for the year, disclosed pursuant to the Listing Rules, section 383(1) (a), (b), (c) and (f) of the Hong Kong Companies Ordinance and Part 2 of the Companies (Disclosure of Information about Benefits of Directors) Regulation, is as follows:

	2022 RMB'000	2021 RMB'000
Fees	**1,106**	443
Other emoluments:		
Salaries, allowances and benefits in kind	**1,712**	2,447
Pension scheme contributions	**177**	155
Equity-settled share option expense	**125**	51
	2,014	2,653
	3,120	3,096

During the year, certain directors were granted share options, in respect of their services to the Group, under the share option scheme of the Company, further details of which are set out in note 30 to the financial statements. The fair value of such options, which has been recognised in the statement of profit or loss over the vesting period, was determined as at the date of grant and the amount included in the financial statements for the current year is included in the above directors' and chief executive's remuneration disclosures.

8. DIRECTORS' AND CHIEF EXECUTIVE'S REMUNERATION (CONTINUED)

(a) Independent non-executive directors

The fees paid or payable to independent non-executive directors during the year were as follows:

	2022 RMB'000	2021 RMB'000
Mr. Cao Dequan	**155**	147
Mr. Liu Teng	**155**	147
Ms. Yang Xiaofen	**156**	147
	466	441

There were no other emoluments payable to the independent non-executive directors during the year (2021: Nil).

(b) Executive directors, non-executive directors

	Fees RMB'000	Salaries, allowance and benefits in kind RMB'000	Equity-settled share option expense RMB'000	Pension Scheme contributions RMB'000	Total remuneration RMB'000
2022					
Executive directors:					
Mr. Song Jianliang*	–	600	47	–	647
Mr. Fu Haishu	536	240	–	66	842
Mr. Wang Ying*	104	280	55	18	457
Non-executive directors:					
Ms. Fan Qirui***	–	–	–	–	–
Chief executive					
Ms. Zhang Chunxiu	–	592	23	93	708
	640	1,712	125	177	2,654

8. DIRECTORS' AND CHIEF EXECUTIVE'S REMUNERATION (CONTINUED)

(b) Executive directors, non-executive directors (Continued)

	Fees RMB'000	Salaries, allowance and benefits in kind RMB'000	Equity-settled share option expense RMB'000	Pension Scheme contributions RMB'000	Total remuneration RMB'000
2021					
Executive directors:					
Mr. Song Jianliang*	–	1,371	30	–	1,401
Mr. Yu Kai*	–	516	–	78	594
Mr. Fu Haishu	–	336	–	65	401
Mr. Wang Ying*	2	224	21	12	259
Non-executive directors:					
Mr. Xie Lijun**	–	–	–	–	–
Ms. Fan Qirui***	–	–	–	–	–
	2	2,447	51	155	2,655

* On 28 December 2021, Mr. Yu Kai resigned from the position of executive director and the chief executive officer and Mr. Song Jianliang, an executive director, was appointed as the chief executive officer of the Company. Mr. Wang Ying was appointed as an executive director.

** On 5 August 2021, Mr. Xie Lijun resigned from the position as a non-executive director.

*** On 19 September 2022, Ms. Fan Qirui resigned from the position as a non-executive director.

No remuneration was paid by the Group to directors as an inducement to join or upon joining the Group or as compensation for the loss of office as a director of any member of the Group or of any other office in connection with the management of the affairs of any member of the Group distinguishing between contractual and other payments.

9. FIVE HIGHEST PAID EMPLOYEES

The five highest paid employees during the year included one director (2021: one director), details of whose remuneration are set out in note 8 above. Details of the remuneration for the year of the remaining three (2021: four) highest paid employees who are neither a director nor chief executive of the Company are as follows:

	2022 RMB'000	2021 RMB'000
Salaries, allowances and benefits in kind	**1,819**	4,172
Equity-settled share option expense	**5**	2
Pension scheme contributions	**33**	112
	1,857	4,286

No remuneration was paid by the Group to the five highest paid employees as an inducement to join or upon joining the Group or as compensation for the loss of any office in connection with the management of the affairs of any member of the Group distinguishing between contractual payments and other payments (excluding the amounts as disclosed in the table above). The number of non-director and non-chief executive highest paid employees whose remuneration fell within the following bands is as follows:

	Number of employees 2022	2021
Nil to HK$1,000,000	**3**	–
HK$1,000,001 to HK$2,000,000	**–**	4
	3	4

During the year and in prior years, share options were granted to a non-director and non-chief executive highest paid employee in respect of his services to the Group, further details of which are included in the disclosures in note 30 to the financial statements. The fair value of such options, which has been recognised in the statement of profit or loss over the vesting period, was determined as at the date of grant and the amount included in the financial statements for the current year is included in the above non-director and non-chief executive highest paid employees' remuneration disclosures.

10. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

	2022 RMB'000	2021 RMB'000
Current tax		
Charge for the year	**187**	224
Overprovision in prior years	**–**	(107)
Deferred *(note 27)*	**(2,041)**	(4,799)
Total tax credit for the year	**(1,854)**	(4,682)

The majority of the Company's subsidiaries are domiciled in Mainland China. A reconciliation of the tax expenses applicable to loss before tax at the statutory rate for Mainland China to the tax expenses at the Group's effective tax rate is as follows:

	2022 RMB'000	2021 RMB'000
Loss before tax	**(22,101)**	(22,948)
Tax at the PRC statutory income tax rate*	**(5,525)**	(5,737)
Effect of different tax rates of subsidiaries**	**722**	1,421
Adjustments in respect of current tax of previous periods	**–**	(107)
Losses attributable to associates	**41**	38
Expenses not deductible for tax	**967**	43
Utilisation of deductible temporary differences previously not recognised	**–**	(356)
Deductible temporary differences and tax losses not recognised	**1,941**	16
	(1,854)	(4,682)

* The provision for current income tax in Mainland China is based on the statutory rate of 25% of the assessable profit of the Group as determined in accordance with the PRC Corporate Income Tax Law which was approved and became effective on 1 January 2008.

** Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands ("BVI"), the Group is not subject to any income tax in the Cayman Islands and the BVI. The subsidiary incorporated in Hong Kong is subject to Hong Kong profits tax at the rate of 16.5% on any estimated assessable profits arising in Hong Kong. Pursuant to Caishui 2017 Circular No.43, 2019 circular No.13, 2021 circular No.12 and 2022 circular No. 13 announcement of the State Taxation Administration, Ningbo Zhuerli, Ruian Raily, Raily Equipment, Shenzhen Ruiquan, Hainan Bellafill, Hangzhou Ruiquan, as small micro-enterprises, enjoyed preferential tax rate of 2.5% (2021: 2.5%) for the year ended 31 December 2022.

11. DIVIDENDS

	2022 RMB'000	2021 RMB'000
Dividend	–	–

No dividend was paid or declared by the Company for the year ended 31 December 2022.

12. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amounts is based on the loss for the year attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 2,089,040,000 (2021: 2,087,268,055) in issue during the year, as adjusted to reflect the rights issue during the year.

The weighted average number of ordinary shares used to calculate the basic earnings per share amount for the year ended 31 December 2021 included the weighted average of 34,040,000 ordinary shares issued in connection with the Company's over allotment of initial public offering and the aforesaid 2,055,000,000 ordinary shares.

No adjustment has been made to the basic loss per share amounts presented for the years ended 31 December 2022 and 2021 in respect of a dilution as the impact of the option outstanding had an anti-dilutive effect on the basic loss per share amounts presented.

The calculation of basic earnings per share is based on:

	2022 RMB'000	2021 RMB'000
Loss		
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	**(15,911)**	(17,691)
Shares		
Weighted average number of ordinary shares in issue during the year used in the basic earnings per share calculation	**2,089,040,000**	2,087,268,055

* Because the diluted earnings per share amount is increased when taking share options into account, the share options had an anti-dilutive effect on the basic earnings per share for the year and were ignored in the calculation of diluted earnings per share.

13. PROPERTY, PLANT AND EQUIPMENT

	Machinery equipment RMB'000	Office and other equipment RMB'000	Lease hold improvements RMB'000	Motor vehicles RMB'000	Construction in progress RMB'000	Total RMB'000
31 December 2022						
At 1 January 2022:						
Cost	35,785	6,991	21,559	3,020	1,489	68,844
Accumulated depreciation and impairment	(19,617)	(5,806)	(9,619)	(1,602)	–	(36,644)
Net carrying amount	16,168	1,185	11,940	1,418	1,489	32,200
At 1 January 2022, net of accumulated depreciation and impairment	16,168	1,185	11,940	1,418	1,489	32,200
Additions	1,555	1,132	12,383	404	3,435	18,909
Disposals	(30)	(3)	–	–	–	(33)
Depreciation provided during the year	(5,221)	(496)	(4,142)	(454)	–	(10,313)
Transfer	–	–	2,209	–	(2,209)	–
At 31 December 2022, net of accumulated depreciation	12,472	1,818	22,390	1,368	3,949	41,996
At 31 December 2022:						
Cost	36,735	8,062	36,150	3,424	2,715	87,086
Accumulated depreciation	(24,263)	(6,244)	(13,760)	(2,056)	–	(46,323)
Net carrying amount	12,472	1,818	22,390	1,368	2,715	40,763

13. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

	Machinery equipment RMB'000	Office and other equipment RMB'000	Leasehold improvements RMB'000	Motor vehicles RMB'000	Construction in progress RMB'000	Total RMB'000
31 December 2021						
At 1 January 2021:						
Cost	32,124	6,927	12,484	3,822	–	55,357
Accumulated depreciation and impairment	(14,610)	(5,895)	(8,281)	(2,084)	–	(30,870)
Net carrying amount	17,514	1,032	4,203	1,738	–	24,487
At 1 January 2021, net of accumulated depreciation and impairment	17,514	1,032	4,203	1,738	–	24,487
Additions	3,897	633	9,211	359	1,489	15,589
Disposals	(117)	(19)	–	(279)	–	(415)
Depreciation provided during the year	(5,126)	(461)	(1,474)	(400)	–	(7,461)
At 31 December 2021, net of accumulated depreciation	16,168	1,185	11,940	1,418	1,489	32,200
At 31 December 2021:						
Cost	35,785	6,991	21,559	3,020	1,489	68,844
Accumulated depreciation	(19,617)	(5,806)	(9,619)	(1,602)	–	(36,644)
Net carrying amount	16,168	1,185	11,940	1,418	1,489	32,200

14. LEASES

Group as a lessee

The Group has lease contracts for working spaces used in its operations. Leases of working spaces generally have lease terms between 3 and 10 years. There are several lease contracts that include extension and termination options, which are further discussed below.

(a) Right-of-use assets

The carrying amounts of the Group's right-of-use assets and the movements during the year are as follows:

	Working spaces RMB'000
As at 1 January 2021	19,709
Additions	47
Depreciation charge	(6,023)
Revision of a lease term arising from a change in the non-cancellable period of a lease	34,126
As at 31 December 2021 and 1 January 2022	**47,859**
Additions	**3,794**
Depreciation charge	**(9,339)**
Revision of a lease term arising from a change in the non-cancellable period of a lease	**929**
As at 31 December 2022	**43,243**

14. LEASES (CONTINUED)

(b) *Lease liabilities*

The carrying amounts of lease liabilities and the movements during the year are as follows:

	2022 RMB'000	2020 RMB'000
Carrying amount at 1 January	**47,454**	19,185
New leases	**3,793**	47
Accretion of interest recognised during the year	**2,583**	1,749
Payments	**(10,411)**	(7,653)
Payments waived	**(1,127)**	–
Revision of a lease term arising from a change in the non-cancellable period of a lease	**929**	34,126
Carrying amount at 31 December	**43,221**	47,454
Analysed into:		
Current	**8,666**	7,760
Non-current	**34,555**	39,694

The maturity analysis of lease liabilities is disclosed in note 38 to the financial statements.

(c) The amounts recognised in profit or loss in relation to leases are as follows:

	2022 RMB'000	2021 RMB'000
Interest charge on lease liabilities	**2,583**	1,749
Depreciation charge of right-of-use assets	**9,339**	6,023
Expense relating to short-term leases	**709**	1,354
Lease payments waived	**(1,127)**	–
Total amount recognised in profit or loss	**11,504**	9,126

(d) *Extension and termination options*

The Group has several lease contracts that include extension and termination options but the Group did not expect to exercise such options as at 31 December 2022.

(e) The total cash outflow for leases is disclosed in note 32(c) to the financial statements.

15. GOODWILL

	RMB'000
At 1 January 2021:	
Cost	20,639
Accumulated impairment	(429)
Net carrying amount	20,210
Cost at 1 January 2021, net of accumulated impairment	20,210
Acquisition of a subsidiary	42,919
Deregistered of a subsidiary	(429)
Written off of accumulated impairment	429
At 31 December 2021	
Cost	63,129
Accumulated impairment	–
Net carrying amount	63,129
Cost at 1 January 2022, net of accumulated impairment	63,129
Impairment during the year	(6,365)
Cost and net carrying amount at 31 December 2022	56,764
At 31 December 2022:	
Cost	63,129
Accumulated impairment	(6,365)
Net carrying amount	56,764

Impairment testing of goodwill

Goodwill acquired through business combinations is allocated to the following cash-generating units ("CGUs") for impairment testing:

- Aesthetic medical services CGUs; and
- Aesthetic medical equipment products CGU.

15. GOODWILL (CONTINUED)

Impairment testing of goodwill (Continued)

Aesthetic medical services CGUs

The recoverable amount of the aesthetic medical services CGUs had been determined based on a value in use calculation using cash flow projections based on financial budgets covering a five-year period approved by senior management. The discount rate applied to the cash flow projections for 31 December 2022 was 14.71% (2021: 14.07%). The growth rate used to extrapolate the cash flows of the aesthetic medical services CGU beyond the five-year period is 3.00% (2021: 3.00%), which is also an estimate of the long-term rate of inflation.

Sales of aesthetic medical equipment products CGU

The recoverable amount of the sales of aesthetic medical equipment products CGU has been determined based on a value in use calculation using cash flow projections based on financial budgets covering a five-year period approved by senior management. The discount rate applied to the cash flow projections for 31 December 2022 was 16.00% (2021: 15.92%). The growth rate used to extrapolate the cash flows of the sales of aesthetic medical equipment products CGU beyond the five-year period is 2.30% (2021: 3.00%), which is also an estimate of the long-term rate of inflation.

The management made the impairment test of CGUs with the assistance of external valuers.

The carrying amount of goodwill allocated to each of the CGUs is as follows:

	Aesthetic medical services		Aesthetic medical products		Total	
	2022	2021	**2022**	2021	**2022**	2021
	RMB'000	RMB'000	**RMB'000**	RMB'000	**RMB'000**	RMB'000
Carrying amount of goodwill	**13,845**	20,210	**42,919**	42,919	**56,764**	63,129

Assumptions were used in the value in use calculation of the aesthetic medical services and sales of aesthetic medical equipment products CGUs for 31 December 2022 and 31 December 2021. The following describes each key assumption on which management has based its cash flow projections to undertake impairment testing of goodwill:

Discount rates – The discount rates used are before tax and reflect specific risks relating to the relevant units.

Long-term growth rates – The basis used to determine the value assigned to the long-term growth rates are the forecast price indices during the budget year from where the main services are located.

The values assigned to the key assumptions on market development of the aesthetic medical services and aesthetic medical products industries, discount rates and consumer price indexes are based on the long-term growth rates in the industries and the Group's historical experience.

16. OTHER INTANGIBLE ASSETS

	Software RMB'000	Exclusive distributor agreement RMB'000	Others RMB'000	Total RMB'000
31 December 2022				
Cost at 1 January 2022, net of accumulated amortisation	**4,416**	**29,500**	**92**	**34,008**
Amortisation provided during the year	**(521)**	**(3,000)**	**(20)**	**(3,541)**
At 31 December 2022	**3,895**	**26,500**	**72**	**30,467**
At 31 December 2022:				
Cost	**5,216**	**30,000**	**143**	**35,359**
Accumulated amortisation	**(1,321)**	**(3,500)**	**(71)**	**(4,892)**
Net carrying amount	**3,895**	**26,500**	**72**	**30,467**
31 December 2021				
Cost at 1 January 2021, net of accumulated amortisation	4,929	–	112	5,041
Additions	11	–	–	11
Acquisition of a subsidiary	–	30,000	–	30,000
Amortisation provided during the year	(524)	(500)	(20)	(1,044)
At 31 December 2021	4,416	29,500	92	34,008
At 31 December 2021:				
Cost	5,216	30,000	143	35,359
Accumulated amortisation	(800)	(500)	(51)	(1,351)
Net carrying amount	4,416	29,500	92	34,008

17. INVESTMENT IN AN ASSOCIATE

	2022 RMB'000	2021 RMB'000
Investment in the associate	**3,262**	3,348

The following table illustrates the aggregate financial information of the Group's associate that is not individually material:

	2022 RMB'000	2021 RMB'000
Share of the associates' loss for the year	**(86)**	(152)
Share of the associates' total comprehensive income	**(86)**	(152)
Aggregate carrying amount of the Group's investments in the associates	**3,262**	3,348

The Group's shareholding in the associate is held through a wholly-owned subsidiary of the Company.

18. INVENTORIES AND SUPPLIES

	2022 RMB'000	2021 RMB'000
Medical consumables	**6,350**	5,515
Pharmaceuticals	**5,024**	6,218
Aesthetic medical equipment products	**1,304**	1,533
	12,678	13,266

In the opinion of the directors, no impairment provision was needed as at the end of each reporting period.

At 31 December 2022, the Group did not have any inventories (2021: Nil) that have been pledged.

19. TRADE RECEIVABLES

	2022 RMB'000	2021 RMB'000
Trade receivables	**5,377**	6,420
Impairment	**(36)**	(326)
	5,341	6,094

The Group seeks to maintain strict control over its outstanding receivables to minimise the credit risk. Overdue balances are reviewed regularly by management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. Trade receivables are non-interest-bearing.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date, is as follows:

	2022 RMB'000	2021 RMB'000
Within 3 months	**2,032**	5,886
4 to 6 months	**1,148**	36
7 to 12 months	**2,126**	172
1 to 2 years	**35**	–
	5,341	6,094

The movements in the loss allowance for impairment of trade receivables are as follows:

	2022 RMB'000	2021 RMB'000
At beginning of year	**326**	77
Impairment losses, net *(note 6)*	**7**	596
Amount written off as uncollectible	**(297)**	(347)
At end of year	**36**	326

19. TRADE RECEIVABLES (CONTINUED)

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customers with similar loss patterns (i.e., by geographical region, product type and customer type). The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions.

An impairment test is performed at the end of the reporting period using the simplified approach. To measure the ECLs, the balances are grouped based on similar loss patterns (i.e., by product or service type, customer type and rating). The provision rates are calculated on external credit ratings and historical credit loss experience. The calculation reflects the probability-weighted outcome and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions.

Set out below is the information about the credit risk exposure on the Group's trade receivables using a provision matrix:

As at 31 December 2022

		Past due			
	Current	**Less than 3 month**	**3 to 6 months**	**Over 6 months**	**Total**
Expected credit loss rate	**0.67%**	**0.69%**	**0.65%**	**0.00%**	**0.67%**
Gross carrying amount (RMB'000)	**2,045**	**1,156**	**2,141**	**35**	**5,377**
Expected credit losses (RMB'000)	**14**	**8**	**14**	**–**	**36**

As at 31 December 2021

		Past due			
	Current	Less than 3 month	3 to 6 months	Over 6 months	Total
Expected credit loss rate	0.66%	0.00%	37.23%	100%	5.08%
Gross carrying amount (RMB'000)	5,925	36	274	185	6,420
Expected credit losses (RMB'000)	39	–	102	185	326

20. PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

	2022 RMB'000	2021 RMB'000
Prepayments for inventories and supplies	**874**	854
Prepayments for services	**668**	2,898
Prepaid expense	**2,141**	1,921
Deposits	**11,397**	3,173
Other receivables	**689**	1,092
	15,769	9,938
Impairment allowance	**(7)**	(1)
	15,762	9,937

Deposits and other receivables mainly represent rental deposits, deposits with suppliers and petty cash to employees. Expected credit losses are estimated by applying a loss rate approach with reference to the historical loss record of the Group. The loss rate is adjusted to reflect the current conditions and forecasts of future economic conditions, as appropriate.

An impairment analysis is performed at the end of each reporting period. The Group has applied the general approach to provide for expected credit losses for non-trade other receivables under IFRS 9. The Group considers the historical loss rate and adjusts for forward-looking macroeconomic data in calculating the expected credit loss rate.

As at 31 December 2022, the Group estimated the expected losses for other receivables to be RMB7,000 (2021: RMB1,000). The movements in the loss allowance for impairment of other receivables were as follows:

	2022 RMB'000	2021 RMB'000
At beginning of year	**1**	324
Impairment losses *(note 6)*	**6**	(5)
Amounts written off as uncollectible	**–**	(318)
At end of year	**7**	1

21. CASH AND BANK BALANCES AND PLEDGED DEPOSITS

	2022 RMB'000	2021 RMB'000
Cash and bank balances	**78,779**	121,719
Pledged deposits	**1,543**	1,500
	80,322	123,219
Less: Pledged deposits for lease guarantee	**(1,543)**	(1,500)
Cash and cash equivalents	**78,779**	121,719

At the end of the reporting period, the cash and bank balances of the Group denominated in Renminbi ("RMB") amounted to RMB43,937,347 (2021: RMB68,515,369). The RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, and Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Pledged deposits for lease arrangements will be due in December 2024 respectively and earn interest at the respective time deposit rates. The bank balances and pledged deposits are deposited with creditworthy banks with no recent history of default.

22. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	2022 RMB'000	2021 RMB'000
Within 90 days	**8,326**	7,817
91 to 180 days	**389**	2,105
181 to 365 days	**263**	1,629
Over 365 days	**191**	1,014
	9,169	12,565

Trade payables are non-interest-bearing and are normally settled on 90-day terms.

23. OTHER PAYABLES AND ACCRUALS

	2022 RMB'000	2021 RMB'000
Other payables*	**7,551**	5,444
Payroll payable	**5,473**	7,566
Accruals	**–**	28
Tax liabilities (other than income tax)	**997**	766
Advances received	**4,431**	4,020
Other current liabilities	**110**	–
	18,562	17,824

* Other payables are non-interest-bearing and repayable on demand.

24. INTEREST-BEARING BANK BORROWINGS

	2022			2021		
	Effective interest rate (%)	**Maturity**	**RMB'000**	Effective interest rate (%)	Maturity	RMB'000
Current						
Bank loans – unsecured	**5**	**2023**	**2,000**	5	2022	10,000
Bank loans – unsecured	**4**	**2023**	**3,000**	5	2022	10,000
			5,000			20,000

The Group's interest-bearing bank borrowings were repayable within one year at the end of the reporting period.

25. CONTRACT LIABILITIES

Details of contract liabilities are as follows:

	31 December 2022 RMB'000	31 December 2021 RMB'000	1 January 2021 RMB'000
Short-term advances received from customers			
Aesthetic medical services	**16,608**	14,615	7,854
Consulting services	**–**	71	160
Total contract liabilities	**16,608**	14,686	8,014

Contractual liabilities include advances received for the provision of medical and aesthetic services.

26. REFUND LIABILITIES

	Refund liabilities RMB'000
At 1 January 2021	5,352
Additions	8,184
Amounts utilised during the year	(7,956)
At 31 December 2021 and 1 January 2022	5,580
Additions	4,530
Amounts utilised during the year	(6,034)
At 31 December 2022	4,076

27. DEFERRED TAX

The movements in deferred tax liabilities and assets during the year are as follows:

Deferred tax liabilities

	Note	Fair value adjustments arising from acquisition of subsidiaries RMB'000	Right-of-use assets RMB'000	Depreciation RMB'000	Total RMB'000
At 1 January 2021		7,375	11,957	1,694	21,026
Deferred tax (charged)/credited to profit or loss during the year	*10*	(750)	(1,155)	(488)	(2,393)
Gross deferred tax liabilities at 31 December 2022		6,625	10,802	1,206	18,633

Deferred tax assets

	Note	Advertising expenses for offsetting against future profit RMB'000	Accrued payroll and others expenses RMB'000	Loss available for offsetting against future profit RMB'000	Accrued expenses RMB'000	Lease liabilities RMB'000	Bad debt RMB'000	Refund liabilities RMB'000	Total RMB'000
At 1 January 2022		1,765	430	8,694	–	12,755	37	1,395	25,076
Deferred tax credited/(charged) to profit or loss during the year	*10*	(132)	(123)	590	282	(592)	(1)	(376)	(352)
Gross deferred tax assets at 31 December 2022		1,633	307	9,284	282	12,163	36	1,019	24,724

27. DEFERRED TAX (CONTINUED)

Deferred tax liabilities

	Notes	Fair value adjustments arising from acquisition of subsidiaries RMB'000	Right-of-use assets RMB'000	Depreciation RMB'000	Total RMB'000
At 1 January 2021		–	4,854	1,012	5,866
Acquisition of a subsidiary		7,500	–	–	7,500
Deferred tax (charged)/credited to profit or loss during the year	*10*	(125)	7,103	682	7,660
Gross deferred tax liabilities at 31 December 2021		7,375	11,957	1,694	21,026

Deferred tax assets

	Note	Advertising expenses for offsetting against future profit RMB'000	Accrued payroll and others expenses RMB'000	Loss available for offsetting against future profit RMB'000	Fair value adjustment on equity investment RMB'000	Lease liabilities RMB'000	Bad debt RMB'000	Refund liabilities RMB'000	Total RMB'000
At 1 January 2021		954	638	3,516	18	4,725	25	1,338	11,214
Acquisition of a subsidiary		–	–	1,421	(10)	–	–	–	1,411
Deferred tax charged to other comprehensive income during the year		–	–	–	(8)	–	–	–	(8)
Deferred tax credited/(charged) to profit or loss during the year	*10*	811	(208)	3,757	–	8,030	12	57	12,459
Gross deferred tax assets at 31 December 2021		1,765	430	8,694	–	12,755	37	1,395	25,076

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. A lower withholding tax rate may be applied if there is a tax treaty between Mainland China and the jurisdiction of the foreign investors. For the Group, the applicable rate is 10%. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiaries established in Mainland China in respect of earnings generated from 1 January 2008.

27. DEFERRED TAX (CONTINUED)

As at 31 December 2022, subsidiaries established in Mainland China have no distributable retain earnings. Hence, no deferred tax has been recognised for withholding taxes that would be payable on the earnings that are subject to withholding taxes of the Group's subsidiaries established in Mainland China.

For presentation purposes, certain deferred tax liabilities have been offset in the consolidated statement of financial position. The following is an analysis of the deferred tax balances of the Group for financial reporting purposes:

	2022 **RMB'000**	2021 RMB'000
Net deferred tax assets recognised in the consolidated statement of financial position	**12,716**	11,425
Net deferred tax liabilities recognised in the consolidated statement of financial position	**6,625**	7,375

Deferred tax assets have not been recognised in respect of these losses as they have arisen in subsidiaries that have been loss-making for some time and it is not considered probable that taxable profits will be available against which the following items can be utilised:

	2022 **RMB'000**	2021 RMB'000
Tax losses	**7,109**	65
Deductible temporary differences	**2,495**	–
	9,604	65

At 31 December 2022, there was no significant unrecognised deferred tax liability (2021: Nil) for taxes that would be payable on the unremitted earnings of the Group's subsidiaries or associates as the Group has no liability to additional tax should such amounts be remitted due to the availability of double taxation relief.

There are no income tax consequences attaching to the payment of dividends by the Company to its shareholders.

28. CONTINGENT CONSIDERATION

On 29 October 2021, the Group acquired a 90% equity interest in Shenzhen Jiumei from third parties. A contingent consideration liability had been recognised initially at RMB29,437,000 which was measured at fair value. The management remeasured its fair value at each reporting date using valuation techniques based on the estimate of future performance of Shenzhen Jiumei and other future market conditions. The fair value was classified as Level 3 fair value hierarchy.

The carrying amount of contingent consideration is as follows:

	2022 RMB'000	2021 RMB'000
Carrying amount at 31 December	**25,567**	29,437
Analysed into:		
Current	**6,386**	29,437
Non-current	**19,181**	–

Significant unobservable valuation inputs for the fair value measurement of the contingent consideration are as follows:

Volatility	5%-30%
Discount rate after tax	16%

29. SHARE CAPITAL

Shares

	2022 RMB'000	2021 RMB'000
Issued and full paid:		
2,089,040,000 (2021: 2,089,040,000) ordinary shares	**136,267**	136,267

A summary of movements in the Company's share capital is as follows:

	Number of shares in issue	Share capital RMB'000
At 1 January 2021	2,055,000,000	134,060
Issue of shares from over-allotment	34,040,000	2,207
At 31 December 2021	2,089,040,000	136,267
At 31 December 2022	2,089,040,000	136,267

On 20 January 2021, the Company issued and allotted 34,040,000 shares at HK$0.40 per share due to the partial exercise of the over-allotment option of the listing for a total cash consideration before share issue expense of approximately HK$13,616,000 (equivalent to RMB11,388,000).

No change in shares during the year ended 31 December 2022.

Details of the Company's share option scheme and the share options issued under the scheme are included in note 30 to the financial statements.

30. SHARE OPTION SCHEME

The Company operates a share option scheme (the "Scheme") for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. Eligible participants of the Scheme include the Company's directors and other employees of the Group. The Scheme became effective on 23 August 2021 and, unless otherwise cancelled or amended, will remain in force for 10 years from that date.

The maximum number of unexercised share options currently permitted to be granted under the Scheme is an amount equivalent, upon their exercise, to 10% of the shares of the Company in issue at any time. The maximum number of shares issuable under share options to each eligible participant in the Scheme within any 12-month period is limited to 1% of the shares of the Company in issue at any time. Any further grant of share options in excess of this limit is subject to shareholders' approval in a general meeting.

Share options granted to a director, chief executive or substantial shareholder of the Company, or to any of their associates, are subject to approval in advance by the independent non-executive directors. In addition, any share options granted to a substantial shareholder or an independent non-executive director of the Company, or to any of their associates, in excess of 0.1% of the shares of the Company in issue at any time or with an aggregate value (based on the price of the Company's shares at the date of grant) in excess of HK$5 million, within any 12-month period, are subject to shareholders' approval in advance in a general meeting.

The offer of a grant of share options may be accepted within 30 days from the date of offer, upon payment of a nominal consideration of HK$1 in total by the grantee. The exercise period of the share options granted is determinable by the directors, and commences after a vesting period of six months and ends on a date which is not later than ten years from the date of offer of the share options or the expiry date of the Scheme, whichever is earlier.

The exercise price of share options is determinable by the directors, but may not be less than the higher of (i) the Stock Exchange closing price of the Company's shares on the date of offer of the share options; and (ii) the average Stock Exchange closing price of the Company's shares for the five trading days immediately preceding the date of offer.

Share options do not confer rights on the holders to dividends or to vote at shareholders' meetings.

30. SHARE OPTION SCHEME (CONTINUED)

The following share options were outstanding under the Scheme during the year:

	2022		2021	
	Weighted average exercise price HK$	**Number of options '000 per share**	Weighted average exercise price HK$	Number of options '000 per share
At 1 January	**0.492**	**97,161**	N/A	–
Granted during the year	**0.167**	**109,439**	0.492	97,961
Forfeited during the year	**0.492**	**(1,200)**	0.492	(800)
At 31 December	**0.319**	**205,400**	0.492	97,161

No share options were exercised during the year ended 31 December 2022 (2021: Nil).

The exercise prices and exercise periods of the share options outstanding as at the end of the reporting period are as follows:

As at 31 December 2022

Number of options '000	Exercise price HK$ per share	Exercise period
47,980	0.492	23-08-2022 to 22-08-2023
47,981	0.492	23-08-2023 to 22-08-2024
21,888	0.1678	29-08-2023 to 28-08-2032
21,888	0.1678	29-08-2024 to 28-08-2032
32,832	0.1678	29-08-2025 to 28-08-2032
32,831	0.1678	29-08-2026 to 28-08-2032
205,400		

30. SHARE OPTION SCHEME (CONTINUED)

As at 31 December 2021

Number of options '000	Exercise price HK$ per share	Exercise period
48,580	0.492	23-08-2022 to 22-08-2023
48,581	0.492	23-08-2023 to 22-08-2024
97,161		

The fair value of the share options granted during the year was RMB7,287,000 (RMB0.067 or HK$0.076 each) (2021: RMB5,778,000), of which the Group recognised a share option expense of RMB3,770,000 during the year ended 31 December 2022 (2021: RMB1,038,000).

The fair value of equity-settled share options granted during the year was estimated as at the date of grant using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:

	2022	2021
Dividend yield (%)	**–**	–
Expected volatility (%)	**39**	35
Historical volatility (%)	**39**	35
Risk-free interest rate (%)	**3**	2
Weighted average share price (HK$ per share)	**0.319**	0.492

The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.

No other feature of the options granted was incorporated into the measurement of fair value.

At the end of the reporting period, the Company had 205,500,000 share options outstanding under the Scheme. The exercise in full of the outstanding share options would, under the present capital structure of the Company, result in the issue of 205,500,000 additional ordinary shares of the Company and additional share capital of RMB14,312,000 (before issue expenses).

At the date of approval of these financial statements, the Company had 205,500,000 share options outstanding under the Scheme, which represented approximately 5.24% of the Company's shares in issue as at that date.

31. RESERVES

The amounts of the Group's reserves and the movements therein for the year are presented in the consolidated statement of changes in equity on pages 102 of the financial statements.

Pursuant to the relevant laws and regulations for Sino-foreign joint venture enterprises, a portion of the profits of the Group's joint ventures which are established in the People's Republic of China has been transferred to reserve funds which are restricted as to use.

Capital reserve

The capital reserve of the Group represents the paid-up capital of the companies comprising the Group prior to the incorporation of the Company and the reserve arising from the reorganisation during the initial public offering process and the difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid for acquisition of non-controlling interest in a subsidiary. Details of the movements in the capital reserve are set out in the consolidated statement of changes in equity.

Statutory surplus reserve

In accordance with the Company Law of the PRC, a subsidiary of the Group which is a domestic enterprise is required to allocate 10% of its profit after tax, as determined in accordance with the relevant PRC accounting standards, to its statutory surplus reserve until the reserve reaches 50% of its registered capital. Subject to certain restrictions set out in the Company Law of the PRC, part of the statutory surplus reserve may be converted to share capital, provided that the remaining balance after the capitalisation is not less than 25% of the registered capital.

Distributable reserves

At 31 December 2022, the Company do not have reserves available for distribution, calculated in accordance with the provisions of sections 291, 297 and 299 of the Hong Kong Companies Ordinance.

32. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

(a) Major non-cash transactions

During the year, the Group had non-cash additions and revisions to right-of-use assets and lease liabilities of RMB2,343,000 (2021: RMB34,173,000) and RMB2,343,000 (2021: RMB34,173,000), respectively, in respect of lease arrangements for working spaces.

32. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)

(b) Changes in liabilities arising from financing activities

2022

	Notes	Bank borrowings RMB'000	Lease liabilities RMB'000	Total RMB'000
At 1 January 2022		**20,670**	**47,454**	**68,124**
Changes from financing cash flows		**(15,000)**	**(10,411)**	**(25,411)**
New leases and revisions	*14(b)*	**–**	**4,722**	**4,722**
Interest expense	*7*	**(218)**	**2,583**	**2,801**
Payments waived		**–**	**(1,127)**	**(1,127)**
At 31 December 2022		**5,888**	**43,221**	**49,109**

2021

	Notes	Bank borrowings RMB'000	Lease liabilities RMB'000	Total RMB'000
At 1 January 2021		13,000	19,185	32,185
Changes from financing cash flows		7,000	(7,653)	(653)
New leases and revisions	*14(b)*	–	34,173	34,173
Interest expense	*7*	670	1,749	2,419
At 31 December 2021		20,670	47,454	68,124

32. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)

(c) Total cash outflow for leases

The total cash outflow for leases included in the statement of cash flows is as follows:

	2022 **RMB'000**	2021 RMB'000
Within operating activities	**709**	1,354
Within financing activities	**10,411**	7,653
	11,120	9,007

33. PLEDGE OF ASSETS

Details of the Group's assets pledged for its bank facilities are disclosed in note 21 to the financial statements.

For the expansion of the lease arrangements for working spaces, the Group made a three-year deposit amounting to RMB1,543,000, which is disclosed in the note 21 to the financial statements.

34. COMMITMENTS

The Group had the following capital commitments at the end of the reporting period:

	2022 **RMB'000**	2021 RMB'000
Contracted, but not provided for:		
Leasehold improvements	**1,122**	4,022
Plant and machinery	**–**	670
	1,122	4,692

35. RELATED PARTY TRANSACTIONS

(a) In addition to the transactions detailed elsewhere, the Group had the following transactions with related parties during the year:

	2022 RMB'000	2021 RMB'000
The associate:		
Purchases of products	**1,250**	100

The purchases from the associate were made according to the agreement by both parties with reference to market price of similar products.

(b) Outstanding payables to directors:

	2022 RMB'000	2021 RMB'000
Mr. Cao Dequan	**155**	147
Mr. Liu Teng	**155**	–
Ms. Yang Xiaofen	**156**	–
	466	147

The outstanding balance due to independent directors of RMB466,000 at the end of the reporting period represented the fees payable to them.

(c) **Compensation of key management personnel of the Group:**

	2022 RMB'000	2021 RMB'000
Short term employee benefits	**1,712**	2,447
Pension scheme contributions	**177**	155
Equity-settled share option expense	**125**	51
Total compensation paid to key management personnel	**2,014**	2,653

Further details of directors' and the chief executive's emoluments are included in note 8 to the financial statements.

The related party transactions in respect of item (a) above do not constitute connected transactions or continuing connected transactions as defined in Chapter 14A of the Listing Rules.

36. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at the end of the reporting period are as follows:

2022

Financial assets

	Financial assets at amortised cost RMB'000
Trade receivables	5,341
Financial assets included in prepayments, other receivables and other assets	12,087
Pledged deposits	1,543
Cash and bank balances	78,779
	97,750

Financial liabilities

	Financial liabilities at fair value through profit or loss RMB'000	Financial liabilities at amortised cost RMB'000	Total RMB'000
Trade payables	–	9,169	9,169
Interest-bearing bank borrowings	–	5,000	5,000
Contingent consideration	25,567	–	25,567
Financial liabilities included in other payables and accruals	–	12,090	12,090
	25,567	26,259	51,826

36. FINANCIAL INSTRUMENTS BY CATEGORY (CONTINUED)

2021

Financial assets

	Financial assets at amortised cost RMB'000
Trade receivables	6,094
Financial assets included in prepayments, other receivables and other assets	4,265
Pledged deposits	1,500
Cash and bank balances	121,719
	133,578

Financial liabilities

	Financial liabilities at fair value through profit or loss RMB'000	Financial liabilities at amortised cost RMB'000	Total RMB'000
Trade payables	–	12,565	12,565
Interest-bearing bank borrowings	–	20,000	20,000
Contingent consideration	29,437	–	29,437
Financial liabilities included in other payables and accruals	–	9,492	9,492
	29,437	42,057	71,494

37. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

	Carrying amounts		Fair values	
	2022 RMB'000	2021 RMB'000	**2022 RMB'000**	2021 RMB'000
Financial assets				
Pledged deposits, non-current portion	**1,543**	1,500	**1,543**	1,500

Management has assessed that the fair values of cash and bank balances, trade receivables, financial assets included in prepayments, other receivables and other assets, trade payables, interest-bearing bank borrowings, financial liabilities included in other payables and accruals, an amount due to directors and the current portion of lease liabilities approximate to their carrying amounts largely due to the short term maturities of these instruments.

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer. At each reporting date, the finance department analysed the movements in the values of financial instruments and determined the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instruments could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of the non-current portion of pledged deposits have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities.

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Liabilities measured at fair value:

As at 31 December 2022

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000	**Significant observable inputs (Level 2) RMB'000**	**Significant unobservable inputs (Level 3) RMB'000**	**Total RMB'000**
Contingent consideration	–	–	**25,567**	**25,567**

37. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)

Fair value hierarchy (Continued)

Liabilities measured at fair value: (Continued)

As at 31 December 2021

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Contingent consideration	–	–	29,437	29,437

During the year, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (2021: Nil).

Assets for which fair values are disclosed:

As at 31 December 2022

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000	**Significant observable inputs (Level 2) RMB'000**	**Significant unobservable inputs (Level 3) RMB'000**	**Total RMB'000**
Pledged deposits, non-current potion	**–**	**1,543**	**–**	**1,543**

As at 31 December 2021

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Pledged deposits, non-current potion	–	1,500	–	1,500

38. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Group's principal financial instruments comprise cash and bank balances and contingent consideration. The main purpose of these financial instruments is to raise finance for the Group's operations. The Group has various other financial assets and liabilities such as trade receivables and trade payables, which arise directly from its operations.

The main risks arising from the Group's financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarised below.

Interest rate risk

The Group's interest-bearing bank borrowings bore interest at fixed rates as at 31 December 2022, therefore the Group did not have exposure to the risk of changes in market interest rates.

Foreign currency risk

The Group has transactional currency exposures. Such exposures arise from financing activities in currencies other than the units' functional currencies.

The following table demonstrates the sensitivity at the end of the reporting period to a reasonably possible change in the HK$ exchange rates, with all other variables held constant, of the Group's profit before tax.

	Change in foreign currency rate %	Increase/(decrease) in profit before tax RMB'000	Increase/(decrease) in equity* RMB'000
2022			
If RMB weakens against HK$	**5**	**1,010**	**852**
If RMB strengthens against HK$	**(5)**	**(1,010)**	**(852)**
2021			
If RMB weakens against HK$	5	2,088	1,747
If RMB strengthens against HK$	(5)	(2,088)	(1,747)

* Excluding retained profits

38. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

Credit risk

The Group trades only with recognised and creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and the Group's exposure to bad debts is not significant.

Maximum exposure and year-end staging

The table below shows the credit quality and the maximum exposure to credit risk based on the Group's credit policy, which is mainly based on past due information unless other information is available without undue cost or effort, and year-end staging classification as at 31 December.

As at 31 December 2022

	12-month ECLs	Lifetime ECLs			
	Stage 1 RMB'000	Stage 2 RMB'000	Stage 3 RMB'000	Simplified approach RMB'000	Total RMB'000
Trade receivables*	–	–	–	5,341	5,341
Financial assets included in prepayments, other receivables and other assets – normal**	12,087	–	–	–	12,087
Pledged deposits	1,543	–	–	–	1,543
Cash and cash balances	78,779	–	–	–	78,779
	92,409	–	–	5,341	97,750

38. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

Maximum exposure and year-end staging (Continued)

As at 31 December 2021

	12-month ECLs	Lifetime ECLs			
	Stage 1 RMB'000	Stage 2 RMB'000	Stage 3 RMB'000	Simplified approach RMB'000	Total RMB'000
Trade receivables*	–	–	–	6,094	6,094
Financial assets included in prepayments, other receivables and other assets – normal**	4,264	–	–	–	4,264
Pledged deposits	1,500	–	–	–	1,500
Cash and cash balances	121,719	–	–	–	121,719
	127,483	–	–	6,094	133,577

* For trade receivables to which the Group applies the simplified approach for impairment, information based on the expected credit loss rate is disclosed in note 19 to the financial statements.

** The credit quality of the financial assets included in prepayments, other receivables and other assets is considered to be "normal" when they are not past due and there is no information indicating that the financial assets had a significant increase in credit risk since initial recognition. Otherwise, the credit quality of the financial assets is considered to be "doubtful".

Further quantitative data in respect of the Group's exposure to credit risk arising from trade receivables are disclosed in note 19 to the financial statements.

Since the Group trades only with recognised and creditworthy third parties, there is no requirement for collateral. Concentrations of credit risk are managed by customer/counterparty and by geographical region. As at December 31, 2022, the Group had certain concentrations of credit risk as 79% of the Group's trade receivables were due from the Group's largest customer (2021: 29%).

38. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

Liquidity risk

The Group monitors its risk to a shortage of funds using a recurring liquidity planning tool. This tool considers the maturity of both its financial instruments and financial assets (e.g., trade receivables) and projected cash flows from operations.

The maturity profile of the Group's financial liabilities as at the end of the reporting period, based on the contractual undiscounted payments, is as follows:

	2022				
	On demand RMB'000	**Within 1 year RMB'000**	**1 to 5 years RMB'000**	**Over 5 years RMB'000**	**Total RMB'000**
Lease liabilities	**–**	**10,956**	**31,030**	**9,680**	**51,666**
Trade payables	**9,169**	**–**	**–**	**–**	**9,169**
Interest-bearing bank borrowings	**–**	**5,065**	**–**	**–**	**5,065**
Financial liabilities included in other payables and accruals	**12,090**	**–**	**–**	**–**	**12,090**
	21,259	**16,021**	**31,030**	**9,680**	**77,990**

	2021				
	On demand RMB'000	Within 1 year RMB'000	1 to 5 years RMB'000	Over 5 years RMB'000	Total RMB'000
Lease liabilities	–	9,700	33,426	14,189	57,315
Trade payables	12,565	–	–	–	12,565
Interest-bearing bank borrowings	–	20,591	–	–	20,591
Financial liabilities included in other payables and accruals	9,492	–	–	–	9,492
	22,057	30,291	33,426	14,189	99,963

Capital management

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximise shareholders' value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the year ended 31 December 2022 and 31 December 2021.

39. EVENT AFTER THE REPORTING PERIOD

On 10 January 2023, the Group entered into an agreement with Hangzhou Tianxin Aesthetic Medical Hospital Co., Ltd. (杭州天鑫醫療美容醫院有限公司) (the "Target Company") and the shareholders of the Target Company. Pursuant to the agreement, the Group conditionally agreed to subscribe for an equity interest in the Target Company of up to 9.0% of the registered capital of the Target Company, at the consideration of up to RMB25 million. As at the date of this financial statements, a refundable deposit of RMB20 million was paid to the Target Company.

40. STATEMENT OF FINANCIAL POSITION OF THE COMPANY

Information about the statement of financial position of the Company at the end of the reporting period is as follows:

	2022 RMB'000	2021 RMB'000
NON-CURRENT ASSET		
Investment in a subsidiary	**5,130**	1,360
CURRENT ASSETS		
Prepayments, other receivables and other assets	**419**	354
Due from related companies	**150,200**	147,050
Cash and cash equivalents	**2,229**	689
Total current assets	**152,848**	148,093
CURRENT LIABILITIES		
Due to related companies	**2,442**	2,462
Due to independent directors	**466**	147
Other payables and accruals	**572**	26
Total current liabilities	**3,480**	2,635
NET CURRENT ASSETS	**149,368**	145,458
TOTAL ASSETS LESS CURRENT LIABILITIES	**154,498**	146,818
NET ASSETS	**154,498**	146,818
EQUITY		
Equity attributable to owners of the parent		
Share capital	**136,267**	136,267
Reserves	**18,231**	10,551
Total equity	**154,498**	146,818

40. STATEMENT OF FINANCIAL POSITION OF THE COMPANY (CONTINUED)

A summary of the Company's reserves is as follows:

	Notes	Capital reserve RMB'000	Share option reserve RMB'000	Retained earnings RMB'000	Total RMB'000
At 1 January 2021		34,308	–	(19,645)	14,663
Total comprehensive loss for the year		–	–	(11,920)	(11,920)
Over-allotment of shares	*30*	9,181	–	–	9,181
Share issue expenses		(2,411)	–	–	(2,411)
Equity-settled share option arrangements	*30*	–	1,038	–	1,038
At 31 December 2021		41,078	1,038	(31,565)	10,551
At 1 January 2022		**41,078**	**1,038**	**(31,565)**	**10,551**
Total comprehensive profit for the year		**–**		**3,910**	**3,910**
Equity-settled share option arrangements	*30*	**–**	**3,770**	**–**	**3,770**
At 31 December 2022		**41,078**	**4,808**	**(27,655)**	**18,231**

The share option reserve comprises the fair value of share options granted which were yet to be exercised, as further explained in the accounting policy for share-based payments in note 2.4 to the financial statements. The amount would either be transferred to share capital when the related options are exercised, or be transferred to retained profits should the related options expire or be forfeited.

41. APPROVAL OF THE FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on 31 March 2023.

FIVE-YEAR FINANCIAL SUMMARY

	Year ended 31 December				
	2022	2021	2020	2019	2018
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Results					
Revenue	**164,522**	188,367	164,545	191,156	158,935
(Loss)/Profit before tax	**(22,101)**	(22,948)	11,567	16,388	26,383
Income tax credit/(expense)	**1,854**	4,682	(6,656)	(6,111)	(7,965)
(LOSS)/PROFIT FOR THE YEAR	**(20,247)**	(18,266)	4,911	10,277	18,418

	As at 31 December				
	2022	2021	2020	2019	2018
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Assets and liabilities					
Total assets	**302,651**	344,725	272,332	183,133	117,836
Total liabilities	**136,774**	162,371	85,582	89,858	102,846
Equity attributable to owners of the Company	**165,877**	178,221	185,873	93,058	15,041